


U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV 1001)		ATTORNEY'S DOCKET NUMBER SW-046XX
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 36 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/019816
INTERNATIONAL APPLICATION NO. PCT/AU00/00729	INTERNATIONAL FILING DATE 28 June 2000 (28.06.00)	PRIORITY DATE CLAIMED 28 June 1999 (28.06.99)
TITLE OF INVENTION A METHOD OF MODULATING INTEGRIN MEDIATED CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME		
APPLICANT(S) FOR DO/EO/US Michael Valentine AGREZ, Nuzhat AHMED		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> is attached hereto (required only if not transmitted by the International Bureau).</p> <p style="margin-left: 20px;">b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(3)).</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> is attached hereto.</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> had been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> are attached herewith (required only if not transmitted by the International Bureau).</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p style="margin-left: 20px;">d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (unsigned)</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>		
Items 11. to 20. below concern document(s) or information included:		
<p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input type="checkbox"/> A computer readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input type="checkbox"/> Other items or information:</p>		

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) <div style="font-size: 1.2em; font-weight: bold;">10/019816</div>	INTERNATIONAL APPLICATION NO PCT/AU00/00729	ATTORNEY'S DOCKET NUMBER SW-046XX			
21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1,040.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00		CALCULATIONS PTO USE ONLY			
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$1,040.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$			
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	120 - 20 =	100	X \$18.00	\$1,800.00	
Independent claims	41 - 3 =	38	X \$84.00	\$3,192.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$280.00	\$ 280.00
TOTAL OF ABOVE CALCULATIONS =				\$6,312.00	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$3,156.00	
SUBTOTAL =				\$3,156.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 Months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$3,156.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	
TOTAL FEES ENCLOSED =				\$3,156.00	
				Amount to be Refunded:	\$
				Charged:	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>3,156.00</u> to cover the above fees is enclosed. A check in the amount of \$ _____ is enclosed for the assignment recordation fee.					
b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>23-0804</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
Customer Number 207 SEND ALL CORRESPONDENCE TO: Weingarten, Schurgin, Gagnebin & Lebovici LLP Ten Post Office Square Boston, Massachusetts 02109					
				 SIGNATURE	
				NAME: Holliday C. Heine REGISTRATION NUMBER: 34,346	
				Date: <u>Dec. 28, 2007</u>	

1001049816 22702
PATENT
JC13 Rec'd PCT/PTO 28 DEC 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : MICHAEL VALENTINE AGREZ, ET AL.
Application No. :
Filed : Herewith
For : A METHOD OF MODULATING INTEGRIN MEDIATED
CELLULAR ACTIVITY AND AGENTS USEFUL FOR
SAME
Examiner :
Attorney's Docket : SW-046XX

Group Art Unit:

I hereby certify that this correspondence is being deposited
with the United States Postal Service as first class mail in an
envelope addressed to: Commissioner for Patents, Washington,
D.C. 20231 on _____.

By: _____
Holliday C. Heine
Registration No. 34,346
Attorney for Applicant(s)

PRELIMINARY AMENDMENT

BOX PCT
Commissioner for Patents
Washington, D.C. 20231

Sir:

Kindly enter the following Preliminary Amendment in the
above-identified application:

In the Claims:

WEINGARTEN, SCHURGIN,
GARDENIN & LEWOWICZ LLP
TEL.: (617) 542-2290
FAX: (617) 451-0313

Express Mail Number

EV 009950555 US _____

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

In the Amended Claims of the International Preliminary
Examination Report dated 15 October 2001:

Please CANCEL claims 1-123.

Please add the following new claims 124-239:

124. A fragment of an integrin subunit wherein the fragment consists of a binding domain of the integrin subunit for a MAP kinase, or an analog or derivative of the fragment that is capable of binding with the MAP kinase.

125. An isolated or purified fragment of an integrin subunit, wherein the fragment comprises a binding domain of the integrin subunit for a MAP kinase and has a length of 15 amino acids or less, or a partial amino acid sequence of the binding domain that is capable of binding to the MAP kinase and thereby inhibiting binding of the MAP kinase to the integrin subunit, or an analog or derivative of the fragment or the partial amino acid sequence and which is capable of binding with the MAP

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

kinase and thereby inhibiting binding of the MAP kinase to the integrin subunit.

126. A fragment according to claim 125, wherein the MAP kinase is a member of the ERK family or the JNK family.

127. A fragment according to claim 125, wherein the MAP kinase is ERK2.

128. A fragment according to claim 125, wherein the integrin subunit is selected from the group consisting of $\beta 3$, $\beta 5$ and $\beta 6$.

129. A fragment according to claim 128, wherein the integrin subunit is $\beta 6$.

130. A fragment according to claim 125 comprising an amino acid sequence selected from the group consisting of RSKAKWQTGTNPLYR, RARAKWDTANNPLYK and RSRARYEMASNPLYR.

131. An isolated or purified polypeptide capable of binding with a binding site of a MAP kinase for an integrin and thereby inhibiting binding of the MAP kinase with the integrin, or an analog or derivative of the polypeptide that is capable of

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

binding with the MAP kinase and thereby inhibiting binding of the MAP kinase with the integrin, wherein the polypeptide is other than in an integrin subunit or a fragment of an integrin subunit.

132. A polypeptide according to claim 131, wherein the MAP kinase is a member of the ERK family or the JNK family.

133. A polypeptide according to claim 132, wherein the MAP kinase is ERK2.

134. A polypeptide according to claim 131, wherein the integrin comprises an integrin subunit selected from the group consisting of $\beta 3$, $\beta 5$ and $\beta 6$.

135. A polypeptide according to claim 134, wherein the integrin subunit is $\beta 6$.

136. A polypeptide according to claim 131 comprising the amino acid sequence RSKAKNPLYR.

137. A polypeptide according to claim 131 comprising one or both of amino acid sequences RSKAK and NPLYR.

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

138. A polypeptide according to claim 131 comprising core amino acid sequence of a binding domain of an integrin subunit for a MAP kinase.

139. A fusion protein incorporating an inhibitor moiety for inhibiting binding of a MAP kinase with an integrin.

140. A fusion protein according to claim 139 adapted for passing across a cell membrane.

141. A fusion protein according to claim 139 comprising a carrier moiety for facilitating passage across the cell membrane.

142. A fusion protein according to claim 140 adapted for releasing the fragment or the polypeptide after passing across the cell membrane.

143. An agent for inhibiting binding of a MAP kinase to an integrin, comprising:

a targeting moiety for targeting a cell expressing the integrin;

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

an inhibitor moiety for inhibiting binding of the MAP kinase with the integrin; and

a carrier moiety for facilitating passage of the inhibitor moiety across the cell membrane of the cell.

144. An agent according to claim 143, wherein the inhibitor and carrier moieties are capable of being released from the targeting moiety at the cell for passage of the carrier moiety and the inhibitor moiety across the cell membrane of the cell.

145. An agent according to claim 144, wherein the agent comprises an enzyme cleavage site for being cleaved to thereby release the carrier moiety and the inhibitor moiety at the cell.

146. An agent according to claim 145, wherein the enzyme cleavage site is a cleavage site for matrix-metalloproteinase-9 (MMP-9).

147. An agent according to claim 143 adapted for release of the inhibitor moiety from the carrier moiety after passage of the inhibitor moiety across the cell membrane of the cell.

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

148. An agent according to claim 143 wherein the targeting moiety is an antibody or a binding fragment of an antibody.

149. An agent according to claim 148, wherein the antibody or the binding fragment is specific for an extracellular region of the integrin.

150. An agent according to claim 143, wherein the targeting moiety is an integrin receptor targeted peptide for binding to the integrin.

151. An agent according to claim 143, wherein the inhibitor moiety is capable of binding to a binding site on the MAP kinase for the integrin or the binding domain of the integrin for the MAP kinase.

152. An agent according to claim 151, wherein the inhibitor moiety comprises a binding domain of the integrin for the MAP kinase or a partial amino acid sequence of the binding domain that is capable of binding to the MAP kinase, or an analog or derivative thereof which is capable of binding with the MAP kinase and thereby inhibiting binding of the MAP kinase to the integrin.

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

153. An agent according to claim 152, wherein the inhibitor moiety is an analog of the binding domain of an integrin subunit.

154. An agent for inhibiting binding of a MAP kinase to an integrin.

155. An agent according to claim 154, wherein the agent is an analog of a binding domain of a subunit of the integrin and is capable of binding to a binding site on the MAP kinase for the integrin.

156. An isolated or purified integrin subunit with a mutagenised binding domain for a MAP kinase or in which the binding domain is deleted wherein capability of the integrin subunit to bind with the MAP kinase is thereby reduced, with the proviso that the integrin subunit is other than a $\beta 6$ $\Delta 746-764$ deletion mutant.

157. An integrin subunit according to claim 156, wherein the MAP kinase is an ERK family member or a JNK family member.

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

158. An integrin subunit according to claim 157, wherein the MAP kinase is ERK2.

159. An integrin subunit according to claim 156, wherein the binding domain of the integrin subunit is mutagenised.

160. An integrin subunit according to claim 156, wherein the integrin subunit is a truncated integrin subunit.

161. An isolated nucleic acid sequence encoding a fragment as defined in claim 124 or an analog or derivative of the fragment that is capable of binding with the MAP kinase and thereby inhibiting binding of the MAP kinase with the integrin.

162. An isolated nucleic acid sequence encoding a polypeptide as defined in claim 131 or an analog or derivative of the polypeptide that is capable of binding with the MAP kinase and thereby inhibiting binding of the MAP kinase with the integrin.

163. An isolated nucleic acid sequence encoding a fusion protein as defined in claim 139.

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

164. An isolated nucleic acid sequence encoding an integrin subunit as defined in claim 156.

165. An isolated antisense nucleic acid sequence complementary to a nucleic acid sequence as defined in claim 161.

166. An isolated antisense nucleic acid sequence according to claim 165, wherein the antisense nucleic acid sequence is labelled.

167. An oligonucleotide comprising from 14 to 45 contiguous nucleotides of a nucleic acid sequence as defined in claim 161.

168. An oligonucleotide comprising from 14 to 45 nucleotides and which is capable of hybridising with a nucleic acid sequence as defined in claim 161.

169. An expression vector incorporating a nucleic acid sequence as defined in claim 163 for being expressed in a cell.

170. An expression vector incorporating a nucleic acid sequence as defined in claim 161 or 162 for being expressed in a cell.

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

171. A host cell transformed with a vector as defined in claim 170.

172. A host cell according to claim 171, wherein the host cell is selected from the group consisting of a mammalian cell, an epithelial cell, a neoplastic cell and a cancer cell.

173. A host cell according to claim 172, wherein the host cell is a colon cancer cell.

174. A pharmaceutical composition comprising a fragment as defined in claim 124 or an analog or derivative thereof capable of binding with the MAP kinase and thereby inhibiting binding the MAP kinase with the integrin, together with a pharmaceutically acceptable carrier or diluent.

175. A pharmaceutical composition comprising a polypeptide as defined in claim 131 or an analog or derivative thereof that is capable of binding with the NAP kinase and thereby inhibiting binding of the MAP kinase with the integrin, together with a pharmaceutically acceptable carrier or diluent.

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

176. A pharmaceutical composition comprising a fusion protein as defined in claim 139 together with a pharmaceutically acceptable carrier or diluent.

177. A pharmaceutical composition comprising an agent for inhibiting binding of a MAP kinase with an integrin, together with a pharmaceutically acceptable carrier or diluent.

178. A pharmaceutical composition comprising a vector as defined in claim 170 together with a pharmaceutically acceptable carrier or diluent.

179. A pharmaceutical composition comprising an antisense nucleic acid sequence as defined in claim 165 together with a pharmaceutically acceptable carrier or diluent.

180. A pharmaceutical composition comprising an oligonucleotide as defined in claim 170 together with a pharmaceutically acceptable carrier or diluent.

181. An antibody specific for a binding domain of an integrin for a MAP kinase, or a binding fragment of the antibody.

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

182. An antibody specific for a fragment as defined in claim 124 or an analog or derivative of the fragment that is capable of binding with the MAP kinase and thereby inhibiting binding of the MAP kinase with the integrin.

183. An antibody specific for a polypeptide as defined in claim 131 or an analog or derivative of the polypeptide that is capable of binding with the MAP kinase and thereby inhibiting binding of the MAP kinase with the integrins.

184. An antibody according to claim 181, wherein the antibody is a monoclonal antibody.

185. A method of screening for an agent capable of inhibiting binding of a MAP kinase to a binding domain of an integrin for the MAP kinase, comprising:

- (a) testing a number of agents for ability to bind to either the MAP kinase or the integrin; and
- (b) determining if any said agent is capable of inhibiting binding of the MAP kinase to the binding domain of the integrin on the basis of the testing.

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

186. A method of screening for an agent capable of inhibiting binding of a MAP kinase to a binding domain of an integrin for the MAP kinase, comprising:

(a) testing a number of agents for ability to bind to either the MAP kinase or the integrin;

(b) selecting an agent or agents identified as being able to bind to the MAP kinase or the integrin on the basis of the testing; and

(c) utilising the selected said agent or agents in an assay for indicating whether the or any of the selected said agents is capable of inhibiting the binding of the MAP kinase to the binding domain of the integrin.

187. A method of evaluating whether an agent is capable of inhibiting binding of a MAP kinase to a binding domain of an integrin for the MAP kinase, comprising:

(a) selecting the agent;

(b) utilising the agent in an assay for indicating whether the agent is capable of inhibiting the binding of the MAP kinase to the binding domain of the integrin; and

(c) determining if the agent is capable of inhibiting the binding of the MAP kinase to the binding domain of the integrin on the basis of the assay.

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

188. A method according to claim 187, wherein the integrin comprises $\beta 6$.

189. A method according to claim 187, wherein the MAP kinase is an ERK family member or a JNK family member.

190. A method according to claim 189, wherein the MAP kinase is ERK2.

191. An agent identified to be capable of binding to a binding domain of an integrin for a MAP kinase by a method as defined in claim 187.

192. An agent identified to be capable of inhibiting binding of a MAP kinase to a binding domain of an integrin for the MAP kinase by a method as defined in claim 187.

193. A method of isolating an agent from a sample utilising a molecule immobilised on a solid support and which is capable of binding to a binding site of a MAP kinase for an integrin, comprising:

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

(a) contacting the molecule immobilised on the solid support with the sample under conditions suitable for binding of the agent to the molecule;

(b) eluting the agent, from the solid support; and

(c) collecting the eluted agent.

194. A method according to claim 193, wherein the molecule is an integrin subunit of the integrin or an analog thereof.

195. A method according to claim 193, wherein the molecule is a fragment of an integrin subunit or an analog or derivative thereof.

196. A method according to claim 193, wherein the molecule is a polypeptide as defined in claim 131 or an analog or derivative thereof.

197. A method according to claim 196, wherein the polypeptide comprises amino acid sequence RSKAKNPLYR.

198. A method according to claim 193, wherein the integrin comprises $\beta 6$.

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

199. A method according to claim 193, wherein the MAP kinase is an ERK family member or a JNK family member.

200. A method according to claim 199, wherein the MAP kinase is ERK2.

201. An agent isolated from a sample by a method as defined in claim 193.

202. A method of modulating activity of a cell expressing an integrin subunit with a cytoplasmic binding domain for a MAP kinase, comprising:

treating the cell with an antisense oligonucleotide for hybridising with at least part of a nucleic acid sequence coding for the binding domain of the integrin subunit to thereby cause expression of the integrin subunit to be down-regulated.

203. A method according to claim 202, wherein the antisense oligonucleotide is capable of hybridising with the entire nucleic acid sequence coding for the binding domain.

204. A method according to claim 202, wherein the oligonucleotide is about 50 nucleotides or less in length.

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

205. A method according to claim 202, wherein the oligonucleotide is 45 nucleotides in length or less.

206. A method according to claim 202, wherein the antisense oligonucleotide is an oligonucleotide as defined in claim 168.

207. A method according to claim 202, wherein the cell is transfected with the antisense oligonucleotide or the antisense oligonucleotide is transcribed from a vector introduced into the cell.

208. A method according to claim 202, wherein the cell is a cancer cell.

209. A method according to claim 202, wherein the MAP kinase is an ERK family member or a JNK family member.

210. A method according to claim 202, wherein the MAP kinase is ERK2.

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

211. A method of modulating activity of a cell expressing an integrin subunit with a cytoplasmic binding domain for a MAP kinase, comprising:

transfecting the cell with an expression vector incorporating a nucleic acid sequence encoding the integrin subunit or an analog or variant thereof for being expressed by the cell, and which has a mutagenised binding domain for the MAP kinase or in which the binding domain has been deleted whereby binding of the MAP kinase is thereby reduced, with the proviso that the integrin subunit is other than a $\beta 6$ $\Delta 746$ -764 deletion mutant.

212. A method according to claim 211, wherein the integrin subunit is truncated.

213. A method according to claim 211, wherein the binding domain of the integrin subunit encoded by the nucleic acid is mutagenised.

214. A method according to claim 211, wherein the MAP kinase is an ERK family member or a JNK family member.

215. A method according to claim 211, wherein the MAP kinase is ERK2.

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

216. A method according to claim 211, wherein the integrin subunit is $\beta 6$.

217. A method of modulating activity of a cell expressing an integrin having a binding domain for a MAP kinase, comprising:

treating the cell with an effective amount of an agent for inhibiting binding of the MAP kinase to the binding domain of the integrin.

218. A method according to claim 217, wherein the agent is a fragment as defined in claim 124 or an analog or derivative thereof capable of inhibiting the binding of the MAP kinase to the binding domain of the integrin.

219. A method according to claim 217, wherein the agent is a polypeptide as defined in claim 131 or an analog or derivative thereof capable of inhibiting the binding of the MAP kinase with the binding domain of the integrin.

220. A method according to claim 217, wherein the agent is a fusion protein as defined in claim 139.

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

221. A method according to claim 217, wherein the agent is an agent as defined in claim 143.

222. A method according to claim 217, wherein the agent is a peptide capable of binding with the MAP kinase to thereby inhibit binding of the MAP kinase to the binding domain of the integrin for the MAP kinase.

223. A method according to claim 217, wherein the activity of the cell is growth of the cell.

224. A method according to claim 217, wherein the cell is a cancer cell.

225. A method according to claim 217, wherein the cancer cell is a colon cancer cell.

226. A method of prophylaxis or therapy of cancer in a mammal, comprising:

treating the mammal with an effective amount of an antisense nucleic acid for hybridising with a nucleic acid encoding an integrin subunit to cause expression of the integrin subunit to

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

be down-regulated wherein the integrin subunit has a binding domain for a MAP kinase.

227. A method according to claim 226 comprising administering an effective amount of the antisense nucleic acid to the mammal.

228. A method according to claim 226 comprising administering to the mammal an effective amount of a vector incorporating an nucleic acid sequence complementary to the antisense nucleic acid for generation of the antisense nucleic sequence in vivo.

229. A method according to claim 226, wherein the antisense nucleic acid is an antisense oligonucleotide for hybridising with at least part of the sequence of the nucleic acid encoding the binding domain for the MAP kinase.

230. A method according to claim 229, wherein the oligonucleotide has a length of 150 nucleotides or less.

231. A method according to claim 230, wherein the oligonucleotide has a length of 90 nucleotides or less.

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

232. A method according to claim 231, wherein the oligonucleotide has a length of 50 nucleotides or less.

233. A method according to claim 232, wherein the oligonucleotide has a length of from 15 to 30 nucleotides.

234. A method according to claim 226, wherein the integrin subunit is $\beta 6$.

235. A method according to claim 226, wherein the cancer is colon cancer.

236. A method according to claim 217 comprising administering to a mammal in need of such treatment an effective amount of the agent.

237. A method according to claim 236, wherein the method comprises therapy or prophylaxis of cancer or a condition associated with a predisposition to cancer.

238. A method according to claim 237, wherein the cancer is selected from the group consisting of cancer of the lip, tongue, salivary glands, gums, floor and other areas of the mouth,

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

oropharynx, nasopharynx, hypopharynx and other oral cavities, oesophagus, stomach, small intestine, duodenum, colon, rectum, gallbladder, pancreas, larynx, trachea, bronchus, lung, breast, uterus, cervix, ovary, vagina, vulva, prostate, testes, penis, bladder, kidney, thyroid and skin.

239. A transgenic animal with cells containing heterologeous nucleic acid encoding an integrin subunit with a mutagenised binding domain for a MAP kinase.

Attorney Docket No. SW-046XX
Filed: Herewith
Group Art Unit:

REMARKS

This Preliminary Amendment puts the claims into proper form for examination. Note that claims 1-123 have been cancelled; and new claims 123-239 have been added. Kindly calculate the filing fee based on the amended claims.

The Examiner is encouraged to telephone the undersigned attorney to discuss any matter which would expedite allowance of the present application.

Respectfully submitted,

MICHAEL VALENTINE AGREZ, ET AL.

By: Holliday C. Heine
Holliday C. Heine
Registration No. 34,346
Attorney for Applicant(s)

WEINGARTEN, SCHURGIN, GAGNEBIN
& LEBOVICI LLP
Ten Post Office Square
Boston, MA 02109
Telephone: (617) 542-2290
Telecopier: (617) 451-0313

Date: Dec. 28, 2007

HCH/mc/264533-1

DT11 Rec'd PCT/PTO JUN 14 2002
 10/019816
 PATENT

#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : Michael Valentine Agrez et al.
 U.S. Application No. : 10/019,816
 I.A. Application No. : PCT/AU00/00729
 I.A. Filing Date : June 28, 2000
 For : A METHOD OF MODULATING INTEGRIN MEDIATED
 CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME
 Attorney's Docket : SW-046XX

Group Art Unit:

 I hereby certify that this correspondence is being deposited with the
 United States Postal Service as first class mail in an envelope
 addressed to: Box Sequence, U.S. Patent and Trademark Office P.O. Box
 2327 Arlington, VA 22202 on June 11, 2002.

By

Holliday C. Heine
 Holliday C. Heine, Ph.D.
 Registration No. 34,346
 Attorney for Applicants

SUBMISSION OF SEQUENCE LISTING

Box Sequence
 U.S. Patent and Trademark Office
 P.O. Box 2327
 Arlington, VA 22202

Sir:

In response to Notification of Missing Requirements, (copy
 enclosed) enclosed herewith is a Sequence Listing for the
 above-identified patent including the following items:

- a computer readable form (CRF) copy of the Sequence Listing; and
- a paper copy of the Sequence Listing.

Appl No.: 10/019,816
Filed: June 28, 2000
Group Art Unit:

The undersigned Applicants' representative hereby states that the contents of the paper and computer readable copies are the same and include no new matter as required by 37 CFR 1.821(e)(f)(g) and 1.825(b)(d). The General Information portion of the sequence listing has been updated so as to contain information pertaining to the present application and to the priority application being claimed.

Respectfully submitted,

MICHAEL VALENTINE AGREZ ET AL.

By

Holliday C. Heine
Holliday C. Heine, Ph.D.
Registration No. 34,346
Attorney for Applicants

WEINGARTEN, SCHURGIN,
GAGNEBIN & LEBOVICI LLP

Ten Post Office Square
Boston, Massachusetts 02109
Telephone: (617) 542-2290
Telecopier: (617) 451-0313

HCH/raw
Enclosures
274106-1

**A METHOD OF MODULATING INTEGRIN MEDIATED CELLULAR
ACTIVITY AND AGENTS USEFUL FOR SAME**

Field Of The Invention

The present invention relates to a method of modulating cell activity mediated by a cell adhesion molecule and more particularly, finds application in down regulation of the growth and/or the proliferation of a cell such as a neoplastic cell. In particular, the invention finds use *inter alia* in the prophylaxis or treatment of conditions such as cancers requiring modulation of cell activity. The present invention also provides agents for use in the above.

10 Background Of The Invention

Colorectal cancer is the commonest internal malignancy affecting men and women in Australia. About 4% of individuals develop this disease during the course of their lifetime and it was responsible for 14% of cancer deaths in that country in 1990. In 1995 there were 10,615 cases of colorectal cancer and 4508 deaths in Australia.

15 Worldwide, an estimated 875,000 cases of colorectal cancer occurred in 1996, accounting for 8.5% of all new cases of cancer. Incidence rates vary approximately 20-fold around the world, with the highest rates seen in the developed world and lowest in India. Australian incidence rates are towards the higher end of the scale internationally alongside those for North America and New Zealand. Five-year survival following
20 diagnosis of colon cancer is around 55% in the developed world and has altered little during the past few decades despite advances in chemo-, immuno- and radiotherapy.

Colorectal cancer is a malignant tumour that starts in the bowel wall and is confined locally for a relatively long period before spreading through the bowel wall and

metastasising to lymph nodes and other parts of the body. Survival rates are significantly improved where the disease is detected and treated early.

The aetiology of colorectal cancer is complex and appears to involve interactions between inherited susceptibility and environmental factors. Recognition of the genetic component of colorectal cancer is growing. Mutations are present as inherited germline defects or arise in somatic cells secondary to environmental insult. There are two main inherited predisposition syndromes: Familial Adenomatous Polyposis (FAP) and Hereditary Non-Polyposis Colorectal Cancer (HNPCC); the remaining cases are attributed to so-called sporadic colorectal cancer. FAP and HNPCC contribute to approximately 1% and 4%, respectively, of all colorectal cancers and a strong family history of bowel cancer in first-degree relatives is obtained in another 10 - 15% of patients.

However, in the vast majority of patients the aetiology of large bowel cancer remains unknown. Most colon cancer arises within pre-existing benign precursor lesions or adenomas. Adenomas are classified by histological architecture as tubular, tubulovillous or villous. Villous change is associated with a higher malignant potential, as are large and high-grade epithelial dysplasia. Environmental risk factors for development of colorectal cancer include diets low in fibre and vegetables and high in fat, red meat and alcohol and cigarette smoking which may induce mutations in somatic cells.

Studies have shown that persistent genetic instability and accumulation of mutations in several genes that are mainly concerned with cell growth or DNA repair, may be critical for the development of all colorectal cancers. For example, a normal

mucosal cell with inactivation of tumour suppressor genes such as the Adenomatous Polyposis Coli (APC) gene or Mutated in Colon Cancer (MCC) gene can proliferate and become a small adenomatous polyp. Mutations in oncogenes such as k ras and in tumour suppressor genes such as p53 and the Deleted in Colon Cancer gene (DCC) may then occur and lead to the transformation of the polyp into a large adenoma, from which a carcinoma can eventually arise. The uncontrolled cell growth that leads to the development of neoplasia is believed to result, therefore, from a series of inherited and acquired accumulated genetic changes. This multistep process confers on cells the capacity to survive and proliferate in a manner freed from the constraints imposed on normal cell growth.

Spread of cancer cells involves tumour cell migration through the extracellular matrix scaffold, invasion of basement membranes, arrest of circulating tumour cells, and tumour cell extravasation and proliferation at metastatic sites. Detachment of cells from the primary tumour mass and modification of the peri-cellular environment aid penetration of tumour cells into blood and lymphatic vessels. It is the invasive and metastatic potential of tumour cells that ultimately dictates the fate of most patients suffering from malignant diseases. Hence, tumourigenesis can be viewed as a tissue remodelling process that reflects the ability of cancer cells to proliferate and digest surrounding matrix barriers. These events are thought to be regulated, at least in part, by cell adhesion molecules and matrix-degrading enzymes.

Cell adhesion receptors on the surface of colon cancer cells are involved in complex cell signalling which may regulate cell proliferation, migration, invasion and metastasis and several families of adhesion molecules have now been identified

including integrins, cadherins, the immunoglobulin superfamily, hyaluronate receptors, and mucins (Agrez, 1996.) In general, these cell surface molecules mediate both cell-cell and cell-matrix binding, the latter involving attachment of tumour cells to extracellular scaffolding molecules such as collagen, fibronectin and laminin. It is now clear that multiple and varied cell adhesion receptors exist on colon cancer cells at any one time and an understanding of the role of individual receptors in promoting growth and spread of colon cancer is only just beginning to be elucidated.

Of all the families of cell adhesion molecules, the best-characterised at the present time is the family known as integrins. Integrins are involved in several fundamental processes including leucocyte recruitment, immune activation, thrombosis, wound healing, embryogenesis, virus internalisation and tumourigenesis. Integrins are transmembrane glycoproteins consisting of an alpha (α) and beta (β) chain in close association that provide a structural and functional bridge between extracellular matrix molecules and cytoskeletal components with the cell. The integrin family comprises 17 different α and 8 β subunits and the $\alpha\beta$ combinations are subsumed under 3 subfamilies.

Excluding the leucocyte integrin subfamily that is designated by the $\beta 2$ nomenclature, the remaining integrins are arranged into two major subgroups, designated $\beta 1$ and αv based on sharing common chains.

In the $\beta 1$ subfamily, the $\beta 1$ chain combines with any one of nine α chain members ($\alpha 1-9$), and the α chain which associates with $\beta 1$ determines the matrix-binding specificity of that receptor. For example, $\alpha 2\beta 1$ binds collagen and laminin, $\alpha 3\beta 1$ binds collagen, laminin and fibronectin, and $\alpha 5\beta 1$ binds fibronectin. In the αv subfamily of receptors, the abundant and promiscuous αv chain combines with any one of five β

chains, and a distinguishing feature of α_v integrins is that they all recognise and bind with high affinity to arginine-glycine-aspartate (RGD) sequences present in the matrix molecules to which they adhere (Hynes, 1992).

The current picture of integrins is that the N-terminal domains of α and β subunits combine to form a ligand-binding head on each integrin. This head, containing the cation binding domains, is connected by two stalks representing both subunits, to the membrane-spanning segments and thus to the two cytoplasmic domains. The β subunits all show considerable similarity at the amino acid level (Lofus et al, 1994). All have a molecular mass between 90 and 110 kDa, with the exception of β_4 which is larger at 210 kDa. Similarly, they all contain 56 conserved cysteine residues, except for β_4 which has 48. These cysteines are arranged in four repeating patterns which are thought to be linked internally by disulphide bonds. The α -subunits have a molecular mass ranging from 150 - 200 kDa. They exhibit a lower degree of similarity than the β chains, although all contain seven repeating amino acid sequences interspaced with non-repeating domains.

The β subunit cytoplasmic domain is required for linking integrins to the cytoskeleton (Hynes, 1992). In many cases, this linkage is reflected in localisation to focal contacts, which is believed to lead to the assembly of signalling complexes that include α -actinin, talin, and focal adhesion kinase (FAK) (Otey et al, 1990; Guan and Shalloway, 1992; Kornberg et al, 1992). At least three different regions that are required for focal contact localisation of β_1 integrins have been delineated (Reszka et al, 1992). These regions contain conserved sequences that are also found in the cytoplasmic domains of the β_2 , β_3 , β_5 , β_6 and β_7 integrin subunits. The functional differences

between these cytoplasmic domains with regard to their signalling capacity have not yet been established.

Ligation of integrins by their extracellular matrix protein ligands induces a cascade of intracellular signals that include tyrosine phosphorylation of focal adhesion kinase, increases in intracellular Ca^{2+} levels, inositol lipid synthesis, synthesis of cyclins and expression of immediate early genes. In contrast, prevention of integrin-ligand interactions suppresses cellular growth or induces apoptotic cell death (Meredith et al, 1993; Montgomery et al, 1994; Brooks et al, 1994; Varner et al, 1995; Boudreau et al, 1995). Thus, integrins play roles in a number of cellular processes that impact on the development of tumours, including the regulation of proliferation and apoptosis.

The integrin $\beta 6$ subunit was first identified in cultured epithelial cells as part of the $\alpha v\beta 6$ heterodimer, and the $\alpha v\beta 6$ complex was shown to bind fibronectin in an arginine-glycine-aspartate (RGD)-dependent manner in human pancreatic carcinoma cells (Sheppard et al, 1990; Busk et al, 1992). The $\beta 6$ subunit is composed of 788 amino acids and shares 34 - 51% sequence homology with other β integrin subunits $\beta 1$ - $\beta 5$. The $\beta 6$ subunit also contains 9 potential glycosylation sites on the extracellular domain (Sheppard et al, 1990). The cytoplasmic domain differs from other β subunits in that it is composed of a 41 amino acid region that is highly conserved among integrin β subunits, and a unique 11 amino acid carboxy-terminal extension. The 11 amino acid extension has been shown not to be necessary for localisation of $\beta 6$ to focal contacts; in fact, its removal appears to increase receptor localisation. However, removal of any of the three conserved regions previously identified as important for the localisation of $\beta 1$

integrins to focal contacts (Reszka et al, 1992) has been shown to eliminate recruitment of $\beta 6$ to focal contacts (Cone et al, 1994).

The integrin $\alpha v \beta 6$ has previously been shown to enhance growth of colon cancer cells *in vitro* and *in vivo* (Agrez et al, 1994). What makes this epithelial-restricted

5 integrin of particular interest in colon cancer is that it is not expressed in normal cells but is highly expressed during tumourigenesis (Breuss et al, 1995; Agrez et al, 1996).

Invasion of the extracellular matrix and metastatic spread of colon cancer is also likely to reflect the ability of tumour cells to digest their surrounding matrix scaffold through secretion of matrix-degrading enzymes such as matrix metalloproteinases (MMPs). The mechanisms whereby human colon cancer cells escape the constraints on
10 growth imposed on normal cells by cell crowding and dense pericellular matrices is unclear. However, even colon cancer cells are subject to relative growth inhibition *in vitro* in a dense extracellular matrix environment (Agrez, 1989).

Integrins can signal through the cell membrane in either direction. The
15 extracellular binding activity of integrins can be regulated from the cell interior as, for example, by phosphorylation of integrin cytoplasmic domains (inside-out signalling), while the binding of the extracellular matrix (ECM) elicits signals that are transmitted into the cell (outside-in signalling) (Giancotti and Ruoslahti, 1999). Outside-in signalling can be roughly divided into two descriptive categories. The first is 'direct
20 signalling' in which ligation and clustering of integrins is the only extracellular stimulus. Thus, adhesion to ECM proteins can activate cytoplasmic tyrosine kinases (e.g. focal adhesion kinase FAK) and serine/threonine kinases (such as those in the mitogen-activated protein kinase (MAPK) cascade) and stimulate lipid metabolism (eg

phosphatidylinositol-4, 5-bisphosphate (P_1P_2) synthesis. The second category of integrin signalling is 'collaborative signalling', in which integrin-mediated cell adhesion modulates signalling events initiated through other types of receptors, particularly receptor tyrosine kinases that are activated by polypeptide growth factors (Howe et al, 1998). In all cases, however, integrin-mediated adhesion seems to be required for efficient transduction of signals into the cytosol or nucleus.

MAP kinases behave as a convergence point for diverse receptor-initiated signalling events at the plasma membrane. The core unit of MAP kinase pathways is a three-member protein kinase cascade in which MAP kinases are phosphorylated by MAP kinase kinases (MEKs) which are in turn phosphorylated by MAP kinase kinase kinases (e.g. Raf-1) (Garrington and Johnson, 1999). Amongst the 12 member proteins of the MAP kinase family are the extracellular signal-regulated kinases (ERKs) (Boulton et al, 1991) activated by phosphorylation of tyrosine and threonine residues (Payne et al, 1991) which is the type of activation common to all known MAP kinase isoforms. ERK 1/2 (44kD and 42kD MAPks, respectively) share 90% amino acid identity and are ubiquitous components of signal transduction pathways (Boulton et al, 1991). These serine/threonine kinases phosphorylate and modulate the function of many proteins with regulatory functions including other protein kinases (such as $p90^{rk}$) cytoskeletal proteins (such as microtubule-associated phospholipase A_2), upstream regulators (such as the epidermal growth factor receptor and Ras exchange factor) and transcription factors (such as C-Myc and Elk-1).

MAP kinases can be activated through non-receptor tyrosine kinases such as focal adhesion kinase (FAK), cytoplasmic tyrosine kinase (pp60 c-srk) (Schlaepfer and

Hunter, 1998), and growth factors acting through membrane-associated receptor tyrosine kinases. The FAK pathway is activated by most integrins. In addition to activating FAK, some $\beta 1$ and αv integrins also activate the tyrosine kinase Fyn and through it, the adaptor protein Shc (Wang et al, 1996). It is likely that both FAK and Shc contribute to the activation of Ras and thence to the downstream kinase cascade of Raf-1, MEK, and MAP kinases (Schlaepfer et al, 1994; 1997). It is now generally accepted that the activation of ERK in response to integrin ligation requires Ras signalling (Wary et al, 1996; Schlaepfer and Hunter, 1997). The laminin receptor $\alpha 6 \beta 4$, the laminin/collagen receptor $\alpha 1 \beta 1$, the fibronectin receptor $\alpha 5 \beta 1$ and the RGD binding receptor $\alpha v \beta 3$ are linked to the Ras-Raf-MEK-ERK signalling pathway and control of immediate early gene expression (Wary et al, 1996; Maniero et al, 1995; 1997). The ability of integrins to activate ERK may be especially important when the concentration of growth factors available to the cell is limited. In this setting, proliferation is likely to require co-stimulation of ERK through integrins and growth factor receptors (Giancotti and Ruoslahti, 1999). Moreover, activation of ERK in response to integrin ligation may play a role in regulating cell migration (Klemke et al, 1997) possibly by initiating matrix-degrading enzyme secretion.

While there is a good deal of evidence in support of a key role for FAK and the phosphotyrosine-domain-containing adaptor protein Shc (Howe et al, 1998; Giancotti & Ruoslahti, 1999) in the Ras-Raf MEK-MAP kinase activation pathway there are also data implicating alternate pathways independent of MEKs. For example, MEK-independent regulation of MAP kinase activation in NIH3T3 fibroblasts has been shown to be mediated by phosphatidylinositol-3-kinases and the conventional protein kinase C

(PKC) isoforms and is thought to be due to inactivation of a MAP kinase inhibitor (Grammer and Blenis, 1997).

Although the mechanism by which PKC regulates integrin function is not known, PKC has been shown to regulate integrin-induced activation of the MAP kinase pathway upstream of Shc. For example, PKC inhibition has been shown to inhibit ERK2 activation by fibronectin receptors without any effect on integrin-induced FAK or paxillin tyrosine phosphorylation (Miranti et al, 1999). Hence, MAP kinase activation is more complicated than a simple linear pathway, and the mechanistic basis for the commonly observed integrin-mediated activation of MAP kinases remains controversial.

Various intracellular proteins may be linked directly or spatially to integrin cytoplasmic domains. Direct interactions have been identified between cytoskeletal proteins such as α -actinin and talin and $\beta 1$ and $\beta 3$ integrin tails (Horwitz et al, 1986; Otey et al, 1990; Knezevic et al, 1996; Pfaff et al, 1998). A direct association between FAK and the $\beta 1$ integrin tail has been suggested based on *in vitro* $\beta 1$ peptide studies, but this remains to be confirmed (Schaller et al, 1995). More recently, the cytoplasmic domain of the $\alpha 4$ subunit has been found to be physically associated with the signalling adaptor protein paxillin in Jurkat T cells, and this binding event regulates the kinetics of FAK tyrosine phosphorylation (Liu et al, 1999).

Direct integrin links with the intracellular calcium-binding protein, calreticulin, and integrin-linked kinase (ILK) (Hannigan et al, 1996) have been shown to regulate "inside-out" integrin signalling. For example, calreticulin has been shown to bind to α chain cytoplasmic domains (Rojiani et al, 1991) and modify $\alpha 2 \beta 1$ integrin activation by phorbol esters and anti-integrin antibodies (Coppolino et al, 1995). Newly identified

integrin-binding molecules include the serine/threonine integrin-linked kinase, ILK, which can associate with the $\beta 1$, $\beta 2$ and $\beta 3$ subunits. When over-expressed, ILK has been shown to reduce anchorage-independent growth and tumourigenicity in nude mice (Hannigan et al, 1996). Co-immunoprecipitation strategies have also demonstrated interactions between integrins and the integral plasma membrane protein IAP, and members of the four transmembrane domain protein family (tetraspans). The extracellular Ig region of the IAP molecule mediates association with $\alpha v\beta 3$ and is required for cell binding to vitronectin-coated particles (Lindberg et al, 1996). An emerging model for tetraspans is that they recruit signalling enzymes such as phosphatidylinositol-4-kinase and PKC into complexes with integrins (Hemler, 1998).

Integrins have also been shown to be physically linked with matrix-degrading enzymes and growth factors. For example, the integrin $\alpha v\beta 6$ has been shown to bind and activate latent TGF $\beta 1$ in keratinocytes (Munger et al, 1999) which is thought to be important in modulating the inflammatory process following epithelial injury. In melanoma cells, $\alpha v\beta 3$ binds activated gelatinase A (Brooks et al, 1996), and both insulin and platelet-derived growth factor (PDGF) co-immunoprecipitate with this integrin in NIH3T3 mouse fibroblasts (Schneller et al, 1997). Synergism between integrin-mediated signalling processes and growth factor responses is now well-recognised and Schneller et al (1997) showed that a small subset of each of the insulin receptor and PDGF β -receptor is tyrosine phosphorylated upon growth factor stimulation. Interestingly, this subset can associate with the $\alpha v\beta 3$ integrin, and PDGF activity is enhanced in association with increased MAP kinase activity in cells plated on the $\alpha v\beta 3$ ligand, vitronectin.

Summary Of The Invention

Broadly stated, the present invention relates to modulation of integrin expression in neoplastic cells to inhibit the growth of the cells, and the surprising finding that members of the mitogen activated protein (MAP) kinase family associate with the cytoplasmic domain of an integrin molecule. It is believed that no member of the MAP kinase family has previously been found to directly associate with any integrin or for that matter, with any transmembrane protein. The identification of this functional relationship permits the rational design of agents for therapeutically or prophylactically modulating cellular activity mediated by the MAP kinase and integrin interaction.

In an aspect of the present invention there is provided an agent capable of inhibiting binding of a MAP kinase with an integrin.

Typically, the agent will be capable of binding with a binding site on the MAP kinase that binds to a binding domain on the integrin for the MAP kinase. Alternatively, the agent may be capable of binding to the binding domain on the integrin for the MAP kinase or other site on the integrin such that inhibition of binding of the MAP kinase to the integrin is thereby caused.

The agent may be provided either isolated or for instance, coupled to another molecule for facilitating transport of the agent into a cell.

In another aspect of the present invention there is provided an isolated polypeptide capable of binding with a binding site on a MAP kinase which binding site binds with a binding domain on an integrin for the MAP kinase, or a homolog, analog, variant or derivative of the polypeptide, with the proviso that the polypeptide is other than a full length integrin subunit or a $\beta 6(770t)$ or $\beta 6(777t)$ deletion mutant.

Preferably, the polypeptide will comprise the binding domain of the integrin or sufficient core amino acid sequence of the binding domain to enable binding of the polypeptide with the MAP kinase.

Preferably, the polypeptide will comprise amino acid sequence
5 RSKAKWQTGTNPLYR, more preferably RSKAKNPLYR, or one or both amino acid sequences RSKAK and NPLYR. Most preferably, the polypeptide will be a fragment of an integrin subunit.

Accordingly, in a further aspect of the present invention there is provided a fragment of an integrin subunit wherein the fragment is capable of binding with a MAP
10 kinase, or a homolog, analog, variant or derivative of the fragment, with the proviso that the integrin subunit is other than a $\beta 6(770t)$ or $\beta 6(777t)$ deletion mutant.

Preferably, the polypeptide or fragment will have a length of about 150 amino acids or less, more preferably about 100 or 50 amino acids or less and more usually about 40 amino acids or less. Typically, the length will be between about 5 to about 30
15 amino acids.

The fragment may comprise an amino acid sequence incorporating extracellular and cytoplasmic regions of the integrin subunit. Preferably, the fragment will be a fragment of the cytoplasmic domain of the integrin subunit.

In another aspect of the present invention there is provided an integrin subunit with
20 a mutagenised binding domain for a MAP kinase or in which the binding domain is deleted, wherein capability of the integrin subunit to bind with the MAP kinase is thereby reduced, or a homolog, analog, variant or derivative of the integrin subunit, with the proviso that the integrin subunit is other than a $\beta 6 \Delta 746-764$ deletion mutant.

In still another aspect of the present invention there is provided a fusion protein incorporating a polypeptide of the invention or a homolog, analog or variant of the polypeptide.

In a further aspect of the present invention there is provided a fusion protein
5 incorporating a fragment of the invention or a homolog, analog or variant of the fragment.

Typically, the polypeptide or fragment will be coupled to a carrier polypeptide for facilitating entry of the fusion protein into a cell. Preferably, the carrier polypeptide will be penetatin.

10 In another aspect of the present invention there is provided an isolated nucleic acid sequence encoding a polypeptide of the invention or a homolog, analog, or variant of the polypeptide.

In yet another aspect of the invention there is provided an isolated nucleic acid sequence encoding a fragment of the invention or a homolog, analog, or variant of the
15 fragment.

In another aspect of the invention there is provided a nucleic acid sequence encoding an integrin subunit with a mutagenised binding domain for a MAP kinase or in which the binding domain is deleted, wherein capability of the integrin subunit to bind with the MAP kinase is thereby reduced, or a homolog, analog, or variant of the integrin
20 subunit, with the proviso that the integrin subunit is other than a $\beta 6 \Delta 746-764$ deletion mutant.

In a still further aspect of the present invention there is provided an isolated nucleic acid sequence encoding a fusion protein of the invention.

There are also provided antisense nucleic acid sequences complimentary to the sense nucleic sequences of the invention. Such antisense sequences find application in antisense therapy of cells in which down regulation of cellular activity is desired, and include oligonucleotides. Sense oligonucleotides coding for the binding domain of an integrin subunit or that of a homolog, analog or variant thereof, and complimentary antisense oligonucleotides find particular application as primers or probes. A nucleic acid primer or probe of the invention may be labelled with a suitable reporter molecule for enabling detection of hybridisation of the primer or probe to a target nucleic acid sequence.

In yet another aspect of the present invention there is provided a vector incorporating a nucleic acid sequence of the invention. Typically, the vector will be an expression vector and the nucleic acid sequence will be capable of being transcribed.

In a further aspect of the present invention there is provided a host cell transformed with a vector of the invention.

Preferably, the host cell will be selected from the group consisting of a mammalian cell, an epithelial cell, a neoplastic cell, and a cancer cell. Preferably, the host cell will be a mammalian cell and most preferably, a colon cancer cell

In a further aspect of the present invention there is provided a transgenic animal with cells containing heterologous nucleic acid of the invention.

In yet another aspect of the present invention there is provided an antibody generated with the use of a polypeptide or fragment of the invention.

In a still further aspect of the invention there is provided an antibody capable of binding to a binding domain on an integrin for a MAP kinase.

20 In another aspect of the present invention there is provided a method of screening for an agent capable of inhibiting binding of a MAP kinase to a binding domain of an integrin for the MAP kinase, comprising:

(a) testing a number of agents for ability to bind to either the MAP kinase or the integrin; and

(b) determining if any said agent is capable of inhibiting binding of the MAP kinase to the binding domain of the integrin on the basis of the testing.

5 In another aspect of the invention there is provided a method of screening for an agent capable of inhibiting binding of a MAP kinase to a binding domain on an integrin for the MAP kinase, comprising:

(a) testing a number of agents for ability to bind to either the MAP kinase or the integrin;

10 (b) selecting an agent or agents identified as being able to bind to the MAP kinase or the integrin on the basis of the testing; and

(c) utilising the selected said agent or agents in an assay for indicating whether the or any of the selected said agents is capable of inhibiting the binding of the MAP kinase to the binding domain of the integrin.

15 In another aspect of the invention there is provided a method of evaluating whether an agent is capable of inhibiting binding of a MAP kinase to a binding domain of an integrin for the MAP kinase, comprising:

(a) selecting the agent;

20 (b) utilising the agent in an assay for indicating whether the agent is capable of inhibiting the binding of the MAP kinase to the binding domain of the integrin; and

(c) determining if the agent is capable of inhibiting the binding of the MAP kinase to the binding domain of the integrin on the basis of the assay.

Testing or assaying of an agent for ability to bind to the MAP kinase or the integrin and thereby inhibit binding of the MAP kinase to the integrin, may comprise exposing the integrin to the agent(s) to enable binding of the agent(s) to the integrin to occur either in the presence of the MAP kinase or prior to the addition of the MAP

5 kinase. Rather than using the integrin, a polypeptide or fragment of the invention or other molecule capable of binding with the binding site on the MAP kinase that binds to the integrin may be used. Alternatively, the testing or assaying may comprise exposing the MAP kinase to the agent(s) to enable binding of the agent(s) to the MAP kinase to occur either in the presence of the integrin or other molecule capable of binding with the

10 binding site on the MAP kinase, or prior to the addition of the integrin or molecule.

In still another aspect of the present invention there is provided a method of screening for an agent capable of binding to a binding domain of an integrin for a MAP kinase, comprising:

- (a) testing a number of agents for ability to bind to the binding domain of the
- 15 integrin for the MAP kinase; and
- (b) determining if any said agent is capable of binding to the binding domain of the integrin on the basis of the testing.

In yet another aspect of the invention there is provided a method of screening for an agent capable of binding to a binding domain of an integrin for a MAP kinase,

20 comprising:

- (a) testing a number of agents for ability to bind to the integrin;
- (b) selecting an agent or agents identified as being able to bind to the integrin on the basis of the testing; and

(c) utilising the selected said agent or agents in an assay for indicating whether the or any of the selected said agents is capable of binding to the binding domain on the integrin for the MAP kinase.

In another aspect of the present invention there is provided a method of
5 evaluating whether an agent is capable of binding to a binding domain of an integrin for a MAP kinase, comprising:

(a) testing the agent for ability to bind to the binding domain of the integrin for the MAP kinase; and

(b) determining if the agent is capable of binding to the binding domain on the
10 basis of the testing.

Preferably, a polypeptide or fragment of the invention consisting of the binding domain of the integrin or core amino acid sequence of the binding domain or a homolog, analog or variant of the polypeptide or fragment is used in the testing or assaying for whether an agent is capable of binding to the binding domain of the integrin. Most
15 preferably, the polypeptide or fragment will consist of the amino acid sequence RSKAKWQTGTNPLYR or RSKAKNPLYR.

An agent of the invention will usually be provided in the form of a pharmaceutical composition. Accordingly, in another aspect of the present invention there is provided a pharmaceutical composition comprising an agent of the invention capable of inhibiting
20 binding of a MAP kinase to a binding domain on an integrin for the MAP kinase, and a pharmaceutically acceptable carrier or diluent.

The agent may or not be proteinaceous in nature. Preferably, the agent will comprise a fusion protein, or polypeptide. Most preferably, the agent will be coupled to a carrier molecule for facilitating entry of the agent into a cell.

In a further aspect of the invention there is provided a pharmaceutical composition
5 comprising a nucleic acid sequence of the invention and a pharmaceutically acceptable carrier or diluent. Preferably, the nucleic acid sequence is incorporated into a vector as described herein. Alternatively, the nucleic acid sequence may be joined to a carrier molecule for facilitating entry of the nucleic acid sequence into a target cell.

In a further aspect of the present invention there is provided a method of
10 modulating activity of a cell, comprising:

transfecting the cell with a nucleic acid sequence encoding an integrin subunit for being expressed by the cell, wherein the integrin subunit has a mutagenised binding domain for a MAP kinase or in which the binding domain is deleted, or a homolog, analog or variant of the integrin subunit.

15 In yet another aspect of the present invention there is provided a method of modulating activity of a cell, comprising:

transfecting the cell with a nucleic acid encoding a polypeptide for being expressed by the cell wherein the polypeptide is capable of inhibiting binding of a MAP kinase with a binding domain on an integrin for the MAP kinase, or a homolog, analog
20 or variant of the polypeptide.

Preferably, the polypeptide will be capable of binding with the binding site on the MAP kinase which binding site binds to the binding domain on the integrin.

In still another aspect of the invention there is provided a method of modulating activity of a cell, comprising causing the expression of an integrin to which a MAP kinase is able to bind to be down-regulated.

Preferably, down-regulation of the expression of the integrin is achieved using an
5 antisense nucleic acid sequence that inhibits expression of the gene encoding the integrin. The antisense nucleic acid sequence may be administered to the cell or generated *in vivo* with the cell. Preferably, the cell will be transformed with a vector of the invention for generation of the antisense nucleic acid sequence *in vivo*.

Preferably, the antisense nucleic acid sequence will specifically hybridise with the
10 sense nucleic acid sequence coding for the binding domain of the integrin for the MAP kinase and/or intron sequence between such coding sequence.

In another aspect of the present invention there is provided a method of prophylaxis or treatment of cancer in a mammal, comprising:

treating the mammal with an effective amount of an antisense nucleic acid for
15 hybridising with a nucleic acid encoding an integrin subunit to cause expression of the integrin subunit to be down-regulated wherein the integrin subunit has a binding domain for a MAP kinase.

In a still further aspect of the invention there is provided a method of modulating activity of a cell, comprising contacting the cell with an effective amount of an agent for
20 down regulating functional activity of an integrin expressed by the cell and thereby the activity of the cell.

In another aspect of the present invention there is provided a method of modulating activity of a cell, comprising:

contacting the cell with an effective amount of an agent capable of inhibiting
25 binding of a MAP kinase to a binding domain on an integrin expressed by the cell.

In a further aspect of the invention there is provided a method of modulating activity of a cell, comprising:

contacting the cell with an effective amount of an agent capable of binding to a MAP kinase to thereby inhibit binding of the MAP kinase to a binding domain on the integrin for the MAP kinase.

Preferably, the agent will be capable of binding to the binding site on the MAP
5 kinase which binding site binds to the binding domain on the integrin for the MAP kinase.

In a further aspect of the present invention there is provided a method of prophylaxis or treatment of a disease or condition in a mammal wherein modulation of cell activity is desirable, comprising:

10 administering to the mammal an effective amount of a nucleic acid sequence encoding an integrin subunit for being expressed, wherein the integrin subunit has a mutagenised binding domain for a MAP kinase or in which the binding domain is deleted, or a homolog, analog or variant of the integrin subunit.

In another aspect of the invention there is provided a method of prophylaxis or
15 treatment of a disease or condition in a mammal wherein modulation of cell activity is desirable, comprising:

administering to the mammal an effective amount of a nucleic acid of the invention capable of causing the expression of an integrin to which a MAP kinase is able to bind to be down regulated.

20 In still another aspect of the present invention there is provided a method of prophylaxis or treatment of a disease or condition in a mammal wherein modulation of cell activity is desirable, comprising:

administering to the mammal an effective amount of a nucleic acid sequence encoding a polypeptide for being expressed, wherein the polypeptide is capable of inhibiting binding of a MAP kinase with a binding domain of an integrin for the MAP kinase to thereby cause down-regulation of MAP kinase integrin binding, or a homolog, analog or variant of the polypeptide.

In another aspect of there is provided a method of treatment or prophylaxis of a disease or condition in a mammal, wherein said condition is responsive to an agent of the invention capable of inhibiting binding of a MAP kinase to binding domain on an integrin for the MAP kinase and the method comprises administering an effective amount of the agent to the mammal.

In another aspect there is provided use of a nucleic acid of the invention in the manufacture of a medicament for administration to a mammal in the prophylaxis or treatment of a disease or condition in which down regulation of cellular activity is desirable.

In a still further aspect of the invention there is provided the use of an agent capable of inhibiting binding of a MAP kinase to a binding domain of an integrin in the manufacture of a medicament for administration to a mammal for the prophylaxis or treatment of a disease or condition where down regulation of cellular activity is desirable.

The cellular activity desired to be down-regulated will typically but not exclusively, be cell growth. Indeed, any activity influenced by signalling mediated by MAP kinase activation is expressly included within the scope of the invention.

The cell may be any cell type in which functional activity of a MAP kinase arising from binding with an integrin may occur. Preferably, the cell will be an epithelial cell and most preferably, a neoplastic cell. By modulating the activity a neoplastic cell, methods of the invention find particular application in the prophylaxis or treatment of cancer. In particular, methods of the invention find particular application in the treatment of colon cancer.

Usually, the MAP kinase will be selected from the group consisting of an extracellular signal-regulated kinase (ERK) and a JNK MAP kinase. Preferably, the MAP kinase is ERK2 or JNK-1. Most preferably, the MAP kinase is ERK2.

The mammal may be any mammal treatable with a method of the invention. For instance, the mammal may be a member of the bovine, porcine, ovine or equine families, a laboratory test animal such as a mouse, rabbit, guinea pig, a cat or dog, a primate or a human being. Preferably, the mammal will be a human being.

The term "modulating" is to be taken as reference to down-regulating the activity of the cell or the functional activity of the integrin. Reference to "down-regulating" should be understood to include preventing, reducing or otherwise inhibiting one or more aspects of the activity of the cell or the functional activity of the integrin molecule or the MAP kinase

In the broadest sense, the term "integrin" unless otherwise specified, is to be taken to encompass an integrin family member or a homolog, derivative, variant or analog of an integrin subunit, or an integrin family member incorporating at least one such homolog, derivative, variant or analog of an integrin subunit. Usually, the integrin will be a member of the αv subfamily. Preferably, the integrin is or incorporates an integrin

By “binding domain” is meant the minimum length of contiguous amino acid sequence required for binding by the MAP kinase. By “core amino acid sequence” is meant regions or amino acids of the binding domain that directly participate in the binding as distinct from any amino acids that do not directly participate in the binding interaction with the MAP kinase. Typically, the core amino acid sequence of the binding domain will comprise regions of the binding domain linked together by a number of intervening amino acids which do not directly participate in the binding.

The term “homolog” is to be taken to mean a molecule that has amino acid sequence similarity. The homology between amino acid sequences can be determined by comparing amino acids at each position in the sequences when optimally aligned for the purpose of comparison. The sequences are considered homologous at a position if the amino acids at that position are the same. Typically, a homolog will have an overall amino acid sequence homology of at least about 30% more preferably at least about 50% or 70% and most preferably, greater than about 80%, 90% or 98% sequence homology. Homology with the binding domain of an integrin may be greater than the overall amino acid sequence homology of the homolog, and will usually be greater than about 60% or 80%, and more usually greater than about 90%, 95% or 98%.

The term “analog” is to be taken to mean a molecule that has one or more aspects of biological function characteristic of the molecule on which at least part of the analog is based or which was otherwise utilised in the design or preparation of the analog. An analog may have substantial overall structural similarity with the molecule or only

structural similarity with one or more regions or domains thereof responsible for the desired characteristic biological function. By "structural" similarity is meant similarity in shape, conformation and/or other structural features responsible for the provision of the biological function or which otherwise have involvement in the provision of the biological function. Alternatively, it will be understood that with knowledge of the region(s) or domain(s) of a molecule that provide(s) the characteristic biological function, analogs may be designed that while differing in structure nevertheless possess such biological function. Indeed, it is not necessary that an analog have amino acid sequence homology, and an analog may not be proteinaceous at all. An analog may for instance be a mimetic of a molecule.

By the term "variant" is meant an isoform of an integrin subunit, an integrin subunit encoded by an allelic variant of a gene for an integrin subunit, a naturally occurring mutant form of a gene for an integrin subunit, or an integrin subunit or polypeptide having an amino acid sequence that differs in one or more amino acids but which retains one or more aspects of desired characteristic biological function. This may be achieved by the addition of one or more amino acids to an amino acid sequence, deletion of one or more amino acids from an amino acid sequence and/or the substitution of one or more amino acids with another amino acid or amino acids. Inversion of amino acids and any other mutational change that results in alteration of an amino acid sequence are also encompassed. A variant may be prepared by introducing nucleotide changes in a nucleic acid sequence that encodes for an integrin subunit or amino acid sequence such that the desired amino acid changes are achieved upon expression of the mutagenised nucleic acid sequence, or for instance by synthesising an integrin subunit or

amino acid sequence incorporating the desired amino acid changes, both of which possibilities are well within the capability of the skilled addressee.

Substitution of an amino acid may involve a conservative or non-conservative amino acid substitution. By conservative amino acid substitution is meant replacing an amino acid residue with another amino acid having similar stereochemical properties (eg. structure, charge, acidity or basicity characteristics) and which does not substantially effect conformation or the desired aspect or aspects of characteristic biological function. Preferred variants include ones having amino acid sequences in which one or more amino acids have been substituted with alanine or other neutrally charged amino acid residue(s), or to which one or more such residues have been added. A variant may also incorporate an amino acid or amino acids that are not encoded by the genetic code.

By the term "derivative" is meant a molecule that is derived or obtained from another molecule and which retains one or more aspects of characteristic biological function of that molecule. A derivative may for instance arise as a result of the cleavage of the parent molecule, cyclisation and/or coupling with one or more additional moieties that improve solubility, lipophilic characteristics to enhance uptake by cells, stability or biological half-life, decreased cellular toxicity, or for instance to act as a label for subsequent detection or the like. A derivative may also result from post-translational or post-synthesis modification such as the attachment of carbohydrate moieties or chemical reaction(s) resulting in structural modification(s) such as the alkylation or acetylation of amino acid residues or other changes involving the formation of chemical bonds.

The term "polypeptide" is used interchangeably herein with "peptide" and encompasses amino acid sequences incorporating only a few amino acid residues or many amino acid residues coupled by peptide bonds.

The term "neoplastic cell" is to be taken to mean a cell exhibiting abnormal growth and may or may not be a malignant cell. "Growth" is to be taken in its broadest sense and includes proliferation of the cell. In this regard, an example of abnormal cell growth is the uncontrolled proliferation of a cell.

Unless the context clearly requires otherwise, throughout the description and the claims, the words 'comprise', 'comprising', and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".

The features and advantages of the present invention will become further apparent from the following detailed description of preferred embodiments and the accompanying drawings.

15 Brief Description Of The Accompanying Drawings

Figure 1: Surface biotinylation and immunoprecipitation of integrin subunits $\beta 5$ and $\beta 6$ in HT29 colon cancer cells stably transfected with either vector alone (mock transfectants) or antisense $\beta 6$ construct;

Figure 2: Amplification of $\beta 6$ and glyceraldehyde dehydrogenase (GAPDH) mRNA: Ethidium-stained agarose gels with amplification products following RT-PCR from total RNA extracted from transfected HT29 and WiDr cell lines. Equal amounts of PCR product obtained from RT-PCR reactions were loaded on each lane and the $\beta 6$ (141

basepairs) and GAPDH (216 basepairs) bands are indicated (WT, wild-type; S, sense $\beta 6$; A/S, antisense $\beta 6$; mock, vector alone);

Figure 3: Non-transfected HT29 cells (wild) and cells transfected with vector alone (mock), sense $\beta 6$ and antisense $\beta 6$ analysed by FACScan for expression of the $\beta 6$ subunit. White and black histograms represent cells stained in the absence and presence, respectively, of mAb E7P6 (anti- $\beta 6$);

Figure 4: WiDr cells transfected with vector alone (mock) or antisense $\beta 6$ and analysed by FACScan for expression of the $\beta 6$ subunit. White and black histograms represent cells stained in the absence and presence, respectively, of mAb E7P6 (anti- $\beta 6$);

Figure 5: Tumor cell proliferation *in vitro* assessed by (^3H)-thymidine uptake for WiDr wild-type cells and transfectants (mock and antisense $\beta 6$) cultured on plastic for the times indicated.

Figure 6: Tumor cell proliferation *in vitro* assessed by (^3H)-thymidine uptake for HT29 wild-type cells and transfectants (mock, sense $\beta 6$ and antisense $\beta 6$) cultured on plastic for the times indicated.

Figure 7: Tumour growth after 6 weeks following subcutaneous inoculation of 10^6 viable cells of HT29 mock (vector alone) and antisense $\beta 6$ transfectants;

Figure 8: Graph showing average tumour size at weekly intervals for each subgroup of 10 animals following subcutaneous inoculation of clone 1 from WiDr mock (vector alone) and antisense $\beta 6$ transfectants;

Figure 9: Graph showing average tumour size at weekly intervals for each subgroup of 10 animals following subcutaneous inoculation of HT29 mock (vector alone) and antisense $\beta 6$ transfectants;

Figure 10: $\beta 6$ -associated ERK identified by immunoprecipitations of integrin subunits from SW480 $\beta 6$ transfectants. (Top) Cell lysates were immunoprecipitated with mAbs QE2E5 (anti- $\beta 1$), L230 (anti- αv), P1F6 (anti- $\beta 5$), R6G9 (anti- $\beta 6$), or matched isotype control Abs (IgG1 and IgG2A), and (bottom) blotted with anti-ERK1/2 mAb, SC-1647, which recognises total ERK (phosphorylated and non-phosphorylated). Purified, non-phosphorylated ERK2 is shown in the left hand lane;

Figures 11(A) and 11(B): (A) Western blotting: equal protein loads of cell lysates from one representative clone each from WiDr mock and antisense $\beta 6$ blotted with anti-ERK mAb (SC-1647) against total ERK. Purified non-phosphorylated ERK2 is shown in the left hand lane. (B) $\beta 6$ immunoprecipitates (mAb R6G9) from equal protein loads of the cell lysates in (A) probed with anti-ERK mAb (E10). Purified phosphorylated ERK2 is shown in the left hand lane;

Figure 12: $\beta 6$ -bound ERK shown for the high and low SW480 $\beta 6$ -expressing clones by probing $\beta 6$ immunoprecipitates with anti-ERK mAb (E10) against phosphorylated forms of ERK1/2. Purified, phosphorylated ERK2 is shown in the left hand lane;

Figures 13(A) and 13(B): (A) Surface biotinylation of WiDr wild-type cells and $\beta 6$ immunodepletion of the cell lysates by three successive rounds of $\beta 6$ and $\beta 5$ immunoprecipitations using mAb R6G9 and P1F6, respectively or control mAb (IgG2A). The $\beta 6$ and partner αv bands are arrowed. (B) $\beta 6$ -immunodepleted WiDr cell

lysates after 3 successive rounds of $\beta 6$ -immunoprecipitations probed with anti-ERK mAb SC-1647 recognising both phosphorylated and non-phosphorylated forms of ERK1/2 and compared with non- $\beta 6$ immunodepleted lysates and control lysates sequentially immunoprecipitated 3 times with either isotype matched control mAb (IgG2A) or mAb P1F6 (anti- $\beta 5$);

Figure 14: Non-transformed (HaCaT) and Ras-transformed (HaRas) human keratinocytes: $\beta 6$ immunoprecipitation and ERK western blots probed with monoclonal antibody E10 (against Phosphorylated ERK 1/2) and monoclonal antibody SC1647 (against total ERK 1/2), respectively.

Figure 15(A) and 15(B): (A) Depletion of $\beta 6$ with sequential rounds of ERK immunodepletion of cell lysates using anti-ERK mAb (SC-1647). (B) MAP kinase activity in cell lysates before and after 5 rounds of sequential $\beta 6$ immunodepletion from SW480 $\beta 6$ and SW480 mock transfectants (full grey and hatched bars, respectively). MAP kinase activity is shown as the mean of three independent experiments. The reduction in MAP kinase activity following $\beta 6$ immunodepletion was highly significant ($P \leq 0.005$, students T test).

Figure 16: Shows the amino acid sequence of the cytoplasmic domain of the $\beta 6$ subunit as well as the amino acid sequences for the $\beta 1$ to $\beta 3$ subunits, respectively;

Figure 17: Graph showing binding of non-phosphorylated ERK2 (GST.ERK2) to overlapping fragments corresponding to different regions of the cytoplasmic domain of the $\beta 6$ subunit;

Figure 26: SW480 cells transfected with wild-type full length coding sequence for $\beta 6$ or $\beta 6 \Delta 746-764$ deletion mutant analysed by FACScan for expression of wild-type or mutant $\beta 6$. White and black histograms represent cells stained in the absence and presence of the integrin subunit, respectively.

Figures 27(A) and 27(B): (A) Western blotting: equal protein loads of cell lysates from SW480 cells expressing wild-type $\beta 6$ or $\beta 6$ $\Delta 746-764$ deletion mutant. (B) $\beta 6$ immunoprecipitates (mAb R6G9) from equal protein loads of cell lysates (A) probed with anti-ERK mAb (E10).

- 5 Figure 28: Proliferation of HT29 colon cancer cells cultured for 48 hours and treated with penetratin, the fragment of $\beta 6$ cytoplasmic domain having amino acid sequence RSKAKWQTGTNPLYR alone or the fragment coupled to penetratin for the final 24 hours of the incubation period.

- 10 Figure 29: Proliferation of SW480 cells expressing wild-type $\beta 6$ cultured on plastic for 48 hours and treated with penetratin, the RSKAKWQTGTNPLYR peptide alone or the peptide coupled to penetratin for the final 24 hours of the incubation period.

Figures 30 (A) to 29 (C): (A) SW480 cells cultured with control additive for 24 hours; (B) SW480 cells cultured with penetratin for 24 hours; (C) SW480 cells cultured with RSKAKWQTGTNPLYR bound to penetratin for 24 hours.

- 15 Figures 31(A) and 31(B): (A) SW480 mock (- $\beta 6$) and SW480 $\beta 6$ transfectants (+ $\beta 6$) cultured in presence of the RSKAKWQTGTNPLYR peptide coupled to penetratin. (B) Photomicrographs of cells shown in (A) cultured in the presence/absence of the peptide penetratin complex.

- 20 Figures 32(A) to 32(C): (A) SW480 cells cultured in a 3-dimensional collagen type I matrix photographed in the gel at the end of 10 days. (B) The SW480 cells following dissolution of the collagen with collagenase. (C) Graph showing numbers of colonies of the SW480 cells having a diameter exceeding 200 μ .

Figures 33(A) and 33(B): Graphs showing inhibition of proliferation of SW480 cells expressing full length wild-type $\beta 6$ in the presence of RSKAKWQTGTNPLYR peptide bound to penetratin.

Figure 34: Graph showing binding of ERK2 to RSKAKWQTGTNPLYR peptide and peptides corresponding to regions of the cytoplasmic domain of $\beta 3$ and $\beta 5$.

Detailed Description Of Preferred Embodiments Of The Present Invention

The distribution of $\beta 6$ integrin subunit within various tissues has been assessed by both *in situ* hybridisation and immunostaining and reported in the art. For instance, $\beta 6$ mRNA in adult primate tissues was detected only in epithelial cells and at very low or undetectable levels in most normal tissues (Breuss et al, 1993). High-level expression of $\beta 6$ has been observed in secretory endometrial glands while low-level expression was detected in the ductal epithelia of salivary gland, mammary gland and epididymis, in gall and urinary bladder, and in the digestive tract. Immunostaining data has also shown that $\beta 6$ expression is restricted to epithelia and is up-regulated in parallel with morphogenetic events, tumourigenesis and epithelial repair (Breuss et al, 1993; 1995). During development of the kidney, lung and skin, $\beta 6$ is expressed by specific types of epithelial cells, whereas it is mostly undetectable in normal adult kidney, lung and skin. In contrast, high level expression of $\beta 6$ has been observed in several types of carcinoma. For example, $\beta 6$ is almost invariably neo-expressed in squamous cell carcinomas derived from the oral mucosa, and often focally localised at the infiltrating edges of tumour cell islands (Breuss et al, 1995; Thomas et al, 1997). Moreover, expression of the $\beta 6$ subunit has been observed in renal cell carcinoma and testicular tumour cell lines (Takiuchi et al,

1994) and 50% of lung cancers have been shown to express this subunit (Smythe et al, 1995).

Expression of $\beta 6$ is also up-regulated in migrating keratinocytes at the wound edge during experimental epidermal wound healing. $\alpha v\beta 6$ is not expressed in normal

epithelium (Jones et al, 1997). However, following experimental wounding, αv appears to switch its heterodimeric association from $\beta 5$ to $\beta 6$ subunit during re-epithelialisation.

At day 3 after wounding, $\beta 6$ is absent but then appears around the perimeter of the basal cells of the migrating epidermis (Clark et al, 1996). By day 14 after wounding, when re-epithelialisation is complete, all suprabasilar cells overlying the wound express $\beta 6$ but

not $\beta 5$. In human mucosal wounds, maximal expression of $\beta 6$ has been observed relatively late when epithelial sheets are fused and granulation tissue is present

(Haapasalmi et al, 1996). Furthermore, those investigators observed maximal expression of tenascin with $\alpha v \beta 6$ expression. Interestingly, freshly isolated keratinocytes have not been found to express $\beta 6$ but begin to express this after subculturing (Haapasalmi et al,

1996). Moreover, TGF- β 1 has been shown to induce the *de novo* expression of α v β 6 at the cell surface on keratinocytes (Zambruno et al, 1995). This is particularly relevant in view of the recent observation that α v β 6 binds and activates latent TGF- β 1 which may be a means of locally regulating TGF- β 1 function *in vivo* during tissue response to injury (Munger et al, 1999).

$\alpha\text{v}\beta 6$ expression is also upregulated in type II alveolar epithelial cells during lung injury caused by injection of live bacteria and $\alpha\text{v}\beta 6$ mRNA is induced within 5 hours of acute injury (Breuss et al, 1995). Interestingly, $\alpha\text{v}\beta 6$ has been shown to be expressed on proximal airway epithelial cells in 50% of smokers undergoing lung resection

(Weinacker et al, 1995). Just as in human keratinocytes, in primary cultures of human airway epithelial cells, TGF- β 1 has been shown to dramatically increase expression of α v β 6 without affecting surface expression of any other integrin. Moreover, epidermal growth factor (EGF) also induces α v β 6 in these cells, and the effect of both growth factors on β 6 expression has been shown to be additive (Wang et al, 1996). α v β 6 expression has also been observed in adult lungs and kidneys at focal sites of sub-clinical inflammation as well as in a variety of clinical specimens from patients with chronic or acute inflammation of the lungs or kidneys (Breuss et al, 1995). Taken together these data indicate that α v β 6 affects cell spreading, migration and growth during re-organisation of epithelia in development, tissue repair and neoplasia.

Recent studies have shown that α v β 6 is a major fibronectin-binding receptor in colorectal cancer (Agrez et al, 1996). Moreover, normal colonic epithelium from cancer patients does not express α v β 6 in immunostaining studies, and as with squamous cell carcinomas from the oral mucosa (Thomas et al, 1997) maximal β 6 expression in colon cancer has been observed at the invading edges of tumour cell islands (Agrez et al, 1996). Importantly, heterologous expression of the β 6 subunit in colon cancer cells lacking constitutive expression of this receptor has been shown to stimulate tumour cell proliferation *in vitro* and tumour growth in athymic immune-deficient mice, and this growth-promoting effect is mediated through the 11 amino acid C-terminal cytoplasmic extension unique to the β 6 subunit (Agrez et al, 1994). These findings suggest that one mechanism of the enhanced growth effect involves induced secretion of matrix-degrading enzymes as has been previously suggested for invasive melanoma cells. Support for this arises from findings that the proliferative capacity of colon cancer cells

within 3-dimensional collagen matrices is inversely related to the density of the extracellular matrix (Agrez, 1989), and the observation that induced expression of $\alpha V\beta 6$ in colon cancer cells markedly enhances gelatinase B secretion (Agrez et al, 1999).

The $\beta 6$ subunit is widely observed in cancers of various origins (Breuss et al, 1995). As described above, $\beta 6$ is detected in at least 50% of bowel cancer tumours. Others have reported its presence in oropharyngeal cancers where it is also present and strongly expressed in the invading margins of the cancer cell islands as is commonly found in bowel cancer. In the oropharyngeal mucosa, no $\beta 6$ is observed in the normal lining cells of the mouth but in both primary and metastatic tumours from the oropharyngeal mucosa, strong $\beta 6$ expression is seen which does not correlate with degree of differentiation and in particular, is restricted to the basal layer of epithelial cells. In colon cancer, $\beta 6$ expression is similarly maximal at the advancing edges of tumour cell islands (Agrez et al, 1996).

Hence, modulation of MAP kinase interaction with the $\beta 6$ subunit in epithelial cells may be used in the prophylaxis or treatment of cancer of the lip, tongue, salivary glands, gums, floor and other areas of the mouth, oropharynx, nasopharynx, hypopharynx and other oral cavities, oesophagus, stomach, small intestine, duodenum, colon, rectum, gallbladder, pancreas, larynx, trachea, bronchus, lung, female and male breast, uterus, cervix, ovary, vagina, vulva, prostate, testes, penis, bladder, kidney, thyroid and skin.

In terms of prophylactic use, a method of the invention may find application in protecting against ultraviolet-induced skin cancer, lung cancer in smokers, cancer of the gut where polyps are present as in polyposis coli or other inheritable disease where a pre-

disposition to the development of polyps exists, breast cancer in high risk patients with a familial history of breast cancer or otherwise identified as carrying known mutations of the breast cancer susceptibility gene BRCA1 or BRCA2 associated with breast cancer, transitional cell cancers arising from bladder papillomas, and cancer of the cervix in
5 individuals deemed to be at high risk.

The epithelial restricted integrin subunit $\beta 6$ is shown herein to interact with at least MAP kinases ERK2 and JNK-1, and its down-regulation in the present study dramatically suppresses growth of colon cancer. Hence, therapeutic strategies to inhibit growth and proliferation of colon cancer and growth of other malignant cancer cells
10 growth by switching off either the permissive $\beta 6$ integrin and/or inhibiting the $\beta 6$ MAP kinase interaction are of particular interest. In particular, the fact that $\beta 6$ expression may be significantly upregulated on tumour cells compared to normal cells offers the potential for tumour cell specificity substantially without impairment of normal cellular function.

15 Down-regulation of the functional activity of an integrin can be achieved in a number of ways and in particular, by preventing or down-regulating the expression of the integrin molecule or by inhibiting the signalling function of the integrin.

Gene therapy is one strategy for treating cancers of different types. The use of recombinant adenoviruses has for instance been utilised for restoring expression of
20 polypeptide encoded by a wild-type p53 tumour suppressor gene (Bookstein et al, 1996), and adenoviral vectors for expression of wild-type p53 have been shown to suppress growth of human colon cancers by as much as 60% in animal models following intra-tumoural injection of recombinant virus (Spitz et al, 1996).

Rather than replacing a defective gene with one encoding a polypeptide the expression of which restores normal function of the cell as in the above examples, the possibility exists to achieve down regulation of cancer cells such as colon cells by introducing a gene that encodes an integrin subunit in which the binding domain for
5 interacting with a MAP kinase has been rendered defective by mutagenesis, or in which the binding domain has been wholly or partially deleted, to thereby achieve down regulation through the inhibition of the MAP kinase integrin interaction. The defective integrin subunit will nevertheless usually be able to associate with its normal partner integrin subunit and be expressed on the cell membrane. Preferably, the defective
10 integrin subunit will be expressed at a higher level than the corresponding wild-type integrin subunit such that down regulation is achieved by a dominant negative effect. Alternatively, such therapy may involve the introduction and expression of a nucleic acid sequence that encodes a fragment or truncated form of an integrin subunit that excludes the binding domain for the MAP kinase or in which the binding domain has
15 been partially or wholly deleted or otherwise mutagenised so as to be defective.

Another option is to introduce a nucleic acid sequence encoding a polypeptide capable of binding to the binding domain on the integrin for the MAP kinase or to the binding site on the MAP kinase upon being expressed within the cell to thereby inhibit binding of the MAP kinase to the integrin and thereby achieve down regulation of
20 cellular activity.

A gene or nucleic acid sequence encoding an integrin subunit may also be modified such that although the encoded binding domain for the MAP kinase remains unaltered, the amino acid sequence of a region of the integrin subunit distant from the

binding domain, or the amino acid sequence of either one or both regions flanking the binding domain, is altered to achieve a change in the three dimensional conformation of the integrin subunit such that the binding of the MAP kinase with the binding domain is inhibited.

5 The gene or nucleic acid sequence may be altered to achieve the desired outcome by the deletion, insertion or substitution of one or more nucleotides such that the corresponding amino acid sequence is modified to the extent that the binding of the MAP kinase to the integrin is inhibited. Inhibition in this context may be partial or total inhibition.

10 The gene or nucleic acid sequence can be introduced into a cell in an appropriate expression vector for expression of the gene or nucleic acid sequence extrachromosomally or more preferably, for facilitating integration of the gene or nucleic acid sequence into genomic DNA by heterologous or homologous recombination events.

 In another strategy, down-regulation of the expression of an integrin subunit such as $\beta 6$ and hence an integrin heterodimer such as $\alpha v\beta 6$, is achieved using antisense
15 nucleic acid sequences (e.g. oligonucleotides) for inhibiting expression of the subunit. Typically, this will involve expression of a nucleic acid construct incorporating all or part of a coding region of the gene for the integrin subunit inserted in the reverse orientation resulting in the synthesis of antisense RNA which inhibits translation of
20 mRNA encoding the integrin subunit by hybridisation of the antisense RNA to the mRNA.

 More broadly, a method of down regulating an activity of a cell may comprise contacting the cell with a first nucleic acid molecule that is capable of interacting with a

target nucleic acid sequence, or which first nucleic acid molecule is capable of being transcribed to a nucleic acid molecule capable of interacting with the target sequence whereby the interaction of the first nucleic acid molecule with the target sequence inhibits expression of the integrin subunit.

5 Reference to the first nucleic acid molecule is to be understood as a reference to any nucleic acid molecule which directly or indirectly facilitates reduction, inhibition or other form of down regulation of the expression of the integrin molecule. Nucleic acid molecules which fall within the scope of this definition include antisense sequences administered to a cell and antisense sequences generated *in situ* which have sufficient
10 complementarity with target sequence such as mRNA encoding the integrin subunit or for instance, a transcription regulatory sequence controlling transcription of the gene encoding the integrin subunit, to thereby be capable of hybridising with the target sequence and inhibit the expression of the integrin subunit. The first nucleic acid molecule may also be a ribozyme capable for instance, specifically binding to that region
15 of nucleic acid encoding the binding domain of an integrin subunit and cleaving the nucleic acid.

On *a priori* grounds, targeting the expression of the $\beta 6$ subunit in malignant cells such as in colon cancer by means of adenoviral-mediated antisense therapy is preferred because down-regulating $\beta 6$ by means of a non-adenoviral approach may increase cell
20 surface expression of the $\beta 5$ subunit. The relevance to such therapy is that the vitronectin-binding integrin $\alpha \beta 5$ promotes adenovirus internalisation (Thomas et al, 1993). Given that abundant $\alpha \beta 5$ is always present on the surface of colon cancer cells for example, a secondary benefit of inhibiting $\beta 6$ expression during the course of therapy

may be the concomitant rise of $\beta 5$ in cells already transduced with antisense $\beta 6$ nucleic acid. This is likely to facilitate further virus uptake into such cells since the amount of integrin $\alpha v\beta 5$ present has been shown to be closely related to levels of gene expression following adenovirus-mediated gene transfer (Takayama et al, 1998).

5 Typically, an antisense nucleic acid sequence will hybridise with all or part of that region of the target sense nucleic acid encoding the binding domain. An antisense nucleic sequence may for instance be capable of hybridising to exon and/or intron sequences of pre-mRNA. Preferably, an antisense nucleic acid sequence will be designed for specifically hybridising to mature mRNA in which intron sequences have
10 been spliced out by normal cellular processing events.

It is not necessary that an antisense nucleic acid sequence have total complementarity with its target sequence only that substantial complementarity exists for specificity and to allow hybridisation under cellular conditions. Preferably, an antisense nucleic sequence will have a complementarity of about 70% or greater, more
15 preferably about 80% or greater and most preferably, about 90% or 95% or greater. Preferred antisense sequences are oligonucleotides wherein the complementary sense nucleotides encode for about 50 amino acids or less, preferably about 35 or 30 amino acids or less, more preferably less than about 25 or 20 amino acids, most preferably about 15 amino acids or less and usually between about 5 to about 15 amino acids.

20 Antisense nucleic acid sequences may be generated *in vivo* by transcription of a suitable expression vector within a cell transformed with the vector, or *ex vivo* and then be introduced into a target cell to effect down regulation of the MAP kinase integrin interaction. Antisense sequences will desirably be designed to be resistant to

endogenous exonucleases and/or endonucleases to provide *in vivo* stability in target cells. Modification to the phosphate backbone, sugar moieties or nucleic acid bases may also be made to enhance uptake by cells or for instance solubility, and all such modifications are expressly encompassed. Such modifications include modification of

5 the phosphodiester linkages between sugar moieties, the utilisation of synthetic nucleotides and substituted sugar moieties, linkage to lipophilic moieties and the such like as described in US Patent No. 5,877,309. Methods for the construction of oligonucleotides for use in antisense therapy have previously been described (see Van der Krol et al, 1998 *Biotechniques* 6:958-976; and Stein et al, 1998 *Cancer Res* 48:2659-

10 2668; Bachman et al, 1998, *J. Mol. Med.* 76:126-132).

Any means able to achieve the introduction of a gene or a nucleic acid into a target cell may be used. Gene transfer methods known in the art include viral and non-viral transfer methods. Suitable virus into which appropriate viral expression vectors may be packaged for delivery to target cells include adenovirus (Berkner, 1992; Gorziglia and

15 Kapikian, 1992); vaccinia virus (Moss, 1992); retroviruses of avian (Petropoulos et al, 1992); murine (Miller, 1992) and human origin (Shimada et al, 1991); herpes viruses including Herpes Simplex Virus (HSV) and EBV (Margolskee, 1992; Johnson et al, 1992; Fink et al, 1992; Breakfield and Geller, 1997; Freese et al, 1990); papovaviruses such as SV40 (Madzak et al, 1992), adeno-associated virus (Muzyczka, 1992); BCG and

20 poliovirus. Particularly preferred virus are replication deficient recombinant adenovirus (eg. He et al, 1998). Engineered virus may be administered locally or systemically to achieve delivery of the gene or nucleic acid sequence of interest into a target cell.

Gene transfer methods as described above may be used in the provision of transgenic animals for studying *in vivo* the effect of for instance, modifying the binding site of an integrin for a MAP kinase interaction. A transgenic animal is one with cells that contain heterologous nucleic acid as a result of the deliberate introduction of the nucleic acid. The nucleic acid may be introduced indirectly by viral transfer as indicated above or directly by microinjection into a pronucleus of a fertilised egg prior to transfer of the egg to a surrogate mother for development to term. Alternatively, a gene or nucleic acid sequence of interest may be introduced into an embryonal stem (ES) cell in culture and the transformed cell injected into a recipient blastocyst which is then transferred to a surrogate mother for development to term. Techniques for generation of transgenic animals are for instance described in US Patent No. 4,873,191; Van der Putten, 1985; Thompson et al, 1989 and Lo, 1983.

A transgenic animal homozygous for a transferred gene for instance may be obtained by the mating of animals heterozygous for the gene as will be appreciated. Both animal cells expressing a heterologous gene or nucleic acid sequence and transgenic animals in which a particular gene has been mutagenised by homologous recombination may be provided. A transgenic animal may for instance be a mouse, rat, hamster or pig. Typically, the transgenic animal will be a mouse.

Agents for modulating the functional activity of a cell arising from the interaction of a MAP kinase like ERK2 or JNK-1 with an integrin include antagonists and inhibitors capable of associating with the integrin to thereby inhibit the MAP kinase and integrin interaction. Antagonists and inhibitors include those agents that act by binding the integrin adjacent to the binding domain and sterically hindering the interaction of the

MAP kinase with the integrin, as well as allosteric inhibitors that distort the binding domain upon associating with the integrin.

The binding domain of an integrin may be identified and characterised using protocols and techniques described herein. Specifically, a binding domain may be

5 localised by assessing the capacity of respective overlapping peptide fragments corresponding to different regions of the cytoplasmic domain of an integrin subunit to associate with a MAP kinase. The specific amino acid sequence which constitute the binding domain for the MAP kinase may then be determined utilising progressively smaller peptide fragments of the region of the cytoplasmic domain of the integrin

10 subunit observed to interact with the MAP kinase. In particular, test peptides are readily synthesised to a desired length involving deletion of an amino acid or amino acids from either or both ends of the amino acid sequence corresponding to that region each time, and tested for their ability to associate with the MAP kinase. This process is repeated until the minimum length peptide capable of associating with the MAP kinase

15 substantially without compromising the optimum observed level of association is identified. The specific amino acids that play an active role in the interaction with the MAP kinase is achieved with the use of further synthesised test peptides in which one or more amino acids of the sequence are deleted or substituted with a different amino acid or amino acids to determine the effect on the ability of the peptide of associate with the

20 MAP kinase. Typically, substitution mutagenesis will involve substitution of selected ones of the amino acid sequence with alanine or other relatively neutrally charged amino acid. By deletion is meant deletion of one or more of the amino acids between the N-terminal and C-terminal amino acid residues of the identified amino acid sequence.

Nucleotide and amino acid sequence data for the $\beta 6$ integrin subunit for instance is found in Sheppard et al, 1990. The amino acid sequence for $\beta 6$ is also set out in SEQ ID NO: 1. Reference to such published data allows the ready design of peptide fragments of an integrin subunit cytoplasmic domain for use in the identification and localisation of the binding domain for a MAP kinase, and the identification of the corresponding nucleic acid sequence encoding such peptide fragments as well as the amino acid sequence of the binding domain.

Localisation and characterisation of the binding domain for a MAP kinase enables the design of agents for use in down regulating the functional activity of the integrin and more particularly, the binding interaction of the MAP kinase with the integrin. This will typically involve determining the physical properties of the binding domain such as size and charge distribution, and the tertiary structure of the binding domain.

Specifically, at least the region of the integrin containing the binding domain is modelled taking into account the stereochemistry and physical properties of the binding domain such as size and charge distribution as well as its three dimensional structure as determined using x-ray crystallography, nuclear magnetic resonance and/or commercially available computer modelling software. In a variation of this approach, the modelling will take into account the interaction of the binding domain with the MAP kinase such that any change in conformation arising from the interaction may be taken into account in the design of an agent. Modelling flanking regions adjacent the binding domain also allows the design of agents for associating with such flanking regions but which are nevertheless capable of inhibiting the binding domain MAP kinase interaction

either by steric hindrance or by distorting the conformation of the binding domain (eg. allosteric inhibitors).

The design of a mimetic of the binding domain will usually involve selecting or deriving a template molecule onto which chemical groups are grafted to provide required physical and chemical characteristics. The selection of template molecule and chemical groups is based on ease of synthesis, likely pharmacological acceptability, risk of or potential for degradation *in vivo*, stability and maintenance of biological activity upon administration. Pharmacological acceptability and the like are also taken into consideration in the design of other agent types.

In order to constrain a polypeptide or other agent in a three dimensional conformation required for binding, it may be synthesised with side chain structures or otherwise be incorporated into a molecule with a known stable structure *in vivo*. In particular, a polypeptide or the like may be incorporated into an amino acid sequence at least part of which folds into a β -pleated sheet or helical structure such as an α -helix (eg. see Dedhar et al., 1997).

A polypeptide or other agent may also be cyclised to provide enhanced rigidity and thereby stability *in vivo*. Various methods for cyclising peptides, fusion proteins or the like are known (eg. Schiller et al., 1985). For example, a synthetic peptide incorporating two cysteine residues distanced from each other along the peptide may be cyclised by the oxidation of the thiol groups of the residues to form a disulfide bridge between them. Cyclisation may also be achieved by the formation of a peptide bond between the N-terminal and C-terminal amino acids of a synthetic peptide or for instance through the formation of a bond between the positively charged amino group on the side chain of a

lysine residue and the negatively charged carboxyl group on the side chain of a glutamine acid residue. As will be understood, the position of the various amino acid residues between which such bonds are formed will determine the size of the cycle.

Variation of cycle size for optimisation of binding affinity may be achieved by

5 synthesising peptides in which the position of amino acids for achieving cyclisation has been altered. The formation of direct chemical bonds between amino acids or the use of any suitable linker to achieve cyclisation is also well within the scope of the skilled addressee.

Further strategies for identifying possible agents include large scale screening
10 techniques as are known in the art. For example, peptide library technology provides an efficient way of testing a vast number of potential agents. Such libraries and their use are well known. Prospective agents identified may be then further evaluated in suitable activity, competitive and other immunoassays. A method of screening for an agent or evaluating whether an agent is capable of binding to a MAP kinase or an integrin and
15 thereby inhibiting binding of the MAP kinase to the binding domain of the integrin may for instance involve utilising the agent in an assay whereby the agent has the opportunity of binding to the MAP kinase or the integrin in the presence of the integrin or the MAP kinase as the case may be or prior to the addition of the integrin or the MAP kinase, and determining whether inhibition of binding of the MAP kinase to the integrin results. An
20 alternate screening method may for instance involve selecting a test agent capable of binding with the integrin or MAP kinase, measuring cellular activity in the presence of the test agent, and comparing that activity with cellular activity in the absence of the test agent. Cellular activity may be assessed by cell growth as indicated by [³H]-thymidine

uptake or other measurement of cellular activity. As will be understood, a difference in observed functional activity in the presence of the test agent is indicative of the modulating effect provided by the test agent.

It will also be understood that the integrin in the context of such assays may be an integrin subunit or polypeptide or fragment incorporating the binding domain of the integrin for the MAP kinase, or a homolog, analog, variant or derivative of such a molecule to which the MAP kinase is capable of binding. In addition, determination of whether an agent is capable of binding to the binding domain of an integrin may be readily achieved by using a polypeptide or fragment as described herein consisting of the binding domain of the integrin or core amino acid sequence of the binding domain that directly participates in the binding interaction with the MAP kinase or analogs or the like of such molecules.

It is not necessary that an agent be proteinaceous in character and indeed, mimetics may be prepared which may not be a polypeptide at all but which nevertheless possess the capability of binding with the integrin.

Polypeptides including fusion proteins and fragments of an integrin subunit comprising the binding domain for a MAP kinase or incorporating sufficient core amino acid sequence of the binding domain for binding by the MAP kinase are encompassed by the present invention. Typically, a polypeptide of the invention will have a length of about 150 amino acids or less, more preferably about 100 or 50 amino acids or less and generally, less than about 40 amino acids. Preferably, the length will be from between about 5 to about 30 amino acids, and more preferably from between about 5 amino acids and about 25 amino acids. Preferably, a polypeptide will comprise or incorporate the

amino acid sequence RSKAKWQTGTNPLYR, more usually the amino acid sequence RSKAKNPLYR, or one or both of sequences RSKAK and NPLYR.

- Polypeptides and fusion proteins or the like may be synthesised or produced using conventional recombinant techniques. Nucleic acid encoding a fusion protein may for instance be provided via the joining together of separate DNA fragments encoding peptides or polypeptides having desired three dimensional conformations and/or other characteristics by employing blunt-ended termini and oligonucleotide linkers, digestion to provide staggered termini as appropriate, and ligation of cohesive ends prior to insertion of the resultant chimeric sequence into a suitable expression vector.
- Alternatively, PCR amplification of DNA fragments can be utilised employing primers which give rise to amplicons with complementary termini which can be subsequently ligated together (eg. see Current Protocols in Molecular Biology. John Wiley & Sons, 1992).

- Nucleic acid sequences encoding for the polypeptides, mutagenised integrin subunits and the like as described herein are also encompassed by the present invention as are the respective complementary antisense nucleic acid sequences.

- Sense oligonucleotides encoding for the binding site of an integrin subunit or a partial amino acid sequence of a binding domain, and the complementary antisense oligonucleotides are particularly suitable for use as primers in polymerase chain reaction (PCR) amplification methods or as probes for detection of the presence the respective target nucleic acid sequences with which they hybridise such as in Southern blotting protocols, or in affinity chromatography purification of the target nucleic acid sequence. Probes may be labelled with for instance commonly used isotopes such as P^{32} ,

fluorophores, chemiluminescent agents and enzymes (see eg. Essential Molecular Biology. A Practical Approach Vol. II, Oxford University Press, 1993; Current Protocols in Molecular Biology, Ausubel FM., John Wiley & Sons Inc., 1998). The choice of a label will vary depending on the degree of sensitivity required, ease of conjugation with the probe, safety and other factors.

Oligonucleotides for use as probes or primers will usually have a length of less than about 60 nucleotides, usually less than about 50 or 40 nucleotides preferably, between about 14 and about 30 nucleotides, and more preferably, between about 14 and about 25 nucleotides. While it is desirable that a primer or probe has 100% complementarity with its target sequence, oligonucleotides may be designed with less complementarity but which nevertheless hybridise with the target sequence. Typically, a primer or probe will have a complementarity of about 70% or greater, more preferably about 80% or greater and most preferably about 90% or 95%, or greater. A probe will generally be designed for being capable of hybridising with its target nucleic acid sequence under moderate or high stringency wash conditions. Moderate stringency wash conditions are for example those that employ 0.2 x SSC (0.015M NaCl/0.0015M sodium citrate) /0.1% SDS (sodium dodecylsulfate) wash buffer at 42°C. High stringency wash conditions employ for instance, 0.1 x SSC wash buffer at 68°C. Generally, the content of purine relative to the content of pyrimidine nucleotides in the region of target nucleic acid of interest will be taken into account in the design of such primers and probes as will be their length in accordance with well accepted principles known in the art.

In addition, the present invention provides vectors incorporating nucleic acid sequences of the invention. The term "vector" is to be taken to mean a nucleic acid

Numerous expression vectors suitable for transfection of prokaryotic (eg. bacterial) or eukaryotic (eg yeast, insect or mammalian cells) are known in the art. Expression vectors suitable for transfection of eukaryotic cells include pSV2neo, pEF.PGK.puro, pTk2, pRc/CNV, pcDNA1/neo, non-replicating adenoviral shuttle vectors incorporating the polyadenylation site and elongation factor 1- α promotor and pAdEasy based expression vectors most preferably incorporating a cytomegalovirus (CMV) promotor (eg. see He et al, 1998). For expression in insect cells, baculovirus expression vectors

may be utilised examples of which include pVL based vectors such as pVL1392, and pVL941, and pAcUW based vectors such as pAcUW1. Viral expression vectors are particularly preferred.

Typical cloning vectors incorporate an origin of replication (*ori*) for permitting efficient replication of the vector, a reporter or marker gene for enabling selection of host cells transformed with the vector, and restriction enzyme cleavage sites for facilitating the insertion and subsequent excision of the nucleic acid sequence of interest. Preferably, the cloning vector has a polylinker sequence incorporating an array of restriction sites. The marker gene may be drug-resistance gene (eg. Amp^r for ampicillin resistance), a gene encoding an enzyme such as chloramphenicol acetyltransferase (CAT), β -lactamase, adenosine deaminase (ADA), aminoglycoside phosphotransferase (APH), dihydrofolate reductase (DHFR), hygromycin-B-phosphotransferase (HPH), thymidine kinase (TK), or for instance β -galactosidase encoded by the *E. coli lacZ* gene (*LacZ'*). Yeast reporter genes include imidazole glycerolphosphate dehydratase (HIS3), *N*-(5'-phosphoribosyl)-anthranilate isomerase (TRP1) and β -isopropylmalate dehydrogenase (LEU2). As will be appreciated, expression vectors of the invention may also incorporate such marker genes.

Cloning vectors include cloning vectors for mammalian, yeast and insect cells. Particular vectors that may find application include pBR322 based vectors and pUC vectors such as pUC118 and pUC119. Suitable expression and cloning vectors are for instance described in Molecular Cloning. A Laboratory Manual., Sambrook et al., 2nd Ed. Cold Spring Harbour Laboratory., 1989.

Host cells suitable for being transformed by vectors of the invention include bacteria such as *E. coli*, Bacillus such as *B. subtilis*, Streptomyces and Pseudomonas bacterial strains, yeast such as Sacchromyces and Pichia, insect cells, avian cells and mammalian cells such as Chinese Hamster Ovary cells (CHO), COS, HeLa, HaRas, WI38, SW480, and NIH3T3 cells. Host cells may be cultured in a suitable culture medium and under conditions for facilitating expression of nucleic acid sequences of the invention or replication of cloning vectors, prior to purification from the host cells, and/or supernatants as the case may be using standard purification techniques.

Rather than utilising viral mediated transfection of cells, nucleic acid sequences and other molecules of the invention may also be delivered to a cell *in vitro* or *in vivo* by liposome mediated transfection. The liposomes may carry targeting molecules for maximising delivery of the agent or agents contained therein to specific cell types of interest. Such targeting molecules may be for instance antibodies, ligands or cell surface receptors for facilitating fusion of liposomes to the specific cells of interest. Agents may also be intracellularly delivered *in vitro* using conventional cold or heat shock techniques or for instance, calcium phosphate coprecipitation or electroporation protocols. Yet another strategy is to design the agent to have the inherent ability to pass across the lipid bilayer of a cell.

A particularly preferred way of achieving intracellular delivery of an agent is to use "carrier peptides" which have the ability to deliver macro-molecules across cell membranes in an energy-independent manner (Prociantz, 1996). Indeed, such peptides provide the possibility of both testing potential agents in cell culture without drastically altering cell membrane integrity and of delivering agents *in vivo*. Carrier peptides that

are known in the art include penetratins and variants thereof (Derossi et al, 1994, 1996), human immunodeficiency virus Tat derived peptide (Prociantz, 1996), and transportan derived peptide (Pooga et al. 1998). Indeed, carrier peptides have been successfully used to facilitate internalisation of mimetics of Src homology 2 binding sites, and peptides which inhibit protein kinase C mediated axon development and CD44 (hyaluronate receptor) dependent migration (Theodore et al, 1995; Williams et al, 1997; Peck Isacke, 1998; Derossi et al, 1998).

Specific targetting to $\beta 6$ -expressing cancer cells may also be achieved by coupling humanised anti- $\beta 6$ antibody to carrier molecules such as penetratin coupled to an agent capable of inhibiting binding of a MAP kinase with an integrin expressed by the cell or down regulation of the expression of the integrin. Coupling may for instance be by a peptide bond or disulfide bridge. Given that $\beta 6$ expression enhances effective proteolysis at the cell surface by matrix metalloproteinase-9 (Agrez et al, 1999), such targetting approaches may include engineering an MMP-9 cleavage site between the antibody and the carrier peptide penetratin to facilitate internalisation of the penetratin-agent complex. Another approach may employ coupling the penetratin-agent complex to $\beta 6$ integrin receptor-targetted peptides, targetted for binding to the extracellular $\beta 6$ domain by virtue of their DLXXL sequence. For example, a ligand recognition motif for $\alpha V \beta 6$ integrin, RTDLSLRITYTL (Kraft et al, 1999) may be used in conjunction with or without an engineered MMP-9 cleavage site to release the penetratin-agent complex at the cell surface. Further protocol for targetting nucleic acids to cells by targetting integrins is described in Bachmann et al, 1998.

The toxicity profile of an agent of the invention may be tested on normal and malignant cells by evaluation of cell morphology, trypan-blue exclusion, assessment of apoptosis and cell proliferation studies (eg cell counts, ^3H -thymidine uptake and MTT assay).

5 Agents of the invention may be co-administered with one or more other compounds or drugs. For example, an agent or agents may be administered in combination with antisense therapy or chemotherapeutic drugs. Alternatively, an agent may be administered in conjunction with antisense therapy and/or chemotherapeutic drugs. By "co-administered" is meant simultaneous administration in the same
10 formulation or in two different formulations by the same or different routes, or sequential administration by the same or different routes. By "sequential" administration is meant a time difference of between the administration of the agents, drugs and other therapies which can be administered in any order. The time difference may range from very short times up to hours or for instance days or weeks.

15 The agent or agents will typically be formulated into pharmaceutical composition incorporating pharmaceutically acceptable carriers, diluents and/or excipients for administration to the intended subject.

Pharmaceutical forms include sterile aqueous solutions suitable for injection, (where the agent or agents is water soluble) and sterile powders for the extemporaneous
20 preparation of sterile injectable solutions. Such injectable compositions will be fluid to the extent that the syringability exists and typically, will be stable to allow for storage after manufacture. The carrier may be a solvent or dispersion medium containing one or more of ethanol, polyol (eg glycerol, propylene glycol, liquid polyethylene glycol and

the like), vegetable oils, and suitable mixtures thereof. Fluidity may be maintained by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of a dispersion and by the use of surfactants.

Sterile injectable solutions will typically be prepared by incorporating the active
 5 agents in the desired amount in the appropriate solvent with various other components enumerated above, prior to sterilising the solution by filtration. Generally, dispersions will be prepared by incorporating the sterile active agents into a sterile vehicle which contains the dispersion medium and other components. In the case of sterile powders for the preparation of sterile injectable solutions, preferred methods of preparation are
 10 vacuum drying and freeze-drying techniques which yield a powder of the active agent plus any additional desired ingredient from previously sterile filtered solutions thereof.

For oral administration, the active agents may be formulated into any orally acceptable carrier deemed suitable. In particular, the active ingredient may be formulated with an inert diluent, an assimilable edible carrier or it may be enclosed in a
 15 hard or soft shell gelatin capsule. Alternatively, it may be incorporated directly into food. Moreover, an active agent may be incorporated with excipients and used in the form of ingestable tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, and the like.

Such compositions will generally contain at least about 1% by weight of the active
 20 agent or agents. The percentage may of course be varied and may conveniently be between about 5 to about 80% w/w of the composition or preparation. As will be appreciated, the amount of active agent or agents in such compositions will be such that a suitable effective dosage will be delivered to the subject taking into account the

proposed mode of administration. Preferred oral compositions according to the invention will contain between about 0.1 μ g and 2000mg of each active agent, respectively.

Active agents may also be formulated into topically acceptable carriers conventionally used for forming creams, lotions, ointments and the like for internal or external application.

Typically, a composition of the invention will incorporate one or more preservatives such as parabens, chlorobutanol, phenol, sorbic acid, and thimersal. In many cases, a composition may furthermore include isotonic agents such as sugars or sodium chloride. In addition, prolonged absorption of the composition may be brought about by the use in the compositions of agents for delaying absorption such as aluminium monosterate and gelatin.

Tablets, troches, pills, capsules and the like may also contain one or more of the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; a sweetening agent such as sucrose, lactose or saccharin or a flavouring agent such as peppermint, oil of wintergreen, orange or cherry flavouring. When the dosage unit form is a capsule, it may contain in addition to one or more of the above ingredients a liquid carrier. Various other ingredients may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills or capsules may be coated with shellac, sugars or both. In addition, an active agent may be incorporated into any suitable sustained-release preparation or formulation.

Pharmaceutically acceptable carriers, diluents and/or excipients include any suitable conventionally known solvents, dispersion media and isotonic preparations or solutions. Use of such ingredients and media for pharmaceutically active substances is well known. Except insofar as any conventional media or agent is incompatible with the active agent, use thereof in therapeutic and prophylactic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions if desired.

It is particularly preferred to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein is to be taken to mean physically discrete units suited as unitary dosages for the subject to be treated, each unit containing a predetermined quantity of active agent calculated to produce the desired therapeutic or prophylactic effect in association with the relevant carrier, diluent and/or excipient.

A unit dosage formed will generally contain each active agent in amounts ranging from about 0.5 μg to about 2000mg/ml of carrier respectively.

A pharmaceutical composition may also comprise vectors capable of transfecting target cells where the vector carries a nucleic acid molecule for modulating functional activity or expression of an integrin or MAP kinase. The vector may for instance, be packaged into a suitable virus for delivery of the vector into target cells as described above.

The dosage of an active agent will depend on a number of factors including whether the agent is to be administered for prophylactic or therapeutic use, the condition for which the agent is intended to be administered, the severity of the condition, the age

of the subject, and related factors including weight and general health of the subject as may be determined by the physician or attendant in accordance with accepted principles. Indeed, a low dosage may initially be given which is subsequently increased at each administration following evaluation of the subjects response. Similarly, frequency of administration may be determined in the same way that is, by continuously monitoring the subjects response between each dosage and if necessary, increasing the frequency of administration or alternatively, reducing the frequency of administration.

The route of administration of a pharmaceutical composition will again depend on the nature of the condition for which the composition is to be administered. Suitable routes of administration include but are not limited to respiratorally, intratracheally, nasopharyngeally, intravenously, intraperitoneally, subcutaneously, intracranially, intradermially, intramuscularly, intraocularly, intrathecally, intranasally, by infusion, orally, rectally, via IV group patch, topically and by implant. With respect to intravenous routes, particularly suitable routes are via injection into blood vessels which supply a tumour or particular organs to be treated. Agents may also be delivered into cavities such for example the pleural or peritoneal cavity, or be injected directly into tumour tissue.

The production of antibodies and monoclonal antibodies is well established in the art (eg. see Antibodies, A Laboratory Manual. Harlow & Lane Eds. Cold Spring Harbour Press, 1988). For polyclonal antibodies, a mammal such as a sheep or rat for instance is immunised with a polypeptide of the invention and antisera subsequently isolated prior to purification of the antibodies therefrom by standard affinity chromatography techniques such as Sepharose-Protein A chromatography. Desirably, the mammal is

periodically challenged with the relevant antigen to establish and/or maintain high antibody titre. To produce monoclonal antibodies, B lymphocytes can be isolated from the immunised mammal and fused with immortalising cells (eg. myeloma cells) by standard somatic cell fusion techniques (eg. utilising polyethylene glycol) to produce

5 hybridoma cells (Kohler and Milstein, 1975; see also Handbook of Experimental Immunology, Weir et al Eds. Blackwell Scientific Publications. 4th Ed. 1986). The resulting hybridoma cells may then be screened for production of antibodies specific for the peptide by an enzyme linked immunosorbant assay (ELISA) or other immunoassay. Conventionally used methods for preparing monoclonal antibodies include those

10 involving the use of Epstein-Barr virus (Cole et al. Monoclonal Antibodies and Cancer Therapy, Allen R. Liss Inc. pp. 77-96, 1985). The term "antibody" or "antibodies" as used herein is to be taken to include within its scope entire intact antibodies as well as binding fragments thereof such as Fab and (Fab')₂ fragments which may be obtained by papain or pepsin proteolytic cleavage, respectively.

- 15 An antibody of the invention may be labelled for enabling detection of antibody binding in immunoassays including competitive inhibition assays. A "label" may be any molecule which by its nature is capable of providing or causing the production of an analytically identifiable signal which allows the detection of an antibody and antigen complex. Such detection may be qualitative or quantitative. An antibody can for
- 20 instance be labelled with radioisotopes including ³²P, ¹²⁵I or ¹³¹I, an enzyme, a fluorescent label, chemiluminescent molecule or for instance an affinity label such as biotin, avidin, streptavidin and the like.

An enzyme can be conjugated with an antibody by means of coupling agents such as glutaraldehyde, carbodiimides, or for instance periodate although a wide variety of conjugation techniques exist. Commonly used enzymes include horseradish peroxidase, glucose oxidase, β -galactosidase and alkaline phosphatase amongst others. Detection
5 utilising enzymes is achieved with use of a suitable substrate for the selected enzyme. The substrate is generally chosen for the production upon hydrolysis of a detectable colour change. However, fluorogenic substrates may also be used which yield a fluorescence product rather than a chromogen. Suitable fluorescent labels are those capable of being conjugated to an antibody substantially without altering the binding
10 capacity of the antibody and include fluorescein, phycoerythrin (PE) and rhodamine which emit light at a characteristic wavelength in the colour range following illumination with light at a different wavelength. Methods for labelling of antibodies can be found in Current Protocols in Molecular Biology. Ausubel FM., John Wiley & Sons Inc.

Immunoassays in which antibodies of the invention may be utilised include
15 radioimmunoassays (RIA) and ELISA (eg., see Handbook of Experimental Immunology, Weir et al., Vol. 1-4, Blackwell Scientific Publications 4th Edition, 1986). Such assays include those in which a target antigen is detected by direct binding with a labelled antibody, and those in which the target antigen is bound by a first antibody, typically immobilised on a solid substrate (eg., a microtitre tissue culture plate formed from a
20 suitable plastics material such as polystyrene or the like) and a labelled second antibody specific for the first antibody used to form an antigen-first antibody-second antibody complex that is detected by a signal emitted by the label. Sandwich techniques in which the antigen is immobilised by an antibody for presentation to a labelled second antibody

specific for the antigen are also well known. An antibody can be bound to a solid substrate covalently utilising commonly used amide or ester linkers, or by adsorption.

Optimal concentrations of antibodies, temperatures, incubation times and other assay conditions can be determined by the skilled addressee with reference to conventional

5 assay methodology and the application of routine experimentation.

Antibodies and other molecules of the invention including polypeptides and oligonucleotides as described herein when bound to a solid support can be used in affinity chromatography for the purification of a binding partner for which they are specific. In particular, a polypeptide either alone or as a fusion protein comprising the

10 binding domain for a MAP kinase for instance can be utilised in the purification, isolation or concentration of the MAP kinase. It may also be used for assaying levels of MMP kinase in cell extracts. Similarly, an antibody that specifically binds to the binding domain of an integrin has use in the purification of the integrin or fragments thereof incorporating the binding domain from a relatively crude preparation or mixture.

15 Suitable solid supports include agarose, sepharose and other commercially available supports such as beads formed from latex, polystyrene, polypropylene, dextran, glass or synthetic resins, typically packed in an affinity column through which the relevant sample containing the binding partner is passed at a pH and conditions (eg., low salt concentration) under which the binding partner becomes bound by the antibody,

20 polypeptide or other such molecule. The column is then washed utilising a suitable buffer whereby the binding partner is retained bound on the column, prior to being eluted therefrom utilising a suitable elution buffer (eg., with a higher salt concentration and at an altered pH, typically pH 2.5 or pH 11) that facilitates the release of the binding

inhibit tumour cell invasion *in vitro* and tumour metastases from melanoma in an animal model (Humphries et al, 1986; Gehlsen et al, 1988).

In colon cancer, the contribution made by the $\alpha 5 \beta 1$ receptor to regulation of growth appears to be ligand (fibronectin)-dependent. For example, induced expression of $\alpha 5 \beta 1$ in human colon cancer cells constitutively lacking this integrin has been shown to result in decreased tumour cell proliferation *in vitro* (Varner et al, 1995).

Interestingly, when the appropriate ligand was present, cell proliferation was restored, indicating that the unoccupied receptor mediated a negative growth signal in these cells (Varner et al, 1995). Moreover, induction of $\alpha 5 \beta 1$ expression was associated with a marked reduction of tumourigenicity in immune-deficient mice. Failure to ligate all of the tumour cell $\alpha 5 \beta 1$ molecules with sufficient murine fibronectin most likely accounts for the *in vivo* tumour suppression in these studies (Varner et al, 1995). In the present study the effect of down-regulating $\alpha \nu \beta 6$ expression on colon cancer growth was examined.

1.1 Methods

1.1.1 Generation of sense and antisense $\beta 6$ constructs in pEF.PGK.puro vector.

For $\beta 6$ antisense constructs, $\beta 6$ cDNA was excised from the vector pcDNA1neo $\beta 6$ (Weinacker et al, 1994) using the restriction enzymes SnaB1 and Xba1. This produced a 5' overhang (Xba1) and a 3' blunt end (SnaB1). The 5' overhang was blunted with Klenow (Promega) prior to ligation. pEF.PGK.puro vector (a gift from D. Huang, the Walter & Eliza Hall Institute, Melbourne Australia) was cut with EcoRV which produced blunt ends. The pEF.puro vector was de-phosphorylated using calf intestinal alkaline phosphatase (CIAP, Promega) and the $\beta 6$ cDNA ligated overnight into

pEF.puro using T4 DNA ligase (Promega) at a ratio of vector:insert of 1:5. After ligation all the reaction mix was used for transformation into competent JM109 cells and the cells plated onto LB plates containing ampicillin. After overnight incubation at 37°C, colonies were selected, the plasmid DNA extracted by microprepping, and the DNA cut with BstE11 to confirm the antisense orientation of $\beta 6$. Digestion with BstE11 produced the expected two fragments, one of 6.0 basepairs and the other 3.5 basepairs.

To provide $\beta 6$ sense constructs, $\beta 6$ cDNA was also excised from the pcDNA1neo $\beta 6$ vector using the restriction enzymes SnaB1 and Xba1 as described above. The pEF.puro vector was then cut with Xba1 and EcoRV and the insert was ligated in sense direction into the pEF.PGK.puro vector without having to blunt the insert. The ligation reaction was prepared at a ratio of vector:insert of 1:1. Digestion with BstE11 produced two expected fragments, one of 7.5 basepairs and the other 2.0 basepairs.

1.1.2 Transfection of WiDr and HT29 colon cancer cells

The human colon cancer cell lines, WiDr and HT29 were obtained from the American Type Culture Collection (ATCC), Rockville, Maryland, USA and maintained as monolayers in standard medium comprising Dulbecco's Modified Eagle's medium (DMEM; 4.5gm/litre of glucose) with 10% heat-inactivated foetal bovine serum (FBS) supplemented with HEPES and penicillin/streptomycin. WiDr and HT29 cell lines constitutively express $\alpha \beta 6$. Stable transfectants of WiDr and HT29 cells expressing $\beta 6$ in sense and antisense direction were generated using lipofectamine and puromycin as the selection antibiotic. One stable antisense $\beta 6$ transfectant from HT29 cells and three stable clones from WiDr cells were successfully established for use in all experiments. Mock transfectants using vector alone were also generated as controls. Initial killing

curves performed using a range of concentrations of puromycin established that WiDr and HT29 cells could be stably transfected with puromycin concentrations of 1.0 μ g and 2.5 μ g/ml, respectively.

1.1.3 Assessment of $\beta 6$ expression in the transfected cell lines

$\beta 6$ expression was assessed by means of FACScan analyses of parent cell lines and clones generated therefrom by means of limiting-dilution experiments. Stability of the transfectants was confirmed regularly by repeated FACScan analyses, and surface biotinylation and immunoprecipitation as described below.

1.1.4 FACScan analyses

Monolayer cultures of cell lines were harvested with trypsin/EDTA and then blocked with goat serum at 4°C for 10 min. Cells were washed once with PBS, incubated with primary antibody against integrin subunits for 20 min at 4°C and then washed twice with PBS. Cells were then stained with secondary antibody conjugated with phycoerythrin for 20 min at 4°C, washed twice with PBS and resuspended in 0.5ml PBS prior to FACScan analysis (Becton Dickinson, Rutherford, New Jersey, USA).

1.1.5 Integrin immunoprecipitation

Cells were harvested with trypsin/EDTA, the trypsin neutralised with standard culture medium, and the cell pellets washed once with cold PBS. Cell pellets were then exposed to biotin-CNHS-ester (Sigma) in biotinylation buffer (10mM sodium borate, 150mM sodium chloride, pH 8.8) for 30 mins at 4°C with continuous slow mixing. Cell pellets were then centrifuged at 4°C, washed twice with cold PBS and exposed to lysis buffer (containing 100mM Tris, 150mM NaCl, 1mM CaCl_2 , 1% Triton, 0.1% SDS and 0.1% NP-40 at pH 7.4 and containing 1mM phenylmethylsulfonyl fluoride (PMSF)) for

30 min at 4°C. Lysates were then clarified by ultracentrifugation (10,000g) for 30 min and the protein content measured using the BCA protein assay reagent kit. Lysates containing equal protein amounts were pre-cleared with rabbit anti-mouse (RAM) immunoglobulin coupled to Sepharose-4B beads for 12 hrs. Immunoprecipitations were carried out indirectly using RAM-Sepharose 4B and analysed by 7.5% SDS-PAGE under non-reducing conditions.

1.1.6 Reverse transcriptase-PCR (RT-PCR)

mRNA levels for $\beta 6$ expression were evaluated by reverse transcriptase-polymerase chain reaction (RT-PCR). Total RNA was extracted from cell cultures using the commercial TriPure isolation reagent based on the method of Chomczynski and Sacchi (1987). 0.4-2 μ g of RNA was used to prepared cDNA by reverse transcription. Briefly, a reaction mixture in a final volume of 40 μ l containing 8 μ l of 5 x RT reaction buffer (250mM Tris, 15mM MgCl₂, 375mM KCL, pH 8.3), 8 μ l of 2.5mM of each dNTP, 4 μ l of 100mM DTT, 40U of an Rnase inhibitor, Rnasin (Promega, Madison, Wisconsin, USA), 0.5 μ g of random hexamers (Promega) and 200U of Moloney murine leukaemia virus (M-MLV) reverse transcriptase (Promega) were mixed and incubated at 38°C for a minimum of 90min. The reaction was stopped by heating at 95°C for 5 min and cDNA stored at 4°C until PCR. 2-5 μ l of this cDNA was combined with 5 μ l of 10 x PCR buffer (100mM Tris, 500mM KCl, 15mM MgCl₂, pH8.3) 8 μ l of 1.25mM dNTP each and 1.25 μ l of 20 μ M of both forward and reverse primers. The forward primer sequence was 5'AGGATAGTTCTGTTCCTGC3' and the reverse primer sequence 5'ATCATAGGAATATTTGGAGG3'. The reaction was initiated by 2.5U of Taq polymerase in a final volume of 50 μ l. After an initial 5 min incubation at 94°C, 30

cycles of amplification were performed under the following conditions: 94°C 1 min, 54°C 1 min and 72°C for 1 min. The reaction was stopped by incubating at 72°C for 10 min. To verify that equal amounts of RT product from cells were subjected to PCR amplification, the same amounts of cDNA were amplified for the "house-keeping" gene GAPDH using specific primers. The same reaction conditions were used except that the annealing temperature was changed to 48°C and PCR amplification performed for 35 cycles.

1.2 Results

1.2.1 $\alpha v\beta 6$ expression in HT29 and WiDr transfected cell lines

Transfection of the colon cancer cell lines HT29 and WiDr with the $\beta 6$ gene construct in an antisense orientation resulted in a marked reduction of $\beta 6$ expression at the transcript level and on the cell surface as shown in Figs 1 to 4. Transfection of cells with $\beta 6$ in the sense orientation did not enhance $\beta 6$ surface expression. However, a consequence of down-regulation of the $\beta 6$ subunit in antisense transfectants was a marked increase in surface expression of the $\beta 5$ subunit. The changes in surface expression of $\beta 6$ and $\beta 5$ subunits noted on FACScan analyses of antisense $\beta 6$ transfectants was confirmed by surface-labelling cells with biotin and immunoprecipitating integrin subunits with either anti- $\beta 6$ mAb (R6G9) or anti- $\beta 5$ mAb (P1F6).

1.2.2 Effect of Suppression of $\alpha v\beta 6$ expression on cell binding to fibronectin

The major substrate for $\alpha v\beta 6$ is fibronectin and to investigate the effect that reduction in $\beta 6$ surface expression in antisense $\beta 6$ transfectants might have on cell-matrix adhesion, WiDr and HT29 antisense $\beta 6$ transfectants were seeded on fibronectin

in adhesion assays. Since both cell lines can adhere to fibronectin through members of the $\beta 1$ integrin subfamily (either $\alpha 3\beta 1$ or $\alpha 5\beta 1$) $\alpha v\beta 6$ -mediated adhesion to fibronectin was assessed in the absence/presence of blocking anti- $\beta 1$ antibody.

The cell-adhesion assays were performed in wells of non-tissue culture-treated polystyrene 96-well flat bottom microtitre plates (Nunc, Roskilde, Denmark). Culture wells were coated with fibronectin, washed with phosphate-buffered saline (PBS) and then blocked with 0.5% bovine serum albumin (Sigma) in PBS for 1 hr at 37°C. Harvested cells were seeded at a density of 10^5 cells/well for HT29 and 1.5×10^5 cells/well for WiDr cells in 200 μ l of standard DMEM which lacked FBS but contained 0.5% bovine serum albumin. To block adhesion, cells were incubated with anti- $\beta 1$ blocking antibodies for 15 min at 4°C before plating. The plates were centrifuged (top side up) at 10 x g for 5 min, then incubated for 1 hr at 37°C in humidified 5% carbon dioxide. Non-adherent cells were removed by centrifugation top side down at 48 x g for 5 min. The attached cells were fixed and stained with 0.5% crystal violet (in 20% methanol and 1% formaldehyde) and the wells washed with phosphate-buffered saline. The relative number of cells in each well was evaluated by measuring the absorbance at 595nm in a Microplate Reader (Bio-Rad).

With reduction in cell surface expression of $\beta 6$, $\beta 1$ -independent adhesion of cells to fibronectin was reduced compared with mock transfectants (containing vector alone) which express surface $\beta 6$ at similar levels to wild-type cells. The further addition of blocking anti- αv antibody completely prevented binding to fibronectin.

1.2.3 Effect of suppression of $\alpha v\beta 6$ expression on tumour cell proliferation and tumour growth *in vivo*

To investigate the effect of diminished $\alpha v\beta 6$ surface expression on cell proliferation *in vitro*, WiDr and HT29 antisense $\beta 6$ transfectants were seeded as monolayers in 96-well microtitre culture plates (5,000 viable cells per well) in standard culture medium containing the puromycin selection antibiotic. Cells were pulsed with $1\mu\text{Ci}$ (^3H)-thymidine (Amersham) per well for the last 24 hours of each experiment before automated harvesting and measurement of radioactivity. WiDr wild-type, mock and antisense $\beta 6$ transfectants, and HT29 wild-type, mock, sense $\beta 6$ and antisense $\beta 6$ transfectants were harvested second daily during a six-day culture period.

A marked increase in thymidine incorporation was observed for WiDR and HT29 cells expressing normal levels of $\alpha v\beta 6$ compared with antisense $\beta 6$ transfectants (see Figs. 5 and 6).

1.2.4 Effect of Suppression of $\alpha v\beta 6$ expression on Tumour Formation

The ability of HT29 antisense $\beta 6$ transfectants to form tumours in immune-deficient mice was assessed.

BALB/C female athymic mice (8 weeks of age purchased from the Animal Resource Centre, Perth, Western Australia) were maintained under pathogen-free conditions and fed standard mouse chow and water *ad lib*. The mice were divided into groups of ten each and all mice within each group inoculated with a single cell line. Cells used were WiDr mock (transfected with vector alone) and antisense $\beta 6$ transfected clones (clones 1 - 3) and HT29 mock, sense and antisense $\beta 6$ cell lines. Mice received subcutaneous flank injections of 10^6 viable tumour cells suspended in 0.2ml of standard

DMEM culture medium. Animal weights and tumour sizes (breadth and length as measured with calipers) were recorded weekly. Six weeks following the last injection, visible subcutaneous tumours were excised, weighed and fixed in 4% formalin. At the time of euthanasia, all internal organs were routinely inspected for presence of

5 metastases.

Tumour growth after six weeks following inoculation of HT29 mock and antisense $\beta 6$ transfectants is shown in Fig. 7. Measurements of tumour growth for WiDr and HT29 cells are shown in Figs 8 and 9, respectively. Similar tumour growth profiles for mock and antisense $\beta 6$ WiDr clones 2 and 3 each inoculated into 10 mice are not shown.

10 Of a total of 40 mice injected with cells expressing antisense $\beta 6$ (HT29 - 10 mice and WiDr cells lines, 3 clones - 30 mice) tumours completely disappeared in 93% of animals. In the remaining 3 animals tumour sizes diminished to 1mm^2 in size during the six week period compared with tumours at least 15mm^2 in size from cells expressing normal levels of $\beta 6$. To confirm the presence of tumour xenografts histologically at one week

15 following subcutaneous inoculation of mock and antisense $\beta 6$ transfectants, tumour nodules were excised, fixed in formalin and stained with haematoxylin and eosin.

1.2.5 Effect of suppression of $\alpha v\beta 6$ expression on gelatinase B secretion

Serum-free tumour-conditioned medium was collected from each of the 3 WiDr mock and antisense $\beta 6$ clones and concentrated $\times 44$ for measurement of gelatinase B

20 using the Biotrak MMP-9 activity assay system (Amersham Pharmacia Biotech, Uppsala Sweden). Down-regulation of $\alpha v\beta 6$ expression resulted in a marked reduction in gelatinase B secretion.

1.3 Discussion of Results

Induced expression of $\beta 6$ in Chinese hamster ovary (CHO) cells has been shown to result in decreased surface expression of the $\beta 5$ integrin subunit which also partners αv (Weinacker et al, 1994). The concept of integrin switching depends on the availability of the promiscuous αv partner subunit. In the present study, the reverse was observed. As a consequence of down-regulation of $\beta 6$ in colon cancer cells which constitutively express $\alpha v\beta 6$, $\beta 5$ surface expression increased, most likely secondary to increased availability of the αv subunit partner.

Heterologous expression of $\alpha v\beta 6$ in colon cancer cells has previously been reported to enhance tumour growth in immune-deficient mice (Agrez et al, 1994). Suppression of $\alpha v\beta 6$ expression in the present study was shown to result in nearly complete disappearance of tumours in 93% of animals following subcutaneous inoculation of tumour cells. Moreover, in the remaining 7% of animals, a 95% reduction in tumour size was observed over a six week period compared with large tumours seen in all animals injected with cells in which $\alpha v\beta 6$ expression had not been perturbed. Similar findings have been described with loss of the classical vitronectin receptor $\alpha v\beta 3$ in melanoma. For example, in experimental animal models, the loss of $\alpha v\beta 3$ expression in melanoma cells has been shown to lead to reduced *in vivo* proliferation which is restored upon re-expression of the receptor (Felding-Habermann et al, 1992).

Although the mechanisms involved in $\alpha v\beta 6$ -mediated tumour growth remain to be elucidated, the present *in vitro* data show that loss of $\beta 6$ expression is associated with decreased proliferative capacity of the cells. Taken together with the marked reduction in gelatinase B secretion seen for colon cancer cells transfected with antisense $\beta 6$, the

findings reported in the present study suggest that intracellular signalling pathways activated via the integrin $\alpha v\beta 6$ play a major role in promoting progression of this tumour type.

Example 2

- 5 The association of $\alpha v\beta 6$ expression and MAP kinase activity were evaluated using WiDr, HT29 and SW480 cell lines.

2.1 Methods

2.1.1 SW480 colon cancer $\beta 6$ transfectants

- Stable transfectants of SW480 colon cancer cells (ATCC) expressing gene
10 constructs of either wild-type or mutant forms of the $\beta 6$ integrin subunit or the expression plasmid only (pcDNA1neo) have been previously described (Agrez et al, 1994). The transfected SW480 cell lines were maintained in standard medium supplemented with the neomycin analogue G418. Stable transfectants of WiDr and HT29 cells expressing wild-type $\beta 6$ in antisense orientation were generated as described
15 in Example 1.1.2 and maintained in standard medium supplemented with puromycin.

2.1.1 MAP kinase assay.

- Cultures of WiDr and HT29 mock and antisense $\beta 6$ transfectants were established by seeding 1×10^6 cells/5ml of culture medium in 25cm^2 tissue culture flasks. Cells were incubated at 37°C in humidified CO_2 for 24 hours before serum starvation in
20 serum-free medium for the next 16 hours. Foetal calf serum was then added to a final concentration of 10% for 30 mins before MAP kinase assays were performed. Before each experiment the cells were washed twice with PBS, resuspended in extraction buffer (10mM Tris-HCl, 150mM NaCl, 2mM EDTA, 2mM DTT, 1mM orthovanadate, 1mM

PMSF, 4µg/ml aprotinin, 2µg/ml leupeptin and 1µg/ml pepstatin, pH 7.4) and sonicated at a setting of 7, using a Soniprep 150 watt ultrasonic disintegrator for a total of 90 seconds in three 30 second pulses with an interval of 30 seconds between each pulse. Cellular debris was removed by centrifugation at 900g for 10 min at 4°C. The assay was performed on equal cell numbers using a MAP kinase assay system (Amersham Pharmacia Biotech, Uppsala Sweden). The ability of cells to transfer phosphate from [γ - 32 P]-ATP to a synthetic peptide that contains specifically a p42/p44 MAP kinase phosphorylation site was measured as described in the manufacturer's instructions. [32 P]-labelled peptides were spotted onto PE1-cellulose paper, unbound radioactivity was washed with 75mM phosphoric acid and bound [32 P]-labelled peptides were measured by liquid scintillation counting. Protein estimation was performed on each cell lysate used and enzyme activity calculated as described in the manufacturer's instructions. Where MEK inhibitors, PD98059 and U0126 were used, cells were cultured as described above and the inhibitors, at a final concentration of 40µM, were added one hour before the addition of serum to the medium.

2.1.2 Western blotting

To detect the MAP kinases ERK1/2, cells were lysed in lysis buffer containing 100mM Tris, 150mM NaCl, 1mM CaCl₂, 1% Triton, 0.1% SDS and 0.5% NP-40 at pH7.4, supplemented with enzyme inhibitors (1mM PMSF, 1mM sodium orthovanadate, 1µg/ml pepstatin A, 2.5µg/ml aprotinin, 1mM benzamidine, 1µg/ml leupeptin). Lysates were clarified by ultracentrifugation and equal protein loads electrophoresed in 8% or 10% SDS-PAGE under non-reducing conditions. Electrophoresed proteins were transferred to nitrocellulose membranes (Biotrace NT, Gelman Sciences, Ann Arbor,

MI) in transfer buffer (25mM Tris, 192mM glycine, 20% methanol, 0.1% SDS) for 2 hours at a constant voltage of 40 volts in a Transfer Blot Cell (Bio-Rad). Membranes were blocked with 5% casein for 1 hr at room temperature and probed with monoclonal anti-ERK antibodies (E10 which recognises only phosphorylated ERK1/2 (New England BioLabs) and SC-1647 which recognises total ERKs, non-phosphorylated and phosphorylated (Santa Cruz Biotechnology). In some experiments, membranes were probed with polyclonal anti-ERK antibody (New England BioLabs) which also recognises total ERKs. Membranes were then washed three times in Tris buffered saline, containing 0.1% Tween and incubated with HRP-conjugated goat anti-mouse or goat anti-rabbit antibody. Blots were visualised by the enhanced chemi-luminescence detection system according to the manufacturer's instructions (Du Pont).

2.1.3 Integrin β -subunit immunoprecipitations

Tumour cells were harvested and divided into two equal aliquots based on cell counts. One aliquot was surface biotinylated and the cells lysed for integrin immunoprecipitations as described in Example 1.1.5, with the exception that three sequential rounds of immuno-precipitation were performed to deplete the lysates of integrin subunits $\beta 5$ and $\beta 6$. Lysis buffer was the same as that used for Western blotting. The other aliquot, intended for subsequent ERK2 immunoblotting to examine the effect of integrin immunodepletion on ERKs was not biotinylated but lysed immediately and divided into three samples each at a protein concentration of 1mg/ml. Three sequential rounds of immunoprecipitation were performed against anti- $\beta 6$ monoclonal antibody, R6G9 (using isotype matched antibody, IgG2A, and anti- $\beta 5$ monoclonal antibody, P1F6, in control immunoprecipitations).

The integrin-depleted lysates were electrophoresed in 8% or 10% SDS-PAGE under non-reducing conditions and transferred to nitrocellulose membranes. Membranes were blocked with casein as for Western blotting and probed with anti-ERK monoclonal antibodies E10 and SC-1647. In parallel experiments, the sequentially

immunoprecipitated $\beta 6$ subunit bound to rabbit anti-mouse (RAM) coupled Sepharose B4 beads was also electrophoresed in 10% SDS-PAGE under non-reducing conditions, transferred to nitrocellulose membranes, and the membranes probed with anti-ERK monoclonal antibody E10 which recognises only phosphorylated forms of ERK1/2.

2.3 Results

2.3.1 Effect of serum on MAP kinase activity

The effect of MEK (MAP kinase kinase) inhibitors UO126 and PD98059 on MAP kinase activity in WiDr and HT29 wild-type cells was tested in the absence/presence of serum. Adherent cell monolayers on plastic were grown for 24 hrs in standard culture medium, then washed three times in PBS followed by 16 hrs in culture under serum-free conditions. Serum was then added for 30 min and MAP kinase activity assessed before and after addition of serum. The addition of serum markedly stimulated MAP kinase activity for both cell lines and was inhibitable by both MEK inhibitors.

2.3.2 Effect of altered $\beta 6$ expression on MAP kinase activity following serum stimulation.

In these experiments, WiDr transfectants (3 mock and 3 antisense $\beta 6$ clones), HT29 transfectants (mock and antisense $\beta 6$) and SW480 $\beta 6$ transfectants (mock and sense $\beta 6$) were serum-starved for 16 hrs followed by 30 mins exposure to serum. Increased expression of $\alpha v\beta 6$ was associated with a marked increase in MAP kinase

activity upon serum stimulation compared with cells lacking $\alpha\beta 6$ altogether (SW480 mock). Cells in which $\beta 6$ expression had been down-regulated (antisense $\beta 6$ transfectants) exhibited suppressed MAP kinase activity. Induced expression of $\beta 6$ in the non- $\beta 6$ -expressing colon cancer cell line SW480 resulted in a three fold increase in serum-dependent MAP kinase activity.

2.3.3 $\alpha\beta 6$ binds an extracellular signal-related kinase (ERK).

A highly surprising finding arising from phage display screening which underpins the present work is that the integrin $\beta 6$ cytoplasmic domain binds a MAP kinase. Use of phage display to screen a γ gt¹¹ cDNA colon cancer cell library with the $\beta 6$ cytoplasmic domain as bait yielded a clone which coded for ERK2 at the 3' end with 100% nucleotide sequence identity (across 393 bases) to the published sequence of ERK2 (Boulton et al, 1991). This putative association was investigated further.

Integrin immunoprecipitations were performed on equal protein loads of tumour cell lysates and the transferred proteins blotted with antibodies recognising phosphorylated and non-phosphorylated forms of ERK1/2. The specificity of this interaction was examined in integrin immunoprecipitations against $\beta 1$, $\beta 5$, $\beta 6$ and α integrin subunits. As shown in Fig. 10, the anti- ERK mAb SC-1647 identified a $\beta 6$ -specific band migrating at the position of purified ERK2 protein. The integrin-associated ERK band was identified only in immunoprecipitations of the $\beta 6$ subunit and its partner α and not in immunoprecipitations of the $\beta 1/\beta 5$ subunits or in immunoprecipitations using isotype-matched control antibodies.

2.3.4 Effect of altered $\beta 6$ expression on total cellular ERK and $\beta 6$ -bound ERK.

Equal protein loads from one representative clone each from WiDr mock and antisense $\beta 6$ transfectants were electrophoresed, transferred to nitrocellulose and blotted with anti-ERK mAb (SC-1647) as shown in Fig. 11(A). $\beta 6$ immuno-precipitates from equal protein loads of the WiDr mock and antisense $\beta 6$ clones were electrophoresed, transferred and probed with anti-ERK mAb (E10) as shown in Fig. 11(B). As indicated, suppression of $\beta 6$ expression resulted in a reduction of both total cellular and phosphorylated integrin-associated ERK compared with WiDr mock transfectants. Similarly, $\beta 6$ immunoprecipitations from SW480 $\beta 6$ transfected clones expressing high and low levels of $\beta 6$ (confirmed by FACScan and $\beta 6$ immunoprecipitations) showed parallel changes in $\beta 6$ -bound phosphorylated ERK (Fig. 12).

2.3.5 Effect of $\beta 6$ immunodepletion on total cellular ERK and $\beta 6$ -bound ERK

WiDr wild-type cells were surface biotinylated and the cell lysates immunodepleted of $\beta 6$ in three rounds of sequential immunoprecipitation using anti- $\beta 6$ mAb (R6G9) resulting in a marked loss of $\beta 6$ from the lysates as shown in Fig. 13(A). $\beta 6$ -immunodepleted lysates were then transferred and blotted with anti-ERK1/2 antibody (SC-1647), which recognises both phosphorylated and non-phosphorylated forms of ERK1/2. As shown in Fig. 13(B), following three rounds of $\beta 6$ immunodepletion, levels of ERK1/2 in $\beta 6$ -depleted lysates compared with non-immunodepleted lysates, were markedly reduced suggesting a significant contribution of $\beta 6$ -bound ERK to total cellular ERK. In contrast, immunodepletion of $\beta 5$ by three successive rounds of immunoprecipitation with mAb P1F6 or isotype-matched control antibody IgG2A did

not result in any reduction of cellular ERK levels compared with non-immunodepleted cell lysates.

2.3.6 Effect of ERK immunodepletion on β 6-bound ERK

Cell lysates from WiDr wild-type cells were immunodepleted of ERK1/2 by means
5 of sequential immunoprecipitations using the anti-ERK mAb, SC-1647. ERK-
immunodepleted cell lysates probed with either E10 or SC-1647 mAbs contained
markedly less ERKs. To examine the effect of ERK-immunodepletion on β 6-bound
ERK, the ERK-immunodepleted cell lysates were immunoprecipitated with anti- β 6 mAb
(R6G9) and the β 6-immunoprecipitates probed with anti-ERK mAb (E10 recognising
10 phosphorylated ERK1/2). ERK immunodepletion effectively reduced levels of β 6-
bound ERK.

2.3.7 Effect of preventing cell attachment on α v β 6-bound ERK

SW480 mock and β 6 expressing transfected cells were grown to 80-90%
confluency. Cells were washed twice with PBS and harvested after trypsinization. Cells
15 were divided into three equal portions (approximately 4×10^6 /batch). The first group
was plated on a 75 cm^2 plastic flask in normal 10% serum containing medium (attached
cells) while the other two groups were plated on 0.3% agarose underlay in serum free
medium (non-attached cells). Cells were allowed to grow for 24 hours at 37°C , after
which in one group of 0.3% agarose underlay, 15 ml of serum-free medium was added
20 while in the other an equal volume of 10% serum-containing medium was added for 30
mins. Cells were collected washed with PBS and lysed in cell lysis buffer (100 mM
Tris-HCl pH-7.5, 150 mM NaCl, 1 mM CaCl_2 , 1% Triton, 0.1% SDS, 0.1% NP-40, 1
mM vanadate, 1 $\mu\text{g/ml}$ pepstatin, 1 mM PMSF, 5 $\mu\text{g/ml}$ aprotinin and 1 $\mu\text{g/ml}$ of

leupeptin). 10 μ l (10 μ g of protein) was used for the analyses of cell lysates after adding equal volumes of non-reducing Laemmli buffer. For SW480- β 6-transfected cells the rest of the cell lysate was used for immunoprecipitation of α v β 6 integrin. Cell lysates and β 6 immunoprecipitates were subjected to western blotting and probed with E10 monoclonal antibody (recognising phosphorylated ERK1/2).

Cell lysates from the non-attached cells were found to require serum factors to maintain phosphorylation of total cellular ERK. In contrast, non-attached SW480 β 6 colon cancer cells do not require serum factors to maintain the activation (phosphorylation) state of β 6-bound ERK.

10 2.3.8 Effect of PP2A phosphatase on α v β 6-bound ERK

In experiments to examine the effect of protein phosphatase 2A (PP2A) on β 6-bound ERK, SW480 β 6-transfected cells were sonicated in buffer comprising 50mM Tris-HCl (pH 8.0), 10mM $MgCl_2$ and 0.01mM EGTA together with enzyme inhibitors, and cell lysates from both serum-starved and serum-induced cells treated with 0.5 units of PP2A (Promega) at 30°C for 10 minutes. The reaction mixture was stopped by addition of equal volumes of non-reducing Laemmli sample buffer. In parallel, PP2A-treated cell lysates were immunoprecipitated with mAb R6G9 (anti- β 6) followed by Western blot with anti-ERK mAb E10. MAP kinase activity assays were performed according to the manufacturer's instructions (Amersham Pharmacia Biotec) using γ ³²P-ATP.

Exposure of cell lysates prepared from serum-supplemented and serum-starved cells to the PP2A catalytic subunit resulted in dephosphorylation of total ERK. In contrast, dephosphorylation of β 6-bound ERK was not observed in β 6

immunoprecipitates prepared from serum-supplemented or serum-starved cells $\beta 6$

Bound ERK may therefore serve to maintain adjacent growth factor receptors in an activated state and thereby alter their sensitivity to exogenous co-factors.

2.3.9 Inhibition of MAP kinase activity inhibits secretion of gelatinase B.

- 5 SW480 $\beta 6$ transfectants were cultured under serum-free conditions for 48 hours in the absence/presence of the MEK inhibitor PD98059 (40 μ M) or DMSO (vehicle control). Tumour-conditioned medium was assayed for gelatinase B by analysis of equal protein loads in a gelatin zymogram.

Inhibition of MAP kinase activity by the MEK inhibitor reduced gelatinase B
10 secretion compared with controls.

2.3.10 $\beta 6$ -ERK2 association in HaCaT and HaRas Cell Lines

- $\beta 6$ immunoprecipitates were prepared from human keratinocyte cell lines (HaCaT and HaRas were obtained from Prof. N. Fusenig, The German Cancer Research Institute, Heidelberg, Germany) using mAb R6G9 (anti- $\beta 6$) and the immunoprecipitates probed
15 with mab E10 (against phosphorylated ERK 1/2). Fig. 14 shows that ERK2 associates with $\beta 6$ in both of HaCat and HaRas cells.

2.4 Discussion of Results

- The MAP kinase pathway has been shown to be important in experimental tumour metastases (Mansour et al, 1994) and recent data implicate MAP kinases in tumour
20 growth and invasiveness of colon cancer cells (Sebolt-Leopold et al, 1999). In the present study, up-/down-regulation of $\beta 6$ expression in various colon cancer cell lines was shown to enhance/suppress respectively, MAP kinase activity. The presence of serum induced a three-fold increase in MAP kinase activity above that observed for

serum-starved $\beta 6$ -expressing cells. In contrast, only a one-fold increase in serum-dependent MAP kinase activity was observed for cells in which $\beta 6$ had been down-regulated consequent upon transfection with antisense $\beta 6$. Moreover, induced expression of $\beta 6$ in the non- $\beta 6$ -expressing colon cancer cell line SW480, was associated with a three-fold increase in serum-dependent MAP kinase activity. Serum contains a mixture of growth factors raising the possibility that one role for $\alpha \nu \beta 6$ in colon cancer cells is to lower the threshold for activation of MAP kinase signalling pathways at times when the supply of serum-containing growth factors is limited.

The ERK band co-immunoprecipitated with $\beta 6$ migrated either at or 1 - 2 kD higher than the mobility of purified phosphorylated ERK2 depending on the acrylamide concentration used in SDS-PAGE showing that the kinase does indeed, associate with the $\beta 6$ subunit. Slight differences in mobility of the $\beta 6$ -associated ERK band compared with the pure ERK protein could arise if $\beta 6$ -bound ERK is hyper-phosphorylated and/or exists in an altered conformation consequent upon its association with $\beta 6$. ERK bound to $\beta 6$ may also be an alternatively spliced variant of ERK2 causing it to migrate differently. Finally, the purified ERK2 protein is derived from mouse which differs slightly from human ERK2 by being two amino acid residues shorter and also containing a single amino acid substitution.

In the present study, increased/decreased $\beta 6$ expression in colon cancer cell lines was associated with increased/decreased $\beta 6$ -bound ERK, respectively. In addition, immunodepletion experiments suggest that $\beta 6$ -bound ERK makes a substantial contribution to total phosphorylated ERK within the cell and overall MAP kinase activity (see Figs. 15(A) and 15(B)).

The observation that $\beta 6$ -mediated colon cancer growth *in vitro* is inhibitable by a matrix metalloproteinase inhibitor (Agrez et al, 1999) suggests that the increased gelatinase B secretion by $\beta 6$ -expressing colon cancer cells contributes to tumour progression. Taken together with the finding that inhibition of MAP kinase activity by the MEK inhibitor PD98059 diminished gelatinase B secretion in $\beta 6$ -expressing cells, it seems that activation of MAP kinase signalling plays a role, at least in part, in $\beta 6$ -mediated induction of gelatinase B secretion.

Example 3

3.1 Identification of the binding domain on the $\beta 6$ subunit cytoplasmic tail domain for ERK2

Peptide fragments corresponding to regions of the cytoplasmic tail domain of the $\beta 6$ subunit were screened in an enzyme-linked immunosorbent assay (ELISA) for binding with ERK2. The 52 amino acid long $\beta 6$ cytoplasmic tail is shown in Fig. 16 as are the amino acid sequences for the cytoplasmic domains of the $\beta 1$ to $\beta 3$ subunits. In particular, four synthetic peptides designated fragment 1 to fragment 4 were prepared and biotinylated at the N-terminal end of each, respectively (Auspep Pty Ltd, Melbourne Australia).

The region of the $\beta 6$ tail to which each corresponds is indicated in Fig. 16 and set out below.

Fragment 1: HDRKEVAKFEAERSKAKWQTGT

Fragment 2: RSKAKWQTGTNPLYRGSTST

Fragment 3: NPLYRGSTSTFKNVTYKHRE

Fragment 4: FKNVTYKHREKQKVDLSTDS

The fragments overlap by 10 amino acids and are each 20 amino acids long with the exception of the fragment 1 with a length of 22 amino acids. Fragment 4 was synthesised with a terminal serine rather than a cysteine as found in wild-type $\beta 6$ to avoid formation of a disulfide bridge between peptides.

Overlapping biotinylated fragments 1 to 4 were coated onto streptavidin coated polystyrene plates (Pierce, Rockford IL USA, Cat No. 15125) and the ELISA performed substantially according to manufacturers instructions. Briefly, wells are washed with 3 x 200 μ l of wash buffer (TBS, 0.1% BSA, 0.05% Tween 20 or SuperBlock™ blocking buffer in TBS, Pierce, Prod. No. 37535) prior to addition of biotinylated peptides (100 μ l) and incubation for 1 hr at room temperature to allow for capture of the peptides on the plate. Following another washing step, peptides were overlaid with GST-ERK, ERK (or JNK-1) alone at a volume of 100 μ l per well, and the plates incubated for a further 1 hr at room temperature before removal of any unbound ERK by further washing.

Binding of ERK to the peptides is detected using 100 μ l anti-ERK1/2 mAb SC1647 (Santa Cruz) as the primary antibody at a dilution of 1:700 (isotype matched antibody IgG2b is used as a control). This is followed by another washing step and addition of 100 μ l rabbit anti-mouse antibody (Biorad) conjugated to alkaline phosphatase at a concentration of 1:1000 for 30 minutes again at room temperature. A 100 μ l aliquot of detection reagent (alkaline phosphatase detection kit-Biorad) is then introduced into each well after a final washing step and allowed to react for 15-30 minutes at room temperature in the dark before absorbance is measured at 405nm. All dilutions of

peptides, MAP kinase and antibodies were performed using the wash buffer. GST-ERK is a fusion protein consisting of ERK coupled to glutathione-S-transferase and purified from host cells transfected with pGEX vector.

As shown in Fig. 17, significant binding of non-phosphorylated GST.ERK2 (0.25µg/100µl) to peptide fragment 2 was observed (1µg/100µl) while only negligible or low level binding for the other fragments was found.

Significant binding of non-phosphorylated ERK2 to both fragment 2 and β6 cytoplasmic tail peptide compared to fragments 1, 3 and 4 over a range of concentrations of ERK2 was also observed (see Fig.18). Similar results were observed using a range of concentrations of the peptide fragments as shown in Fig. 19.

To further localise the binding domain on the cytoplasmic tail of the β6 subunit, progressively shorter peptides from the region of the β6 cytoplasmic tail corresponding to peptide fragment 2 were synthesised, biotinylated and the capacity to associate or otherwise bind to ERK2 assessed as described above. The binding of GST.ERK2 to a 15 mer test peptide (seq. 4) having the amino acid sequence RSKAKWQTGTNPLYR and a 10 mer test peptide having the sequence RSKAKWQTGT is shown in Fig. 20 compared to fragment 2 over a range of concentrations of the peptides. As can be seen, no reduction in binding to the seq. 4 peptide compared to fragment 2 was found. Binding of ERK2 to the seq. 3 peptide was substantially less than that observed for seq. 4.

A number of 10 mer biotinylated peptides corresponding to regions of fragment 2 or fragment 3 were then tested. The amino acid sequence for each peptide is as follows and their location in the β6 cytoplasmic domain is indicated in Fig. 21.

10(1): NPLYRGSTST

10(2): WQTGTNPLYR

10(3): KFEAERSKAK

The results are set out in Fig. 22 and show that GST.ERK binding to the 10 mer peptides is substantially reduced compared to binding to the seq. 4 peptide suggesting
5 that opposite end regions of seq. 4 participate in the binding of ERK2.

Comparable binding of ERK2 to seq. 4 was found using a further 10 mer peptide identified as 10(4) in which amino acid sequence WQTGT of seq. 4 is omitted indicating that WQTGT is a linker sequence that does not participate directly in the binding of ERK to seq. 4. Negligible binding of ERK2 to the 5 mer peptide RSKAK was observed
10 as shown in Fig. 23. ERK2 cleaved from GST-ERK2 by thrombin was used in this assay. Results (not shown) indicate that greater than a 3 fold increase in assay sensitivity can be achieved using thrombin cleaved ERK2 rather than GST-ERK2.

Example 4

15 4.1 MAP kinase JNK-1 binds to the cytoplasmic tail domain of $\beta 6$

In view of the observation that ERK2 associates with the cytoplasmic tail of the $\beta 6$ subunit, the MAP kinase JNK-1 was tested to evaluate whether it also could associate with the cytoplasmic tail of $\beta 6$.

Briefly, 0.05-1.5 μ m/100 μ l of JNK-1 (Santa Cruz) was aliquoted into wells of a 96
20 well culture plate containing increasing concentrations of the $\beta 6$ cytoplasmic domain tail peptide used in Example 3. For comparison purposes, non-phosphorylated GST-ERK2 (0.05-1.5 μ m/100 μ l) was aliquoted into wells containing $\beta 6$ cytoplasmic tail peptide or peptide fragments 1 or 2, respectively. Binding of JNK-1 was detected using

mouse anti-JNK-1 mAb SC 474-G (Santa Cruz) and HRP-conjugated goat anti-mouse antibody. Absorbance was read at 405nm and the results are shown in Fig. 24.

Significant binding of JNK-1 to the $\beta 6$ cytoplasmic tail peptide was found.

5 Example 5

5.1 Evaluation of ability of ERK2 to bind to $\beta 6$ $\Delta 746$ -764 deletion mutant.

To examine the role of the amino acid sequence RSKAKWQTGTNPLYR in the $\beta 6$ cytoplasmic domain *in situ*, a $\beta 6$ deletion construct lacking the coding sequence for AERSKAKWQTGTNPLYRG was transfected into colon cancer cell line SW480 which
10 does not constitutively express the $\alpha V\beta 6$ integrin using the calcium phosphate method previously described for transfections into this cell line (Agrez et al, 1994). The location of the $\beta 6$ $\Delta 746$ -764 deletion is indicated in Fig. 25. Construction of the $\beta 6$ $\Delta 746$ -764 deletion mutant in the vector pcDNA1neo and failure of the expressed receptor to localise to focal adhesions in Chinese hamster ovary cells has been reported (Cone et al,
15 1994). Facscan analysis revealed comparable levels of surface expression of mutant $\beta 6$ to that seen for the full length wild-type receptor (see Fig. 26).

Equal protein loads of cell lysates prepared from SW480 cells were immunoprecipitated with either anti- $\beta 6$ monoclonal antibody (mAb R6G9) or matched isotype control antibody. Surface biotinylation prior to immunoprecipitation confirmed
20 equal surface expression of mutant and wild-type $\beta 6$ (see Fig. 27 (A)). Aliquots of the immunoprecipitates were electrophoresed and transferred to nitrocellulose for Western blotting using monoclonal antibody E10 which recognises ERK1/2. As seen in Fig. 27(B), loss of the RSKAKWQTGTNPLYR sequence in the $\beta 6$ cytoplasmic domain

reduced levels of $\beta 6$ -bound ERK by greater than approximately 75% of that observed for the wild type receptor.

Example 6

5 6.1 Growth inhibition study.

HT29 and SW480 $\beta 6$ -expressing colon cancer cell lines were seeded into wells of 96-well microtitre plates (Nunc) in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% foetal bovine serum, glutamine, Hepes, and antibiotics. Seeding cell densities were 3×10^3 cells per triplicate well for each condition tested and after 24
10 hours incubation of cell cultures in 5% CO₂, 100% humidity at 37°C, the culture medium was exchanged for serum-free DMEM medium supplemented with insulin, transferrin, selenous acid, hydrocortisone, non-essential amino acids, glutamine, Hepes and antibiotics containing either peptide RSKAKWQTGTNPLYR alone or penetratin-peptide complex at a concentration of 10 μ m for HT29 cells or 30 μ m for SW480 $\beta 6$ -
15 expressing cells. Cell cultures were incubated for a further 24 hours following which cultures were photographed (Kodak Techpan Film at 100 ASA setting) and the experiments terminated by addition of the cell proliferation reagent WST-1 (Boehringer Mannheim) to monitor effects of the peptide on cell growth. The cell proliferation reagent WST-1 is designed to be used for the non-radioactive, spectrophotometric
20 quantification of cell growth and viability in proliferation and chemosensitivity assays. The colourimetric assay is based on the cleavage of the tetrazolium salt WST-1 by mitochondrial dehydrogenase in viable cells.

In particular, at the termination of experiments, 30 μ l of WST-1 was added to 270 μ l culture medium volume in each microtitre well and the colour change quantitated in an ELISA plate reader by measuring absorbance of the formazan product at 450nm (using a reference wavelength of more than 600nm). The mean absorbance readings from triplicate wells (\pm standard error of the means) after subtraction of background control wells (culture medium without cells) was determined. Only the carrier penetratin-peptide complex was effective in inhibiting cell proliferation in contrast to either peptide or penetratin alone as shown in Figs. 28 and 29 indicating that the penetratin-peptide complex was internalised by both the HT29 and SW480 cells resulting in the observed suppression of colon cancer growth. Photographs of the SW480 cells treated with penetratin alone or the penetratin-peptide complex are shown in Fig. 30 (A) to (C).

Example 7

SW480 mock and SW480 β 6 transfectants were cultured in DMEM medium supplemented with 1% foetal bovine serum in the presence of 20 μ M seq. 4 coupled to penetratin. Percentage inhibition was assessed by the WST-1 colorimetric dehydrogenase assay described in Example 6. The percentage inhibition of growth observed for the - β 6 and + β 6 expressing cells was 17% and 50%, respectively as indicated in Fig 31A. The - β 6 and + β cultured cells are shown in Fig 31B.

Example 8

The proliferation of SW480 cells expressing a $\beta 6$ $\Delta 746-764$ deletion mutant was compared with non- $\beta 6$ expressing SW480 cells and SW480 cells expressing full length wild-type $\beta 6$. Cells were cultured for 10 days within a 3-dimensional collagen type I matrix. Collagen gels were prepared as bilayers (upper layer cell-containing and lower layer minus cells) in 24 well culture plates as previously described (Agrez, 1989; Agrez, 1994) except for the use of 5% foetal bovine serum as the supplement for DMEM. Colonies were photographed in the gel Fig.32(A) at 10 days (bar represents 200 μ) and following dissolution of the collagen with collagenase Fig.32(B) prior to visual colony counting of all colonies exceeding 200 μ in diameter within each well Fig.32(C). As can be seen, significant proliferation of the SW480 cells expressing the full length wild-type $\beta 6$ was observed compared to the non- $\beta 6$ expressing cells and cells expressing the $\beta 6$ $\Delta 746-764$ deletion mutant.

Example 9

Growth inhibition of SW480 cells expressing full length wild-type $\beta 6$ exposed to seq.4 coupled to penetratin or RSKAKWQTGTNPLYR peptide coupled to penetratin (5, 10, 20, 30 μ M in DMEM minus foetal bovine serum) but which peptide contained alanine substitutions at the four positions indicated was assessed. As shown in Fig.33(A) and Fig 33(B), progressive inhibition of proliferation in a dose-response manner was observed for the seq.4 penetratin complex compared with the alanine substituted peptide-penetratin complex which was without effect at all doses tested.

Example 10

Binding of ERK2 to the seq.4 peptide (RSKAKWQTGTNPLYR) was compared with peptides corresponding to regions of the cytoplasmic domain of integrin subunits

5 β1, β2, β3 and β5. The amino acid sequences for those peptides is shown below:

β1 KFEKEKMNAKWDGTGENPIYK

β2 KEKLKSQWNNDNPLFK

β3 RARAKWDTANNPLYK

β5 RSRARYEMASNPLYR

10 As shown in Fig.34, significant binding of ERK2 to the seq. 4 peptide was observed.

Binding of ERK2 to the β5 and β3 peptides was also found. The results have been corrected for non-specific binding and indicate a hierarchy of binding of ERK2 to integrin subunits.

Although the present invention has been described hereinbefore with reference to a
15 number of preferred embodiments, the skilled addressee will understand that numerous variations and modifications are possible without departing from the scope of the invention.

References Cited:

- Agrez, M.V. and Bates R.C.,** Colorectal cancer and the integrin family of cell adhesion receptors: current status and future directions. *European Journal of Cancer* 30A, 2166-2170 (1994).
- 5 **Agrez, M.V.,** Human colon cancer and fibroblast cell lines cultured in and on collagen gels. *Aust. N. Z. J. Surg.* 59, 415-420 (1989).
- Agrez, M.V., Bates R.C., Mitchell, D., Wilson, N., Ferguson, N., Anseline, P. and Sheppard. D.,** Multiplicity of fibronectin-binding α v integrin receptors in colorectal cancer. *Br. J. Cancer* 73, 887-892 (1996).
- 10 **Agrez, M.V.,** Cell adhesion molecules and colon cancer. *A.N.Z.J. Surgery.* 66, 789-796 (1996).
- Agrez, M.V., Chen, A., Cone, R.I., Pytela, R. and Sheppard, D.,** The α v β 6 integrin promotes proliferation of colon carcinoma cells through a unique region of the β 6 cytoplasmic domain. *J. Cell Biol.* 127, 547-556 (1994).
- 15 **Agrez, M.V., Gu, X., Turton, J., Meldrum, C., Niu, J., Antalis, T. and Howard, E.W.,** The α v β 6 integrin induces gelatinase B secretion in colon cancer cells. *Int. J. Cancer* 81, 90-97 (1999).
- Bachmann, A.S., Surovoy, A., Jung, G. and Moelling, K.,** Integrin receptor-targeted transfer peptides for efficient delivery of antisense oligodeoxynucleotides. *J.*
20 *Mol. Med.* 76, 126-132 (1998).
- Berkner, Curr. Top. Microbiol. Immunology** 158, 39-61 (1992).
- Bookstein, R., Demers, W., Gregory, R., et al,** p53 gene therapy *in vivo* for hepatocellular and liver metastatic colorectal cancer. *Seminars Oncol.* 23, 66-77 (1996).

Boudreau, N., Sympson, C.J., Werb, Z. and Bissell, M., Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. *Science* 267, 891-893 (1995).

Boulton, T.G., Nye, S.H. and Robbins, D. J., ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. *Cell* 65, 663-675 (1991).

Breakfield and Geller, *Mol. Neurobiol.* 1, 337-371 (1987).

Bruss, J.M., Gallo, J., De Lisser, H.M., Klimanskaya, I.V., Folkesson, H.G., Pittet, J.F., Nishimura, S.L., Aldape, K., Landers, D.V., Carreter, W., Gillet, N., Sheppard, D., Mathay, M., Albeda, S.M., Kramer, R.H., and Pytela, R., Expression of the $\beta 6$ integrin in development, neoplasia and tissue repair suggests a role in epithelial remodelling. *J. Cell Sci.* 108, 2241-2251 (1995).

Bruss, J.M., Gillet, N., Lu, L., Sheppard, D. and Pytela, R., Restricted distribution of integrin beta 6 mRNA in primate epithelial tissues. *J. Histochem. Cytochem.* 41, 1521-1527 (1993).

Brooks, P.C., Montgomery, A.M.P., Rosenfeld, M., Reisfeld, R.A., Hu, T., Klier, G. and Cheresh, D.A., Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. *Cell* 79, 1157-1164 (1994).

Brooks, P.C., Stromblad, S., Sanders, L.C., von Schalscha, T.L., Aimes, R.T., Stetler-stevenson, W.G., Quigley, J.P. and Cheresh, D.A., Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin $\alpha v \beta 3$. *Cell* 85, 683-693 (1996).

Busk, M., Pytela, R. and Sheppard, D., Characterisation of the $\alpha v \beta 6$ as a fibronectin-binding protein. *J. Biol. Chem.* 267, 5790-5796 (1992).

Chen, Q., Kinch, M.S. and Lin, T.H., Integrin-mediated cell adhesion activates mitogen-activated protein kinases. *J. Biol. Chem.* 269, 26602-26605 (1994).

5 **Chomczynski, P. and Sacchi, N.,** Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.* 162, 156-159 (1987).

Clark, R.A., Ashcroft, G.S., Spencer, M.J., Larjava, H. and Ferguson, M.W., Re-epithelialization of normal human excisional wounds is associated with a switch
10 from $\alpha v \beta 5$ to $\alpha v \beta 6$ integrins. *Br. J. Dermatol.* 135, 46-51 (1996).

Cone, R.I., Weinacker, A., Chen, A. and Sheppard, D., Effects of beta subunit cytoplasmic domain deletions on the recruitment of the integrin $\alpha v \beta 6$ to focal contacts. *Cell Adhes. Comm.* 2, 101-113 (1994).

Coppolino, M., Leung-Hagsteijn, C. Dedhar, S. and Wilkins, J., Inducible
15 interaction of integrin $\alpha 2 \beta 1$ with calreticulin. Dependence of the activation state of the integrin. *J. Biol. Chem.* 270, 23132-23138 (1995).

Dedhar, S. and Hannigan, G.E., Integrin cytoplasmic interactions and bidirectional transmembrane signalling. *Curr. Opin. Cell Biol.* 8, 657-669 (1996).

Dedhar et al., *J. Cell. Biol.* 104, 585 (1997).

20 **Derossi, D., Calvet, S., Trembleau, A., et al,** Cell internalization of the third helix of the Antennapedia homeo domain is receptor-independent. *J. Biol. Chem.* 271, 18188-18193 (1996).

Derossi, D., Joliot, A.H., Chassaing, G. and Prochiantz, A., The third helix of the Antennapedia homeodomain translocates through biological membranes. *J. Biol. Chem.* 269, 10444-10450 (1994).

- Felding-Habermann, B., Mueller, B.M., Romerdahl, C.A. and Cheresch, D.,**
 5 Involvement of integrin α_v gene expression in human melanoma tumorigenicity. *J. Clin. Invest.* 89, 2018-2022 (1992).

Fink et al., *Hum. Gene Ther.* 3, 11-19 (1992).

Freese et al., *Biochem. Pharmacol.* 40, 2189-2199 (1990).

- Gamble, J.R., Matthias, L.J., Meyer, G., Kaur, P., Russ, G., Faull, R., Berndt,**
 10 **M.C. and Vadas, M.A.,** Regulation of in vitro capillary tube formation by anti-integrin antibodies. *J. Cell Biol.* 121, 931-43 (1993).

Garrington, T.P., and Johnson, G.L., Organization and regulation of mitogen-activated protein kinase signaling pathways. *Curr. Opin. Cell Biol.* 11, 211-218 (1999).

- Giancotti, F.G. and Ruoslahti, E.,** Integrin signalling. *Science* 285, 1028-1032
 15 (1999).

Gorgziglia and Kapikian, J. *Viol.* 66, 4407-4412 (1992).

Grammer, T.C. and Blenis, J., Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases. *Oncogene* 14, 1635-1642 (1997).

- Guan, J.L. and Shalloway, D.,** Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. *Nature* 358, 690-692 (1992).

Haapasalmi, K., Zhang, K., Tonneson, M., Olerud, J., Sheppard, D., Salo, T., Kramer, R., Clark, R.A.F., Uitto, V.-J. and Larjava, H., Keratinocytes in human wounds express avb6 integrin. *J. Invest. Dermatol.* 106, 42-48 (1996).

Hannigan, G.E., Leung-Hagsteijn, C., Fitz-Gibbon, L., Coppelino, M.G.,
5 **Radeva, G., Filmus, J., Bell, J.C. and Dedhar, S.,** Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. *Nature* 379, 91-96 (1996).

He, T.-C., Zhou, S., Da Costa, L.T., Yu, J., Kinzler, K.W. and Vogelstein, B. A
10 **simplified system for generating recombinant adenoviruses. *Proc., Natl. Acad. Sci. USA***
95, 2509-2514 (1998).

Hemler, M.E., Integrin associated proteins. *Curr. Opin. Cell Biol.* 10, 578-585 (1998).

Hergott, G.J., Nagai, H. and Kalnins, V.I., Inhibition of retinal pigment epithelial cell migration and proliferation with monoclonal antibodies against the beta 1
15 **integrin subunit during wound healing in organ culture. *Invest. Ophthalmol. Vis. Sci.* 34,**
2761-2768 (1993).

Horwitz, A., Duggan, K., Buck, C., Beckerle, M.C. and Burridge, K.,
Interaction of plasma membrane fibronectin receptor with talin-a transmembrane linkage. *Nature* 320, 531-533 (1986).

20 **Howe, A., Aplin, A.E., Alahari, S.K. and Juliano, R.L.,** Integrin signaling and cell growth control. *Curr. Opin. Cell Biol.* 10, 220-231 (1998)

Hynes, R. O., Integrins: versatility, modulation and signaling in cell adhesion. *Cell* 69, 11-25 (1992).

Johnson et al., J.Virol. 66, 2952-2965 (1992).

Jones, J., Watt, F.M. and Speight, P.M., Changes in the expression of alpha v integrins in oral squamous cell carcinomas. J. Oral Path. & Med. 26, 63-68 (1997).

Klemke, R.L., Cai, S. Giannini, A.L., Gallagher, P.J., de Lanerolle, P. and

5 **Cheresh, D.A.**, Regulation of cell motility by mitogen-activated protein kinase. J. Cell Biol. 137, 481-492 (1997).

Knezevic, I., Leisner, T.M. and Lam, SC-T., Direct binding of the platelet integrin alpha IIb beta 3 (GPIIb-IIIa) to talin. Evidence that interaction is mediated through the cytoplasmic domains of both alpha IIb and beta 3. J. Biol. Chem. 271,
10 16416-16421 (1996).

Kohler G and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497 (1975).

Kornberg, L., Earp, H.S., Parsons, J.T., Schaller, M. and Juliano, R.L., Cell adhesion or integrin clustering increases phosphorylation of a focal adhesion-associated
15 tyrosine kinase. J. Biol. Chem. 267, 23439-23442 (1992).

Kraft, S., Diefenbach, B., Mehta, R., Jonczyk, A., Luckenbach, G.A. and Goodman, S.L., Definition of an unexpected ligand recognition motif for $\alpha V\beta 6$ integrin. J. Biol. Chem. 274 (4) 1979-1985 (1999).

Lengauer, C., Kinzler, K.W. and Vogelstein, B., Genetic instability in colorectal
20 cancers. Nature 386, 623-7 (1997).

Licato, L.L., Keku, T.O. and Wurzelmann, J.I., In vivo activation of mitogen-activated protein kinases in rat intestinal neoplasia. Gastroenterology 113, 1589-1598 (1997).

Lindberg, F.P., Gresham, H.D., Reinhold, M.I. and Brown, E.J., Integrin-associated protein immunoglobulin domain is necessary for efficient vitronectin bead binding. *J. Cell Biol.* 134, 1313-1322 (1996).

Liu, S., Thomas, S.M., Woodside, D.G., Rose, D.M., Klosses, W.B., Pfaff, M.
5 **and Ginsberg, M.H.,** Binding of paxillin to alpha 4 integrins modifies integrin-dependent biological responses. *Nature* 402, 676-680 (1999).

Lo C.W., Transformation by iontophoretic microinjection of DNA: Multiple integrations without tandem insertions. *Mol. Cell. Biol.* 3,1803 (1983).

Loftus, J.C., Smith, J.W. and Ginsberg, M.H., Integrin-mediated cell adhesion:
10 the extracellular face. *J. Biol. Chem.* 269, 25235-25238 (1994).

Madzak et al., *J.Gen. Virol.* 73, 1533-1536 (1992).

Mainiero, F., Murgia, C., Wary, K.K., Curatoia, A.M., Pepe, A., Blumemberg,
M., Westwick, J.K., Der, C.J. and Giancotti, F.G., The coupling of alpha 6 beta 4
integrin to Ras-MAP kinase pathways mediated by Shc controls keratinocyte
15 proliferation. *EMBO J.* 16, 2365-2375 (1997).

Maniero, F., Pepe, A., Wary, K.K., Spinardi, L., Mohammadi, M.,
Schlessinger, J. and Giancotti F.G., Signal transduction by the alpha 6 beta 4 integrin:
distinct beta 4 subunits mediate recruitment of Shc/Grb2 and association with the
cytoskeleton of hemidesmosomes. *EMBO J* 14, 4470-4481 (1995).

20 **Mansour, S.J., Matten, W.T., Hermann, A.S., Candia, J.M., Rong, S.,**
Fukasawa, K., Vande-Woude, G.F. and Ahn, N.G., Transformation of mammalian
cells by constitutively active MAP kinase kinase. *Science* 265, 966-970 (1994).

Margolskee, Curr. Top. Microbiol. Immunol. 158, 67-90 (1992).

Meredith, J.E. Jr, Fazeli, B. and Schwartz, M.A., The extracellular matrix as a cell survival factor. *Mol. Biol. Cell* 4, 953-961 (1993).

Miller, *Current. Top. Microbiol. Immunol.* 158, 1-24 (1992).

Miranti, C.K., Ohno, S. and Brugge, J.S., Protein Kinase C regulates integrin-induced activation of the extracellular regulated kinase pathway upstream of Shc. *J. Biol. Chem.* 274, 10571-10581 (1999).

Montgomery, A.M.P., Reisfeld, R.A. and Cheresh, D.A., Integrin $\alpha v \beta 3$ rescues melanoma cells from apoptosis in three-dimensional dermal collagen. *Proc. Natl. Acad. Sci. USA* 91, 8856-8860 (1994).

Moss, *Curr. Top. Microbiol. Immunol.* 158, 25-38 (1992).

Munger, J.S., Huang, X., Kawakatsu, H., Griffiths, M.J.D., Dalton, S.L., Wu, J., Pittet, J.F., Kaminski, N., Garat, C., Matthey, M.A., Rifkin, D.B. and Sheppard, D., The integrin $\alpha v \beta 6$ binds and activates latent TGF β 1: a mechanism for regulating pulmonary inflammation and fibrosis. *Cell* 96, 319-328 (1999).

Muzyczka, *Curr. Top. Microbiol. Immunol.* 158, 97-123 (1992).

Otey, C.A., Pavalko, F.M. and Burridge, K., An interaction between alpha-actinin and the beta 1 integrin subunit in vitro. *J. Cell Biol.* 111, 721-729 (1990).

Payne, D.M., Rossomando, A.J., Martino, P., et al, Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). *EMBOJ* 10, 885-892 (1991).

Petropoulos et al., *J. Virol.* 66, 3391-3397 (1992).

Pfaff, M., Liu, S., Erle, D.J., Ginsberg, M.H., Integrin beta cytoplasmic domains differentially bind to cytoskeletal proteins. *J. Biol. Chem.* 273, 6104-6109 (1998).

Sheppard, D., Rozzo, C., Starr, L., Quaranta, V., Erle, D.J. and Pytela, R., Complete amino acid sequence of a novel integrin β subunit ($\beta 6$) identified in epithelial cells using the polymerase chain reaction. *J. Biol. Chem.* 265, 11502-11507 (1990).

Shimada, J. Clin. Invest. 88, 1043-1047 (1991).

Smythe, W.R., Lebel, E., Bavaria, J.E., Kaiser, L.R. and Albelda, S.M.,
Integrin expression in non-small cell carcinoma of the lung. Cancer & Metastasis
Reviews 14, 229-239 (1995).

5 **Spitz, F.R., Nguyen, D., Skibber, J.M., et al,** *In vivo* adenovirus-mediated p53
tumor suppressor gene therapy for colorectal cancer. Anticancer Res. 16, 3415-3422
(1996).

Stein C.A., and Cohen J.S., Oligodeoxynucleotides as inhibitors of gene
expression: A review. Cancer Res. 48(10), 2659-2668 (1998).

10 **Takayama, K., Ueno, H., Pei, X.H., et al,** The levels of integrin alpha v beta 5
may predict the susceptibility to adenovirus-mediated gene transfer in human lung
cancer cells. Gene Ther. 5, 361-368 (1998).

**Takiuchi, H., Kanokogi, M., Fujimoto, N., Hanafusa, T., Kyo, M., Ichikawa,
Y., Nagano, S., Fukunishi, T., Yabumoto, H. and Ihara, H.,** Expression of integrin
15 molecule in urological tumour cell lines by using RT-PCR method. Jap. J. Urology 85,
584-588 (1994).

Thomas, G.J., Jones, J. and Speight, P.M., Integrins and oral cancer. Oral
Oncology 33, 381-388 (1997).

Thomas, J.W., Mathias, P., Cheresch, D.A. and Nemerov, G., Integrins alpha v
20 beta 3 and alpha v beta 5 promote adenovirus internalisation but not virus attachment.
Cell 73, 309-319 (1993).

Widmann, C., Gibson, S., Jarpe, B and Johnson, G.L., Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. *Phys. Rev.* 79, 143-180 (1999).

Williams, E.J., Dunican, D.J., Green, P.J., Howell, F.V., Derossi, D., Walsh, F.S. and Doherty, P., Selective inhibition of growth factor-stimulated mitogenesis by a cell-permeable Grb2-binding peptide. *J. Biol. Chem.* 272, 22349-22354 (1997).

Zambruno, G., Marchisio, P.C., Marconi, A., Vascieri, C., Melchiori, A., Giannetti, A. and De Luca, M., Transforming growth factor - β 1 modulates β 1 and β 5 integrin receptors and induces the de novo expression of the α v β 6 heterodimer in normal human keratinocytes: implications for wound healing. *J. Cell Biol.* 129, 853-865 (1995).

Zhu, X. and Assoian, R.K., Integrin-dependent activation of MAP kinase: a link to shape-dependent cell proliferation. *Mol. Biol. Cell* 6, 273-282 (1995).

- 105 -

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-

1. A fragment of an integrin subunit wherein the fragment consists of a binding domain of the integrin subunit for a MAP kinase, or an analog or derivative of the fragment that is capable of binding with the MAP kinase.
- 5 2. An isolated or purified fragment of an integrin subunit, wherein the fragment comprises a binding domain of the integrin subunit for a MAP kinase and has a length of 15 amino acids or less, or a partial amino acid sequence of the binding domain that is capable of binding to the MAP kinase and thereby inhibiting binding of the MAP kinase to the integrin subunit, or an analog or derivative of the fragment or the partial amino
10 acid sequence and which is capable of binding with the MAP kinase and thereby inhibiting binding of the MAP kinase to the integrin subunit.
3. A fragment according to claim 2, wherein the MAP kinase is a member of the ERK family or the JNK family.
4. A fragment according to claim 2, wherein the MAP kinase is ERK2.
- 15 5. A fragment according to any one of claims 2 to 4, wherein the integrin subunit is selected from the group consisting of $\beta 3$, $\beta 5$ and $\beta 6$.
6. A fragment according to claim 5, wherein the integrin subunit is $\beta 6$.
7. A fragment according to any one of claims 1 to 6 comprising an amino acid sequence selected from the group consisting of RSKAKWQTGTNPLYR,
20 RARAKWDTANNPLYK and RSRARYEMASNPLYR.
8. An isolated or purified polypeptide capable of binding with a binding site of a MAP kinase for an integrin and thereby inhibiting binding of the MAP kinase with the integrin, or an analog or derivative of the polypeptide that is capable of binding with the MAP kinase and thereby inhibiting binding of the MAP kinase with the integrin,

- 106 -

wherein the polypeptide is other than an integrin subunit or a fragment of an integrin subunit.

9. A polypeptide according to claim 8, wherein the MAP kinase is a member of the ERK family or the JNK family.

10. A polypeptide according to claim 9, wherein the MAP kinase is ERK2.

11. A polypeptide according to any one of claims 8 to 10, wherein the integrin comprises an integrin subunit selected from the group consisting of $\beta 3$, $\beta 5$ and $\beta 6$.

12. A polypeptide according to claim 11, wherein the integrin subunit is $\beta 6$.

13. A polypeptide according to any one of claims 8 to 12 comprising the amino acid sequence RSKAKNPLYR.

14. A polypeptide according to any one of claims 8 to 12 comprising one or both of amino acid sequences RSKAK and NPLYR.

15. A polypeptide according to any one of claims 8 to 12 comprising core amino acid sequence of a binding domain of an integrin subunit for a MAP kinase.

16. A fusion protein incorporating a fragment of an integrin subunit as defined in any one of claims 1 to 7 or a polypeptide as defined in any one of claims 8 to 14.

17. A fusion protein according to claim 16 adapted for passing across a cell membrane.

18. A fusion protein according to claim 16 comprising a carrier moiety for facilitating passage across the cell membrane.

19. A fusion protein according to claim 17 adapted for releasing the fragment or the polypeptide after passing across the cell membrane.

20. An agent for inhibiting binding of a MAP kinase to an integrin, comprising:

a targeting moiety for targeting a cell expressing the integrin;

an inhibitor moiety for inhibiting binding of the MAP kinase with the integrin; and

- 107 -

a carrier moiety for facilitating passage of the inhibitor moiety across the cell membrane of the cell.

21. An agent according to claim 20, wherein the inhibitor and carrier moieties are capable of being released from the targeting moiety at the cell for passage of the carrier moiety and the inhibitor moiety across the cell membrane of the cell.

22. An agent according to claim 21, wherein the agent comprises an enzyme cleavage site for being cleaved to thereby release the carrier moiety and the inhibitor moiety at the cell.

23. An agent according to claim 22, wherein the enzyme cleavage site is a cleavage site for matrix-metalloproteinase-9 (MMP-9).

24. An agent according to any one of claims 20 to 23 adapted for release of the inhibitor moiety from the carrier moiety after passage of the inhibitor moiety across the cell membrane of the cell.

25. An agent according to any one of claims 20 to 24, wherein the targeting moiety is an antibody or a binding fragment of an antibody.

26. An agent according to claim 25, wherein the antibody or the binding fragment is specific for an extracellular region of the integrin.

27. An agent according to any one of claims 20 to 24, wherein the targeting moiety is an integrin receptor targeted peptide for binding to the integrin.

28. An agent according to any one of claims 20 to 27, wherein the inhibitor moiety is capable of binding to a binding site on the MAP kinase for the integrin or the binding domain of the integrin for the MAP kinase.

29. An agent according to any one of claims 20 to 28, wherein the inhibitor moiety comprises a fragment of an integrin subunit as defined in any one of claims 1 to 7 or a polypeptide as defined in any one of claims 8 to 14, or an analog or derivative of the

AMENDED
IPEA

- 108 -

fragment or polypeptide which is capable of binding with the MAP kinase and thereby inhibiting binding of the MAP kinase to the integrin.

30. An agent according to any one of claims 20 to 29, wherein the inhibitor moiety is an analog of a binding domain of an integrin subunit of the integrin for the MAP kinase.

5 31. An agent capable of inhibiting binding of a MAP kinase to an integrin, wherein the agent is an analog of a binding domain of a subunit of the integrin for the MAP kinase.

32. An agent according to claim 31, wherein the analog is a mimetic of the binding domain and is capable of binding to a binding site on the MAP kinase for the integrin.

33. An isolated or purified integrin subunit with a mutagenised binding domain for a
10 MAP kinase or in which the binding domain is deleted wherein capability of the integrin subunit to bind with the MAP kinase is thereby reduced, with the proviso that the integrin subunit is other than a $\beta 6 \Delta 746-764$ deletion mutant.

34. An integrin subunit according to claim 33, wherein the MAP kinase is an ERK family membrane or a JNK family member.

15 35. An integrin subunit according to claim 34, wherein the MAP kinase is ERK2.

36. An integrin subunit according to any one of claims 33 to 35, wherein the binding domain of the integrin subunit is mutagenised.

37. An integrin subunit according to any one of claims 33 to 36, wherein the integrin subunit is a truncated integrin subunit.

20 38. An isolated nucleic acid sequence encoding a fragment as defined in any one of claims 1 to 7 or an analog or derivative of the fragment that is capable of binding with the MAP kinase and thereby inhibiting binding of the MAP kinase with the integrin.

39. An isolated nucleic acid sequence encoding a polypeptide as defined in any one of claims 8 to 15 or an analog or derivative of the polypeptide that is capable of binding

- 109 -

with the MAP kinase and thereby inhibiting binding of the MAP kinase with the integrin.

40. An isolated nucleic acid sequence encoding a fusion protein as defined in any one of claims 16 to 19.
- 5 41. An isolated nucleic acid sequence encoding an integrin subunit as defined in any one of claims 33 to 37.
42. An isolated antisense nucleic acid sequence complementary to a nucleic acid sequence as defined in claim 38.
43. An isolated antisense nucleic acid sequence according to claim 42, wherein the
10 antisense nucleic acid sequence is labelled.
44. An oligonucleotide comprising from 14 to 45 contiguous nucleotides of a nucleic acid sequence as defined in claim 38.
45. An oligonucleotide comprising from 14 to 45 nucleotides and which is capable of hybridising with a nucleic acid sequence as defined in claim 38.
- 15 46. A vector incorporating a nucleic acid sequence as defined in any one of claims 38 to 43 or an oligonucleotide as defined in claim 45.
47. An expression vector incorporating a nucleic acid sequence as defined in any one of claims 38 to 41 for being expressed in a cell.
48. A host cell transformed with a vector as defined in claim 46 to 47.
- 20 49. A host cell according to claim 48, wherein the host cell is selected from the group consisting of a mammalian cell, an epithelial cell, a neoplastic cell and a cancer cell.
50. A host cell according to claim 49, wherein the host cell is a colon cancer cell.
51. A pharmaceutical composition comprising a fragment as defined in any one of claims 1 to 8 or an analog or derivative thereof capable of binding with the MAP kinase

- 110 -

and thereby inhibiting binding the MAP kinase with the integrin, together with a pharmaceutically acceptable carrier or diluent.

52. A pharmaceutical composition comprising a polypeptide as defined in any one of claims 9 to 15 or an analog or derivative thereof that is capable of binding with the MAP kinase and thereby inhibiting binding of the MAP kinase with the integrin, together with a pharmaceutically acceptable carrier or diluent.
53. A pharmaceutical composition comprising a fusion protein as defined in any one of claims 16 to 19 together with a pharmaceutically acceptable carrier or diluent.
54. A pharmaceutical composition comprising an agent for inhibiting binding of a MAP kinase with an integrin as defined in any one of claims 20 to 32, together with a pharmaceutically acceptable carrier or diluent.
55. A pharmaceutical composition comprising a vector as defined in claim 47 together with a pharmaceutically acceptable carrier or diluent.
56. A pharmaceutical composition comprising an antisense nucleic acid sequence as defined in claim 42 or 43 together with a pharmaceutically acceptable carrier or diluent.
57. A pharmaceutical composition comprising an oligonucleotide as defined in claim 44 or 45 together with a pharmaceutically acceptable carrier or diluent.
58. An antibody specific for a binding domain of an integrin for a MAP kinase, or a binding fragment of the antibody.
59. An antibody specific for a fragment as defined in any one of claims 1 to 8 or an analog or derivative of the fragment that is capable of binding with the MAP kinase and thereby inhibiting binding of the MAP kinase with the integrin.
60. An antibody specific for a polypeptide as defined in any one of claims 8 to 15 or an analog or derivative of the polypeptide that is capable of binding with the MAP kinase and thereby inhibiting binding of the MAP kinase with the integrins.

- 111 -

61. An antibody according to any one of claims 58 to 60, wherein the antibody is a monoclonal antibody.

62. A method of screening for an agent capable of inhibiting binding of a MAP kinase to a binding domain of an integrin for the MAP kinase, comprising:

5 (a) testing a number of agents for ability to bind to either the MAP kinase or the integrin; and

(b) determining if any said agent is capable of inhibiting binding of the MAP kinase to the binding domain of the integrin on the basis of the testing.

63. A method of screening for an agent capable of inhibiting binding of a MAP kinase
10 to a binding domain of an integrin for the MAP kinase, comprising:

(a) testing a number of agents for ability to bind to either the MAP kinase or the integrin;

(b) selecting an agent or agents identified as being able to bind to the MAP kinase or the integrin on the basis of the testing; and

15 (c) utilising the selected said agent or agents in an assay for indicating whether the or any of the selected said agents is capable of inhibiting the binding of the MAP kinase to the binding domain of the integrin.

64. A method of evaluating whether an agent is capable of inhibiting binding of a MAP kinase to a binding domain of an integrin for the MAP kinase, comprising:

20 (a) selecting the agent;

(b) utilising the agent in an assay for indicating whether the agent is capable of inhibiting the binding of the MAP kinase to the binding domain of the integrin; and

(c) determining if the agent is capable of inhibiting the binding of the MAP kinase to the binding domain of the integrin on the basis of the assay.

Received 28 September 2001

- 112 -

65. A method of screening for an agent capable of binding to a binding domain of an integrin for a MAP kinase, comprising:

(a) testing a number of agents for ability to bind to the binding domain of the integrin for the MAP kinase; and

5 (b) determining if any said agent is capable of binding to the binding domain of the integrin on the basis of the testing.

66. A method of screening for an agent capable of binding to a binding domain of an integrin for a MAP kinase, comprising:

(a) testing a number of agents for ability to bind to the integrin;

10 (b) selecting an agent or agents identified as being able to bind to the integrin on the basis of the testing; and

(c) utilising the selected said agent or agents in an assay for indicating whether the or any of the selected said agents is capable of binding to the binding domain of the integrin for the MAP kinase.

15 67. A method of evaluating whether an agent is capable of binding to a binding domain of an integrin for a MAP kinase, comprising:

(a) testing the agent for ability to bind to the binding domain of the integrin for the MAP kinase; and

20 (b) determining if the agent is capable of binding to the binding domain on the basis of the testing.

68. A method according to any one of claims 62 to 67, wherein the integrin comprises $\beta 6$.

69. A method according to any one of claims 62 to 68, wherein the MAP kinase is an ERK family member or a JNK family member.

25 70. A method according to claim 69, wherein the MAP kinase is ERK2.

- 113 -

71. An agent identified to be capable of binding to a binding domain of an integrin for a MAP kinase by a method as defined in any one of claims 65 to 67.

72. An agent identified to be capable of inhibiting binding of a MAP kinase to a binding domain of an integrin for the MAP kinase by a method as defined in any one of

5 claims 62 to 64.

73. A method of isolating a MAP kinase from a sample utilising a molecule immobilised on a solid support and which is capable of binding to a binding site on the MAP kinase for an integrin, comprising:

- (a) contacting the molecule immobilised on the solid support with the sample
- 10 under conditions suitable for binding of the MAP kinase to the molecule;
- (b) eluting the MAP kinase from the solid support; and
- (c) collecting the eluted MAP kinase.

74. A method according to claim 73, wherein the molecule is an integrin subunit of the integrin or an analog thereof.

15 75. A method according to claim 73, wherein the molecule is a fragment as defined in any one of claims 1 to 8 or an analog or derivative thereof.

76. A method according to claim 73, wherein the molecule is a polypeptide as defined in any one of claims 9 to 15 or an analog or derivative thereof.

77. A method according to claim 76, wherein the polypeptide comprises amino acid

20 sequence RSKAKNPLYR.

78. A method according to any one of claims 73 to 75, wherein the integrin comprises $\beta 6$.

79. A method according to any one of claims 73 to 75, wherein the MAP kinase is an ERK family member or a JNK family member.

25 80. A method according to claim 79, wherein the MAP kinase is ERK2.

AMENDED SHEET

IPEA/hu

- 114 -

81. A MAP kinase isolated from a sample by a method as defined in any one of claims 73 to 80.

82. A kit for determining if a test agent is capable of binding to a binding domain of an integrin for a MAP kinase, wherein the kit comprises:

5 a molecule for forming with a test agent a complex for being detected to indicate the test agent is capable of binding to the binding domain of the integrin; and instructions for use.

83. A kit for determining if a test agent is capable of inhibiting binding of a MAP kinase to a binding domain of an integrin for the MAP kinase, wherein the kit comprises:

10 a molecule for forming with a test agent a complex for being detected to indicate the test agent is capable of inhibiting binding of the MAP kinase to the binding domain of the integrin; and instructions for use.

84. A kit according to claim 82 or 83, wherein the molecule is a fragment as defined in 15 any one of claims 1 to 8 or an analog or derivative of the fragment that is capable of binding with the MAP kinase.

85. A kit according to claim 82 or 83, wherein the molecule is a polypeptide as defined in any one of claims 9 to 15 or an analog or derivative of the polypeptide that is capable of binding with the MAP kinase.

20 86. A kit according to any one of claims 82 to 85, wherein the integrin comprises $\beta 6$.

87. A kit according to any one of claims 82 to 86, wherein the MAP kinase is an ERK family member or a JNK family member.

88. A kit according to claim 87, wherein the MAP kinase is ERK2.

89. A method of modulating activity of a cell expressing an integrin subunit with a 25 cytoplasmic binding domain for a MAP kinase, comprising:

- 115 -

treating the cell with an antisense oligonucleotide for hybridising with at least part of a nucleic acid sequence coding for the binding domain of the integrin subunit to thereby cause expression of the integrin subunit to be down-regulated.

90. A method according to claim 89, wherein the antisense oligonucleotide is capable of hybridising with the entire nucleic acid sequence coding for the binding domain.
91. A method according to claim 90 or 91, wherein the oligonucleotide is about 50 nucleotides or less in length.
92. A method according to any one of claims 89 to 91, wherein the oligonucleotide is 45 nucleotides in length or less.
93. A method according to claim 89, wherein the antisense oligonucleotide is an oligonucleotide as defined in claim 45.
94. A method according to any one of claims 89 to 93 wherein the cell is transfected with the antisense oligonucleotide or the antisense oligonucleotide is transcribed from a vector introduced into the cell.
95. A method according to any one of claims 89 to 94, wherein the cell is a cancer cell.
96. A method according to any one of claims 89 to 95, wherein the MAP kinase is an ERK family member or a JNK family member.
97. A method according to claim 96, wherein the MAP kinase is ERK2.
98. A method of modulating activity of a cell expressing an integrin subunit with a cytoplasmic binding domain for a MAP kinase, comprising:

transfecting the cell with an expression vector incorporating a nucleic acid sequence encoding the integrin subunit or an analog or variant thereof for being expressed by the cell, and which has a mutagenised binding domain for the MAP kinase or in which the binding domain has been deleted whereby binding of the MAP kinase is

- 116 -

thereby reduced, with the proviso that the integrin subunit is other than a $\beta 6 \Delta 746-764$ deletion mutant.

99. A method according to claim 98, wherein the integrin subunit is truncated.

100. A method according to claim 98 or 99, wherein the binding domain of the integrin
5 subunit encoded by the nucleic acid is mutagenised.

101. A method according to any one of claims 98 to 100, wherein the MAP kinase is an ERK family member or a JNK family member.

102. A method according to any one of claims 98 to 101, wherein the MAP kinase is ERK2.

103. A method according to any one of claims 98 to 102, wherein the integrin subunit is $\beta 6$.

104. A method of modulating activity of a cell expressing an integrin having a binding domain for a MAP kinase, comprising:

treating the cell with an effective amount of an agent for inhibiting binding of the
15 MAP kinase to the binding domain of the integrin.

105. A method according to claim 104, wherein the agent is a fragment as defined in any one of claims 1 to 8 or an analog or derivative thereof capable of inhibiting the binding of the MAP kinase to the binding domain of the integrin.

106. A method according to claim 104, wherein the agent is a polypeptide as defined in
20 any one of claims 9 to 15 or an analog or derivative thereof capable of inhibiting the binding of the MAP kinase with the binding domain of the integrin.

107. A method according to claim 104, wherein the agent is a fusion protein as defined in any one of claims 16 to 19.

108. A method according to claim 104, wherein the agent is an agent as defined in any
25 one of claims 20 to 32.

- 117 -

109. A method according to claim 104, wherein the agent is a peptide capable of binding with the MAP kinase to thereby inhibit binding of the MAP kinase to the binding domain of the integrin for the MAP kinase.

110. A method according to any one of claims 89 to 109, wherein the activity of the cell
5 is growth of the cell.

111. A method according to any one of claims 89 to 110, wherein the cell is a cancer cell.

112. A method according to claim 111, wherein the cancer cell is a colon cancer cell.

113. A method of prophylaxis or treatment of cancer in a mammal, comprising
10 treating the mammal with an effective amount of an antisense nucleic acid for hybridising with a nucleic acid encoding an integrin subunit to cause expression of the integrin subunit to be down-regulated wherein the integrin subunit has a binding domain for a MAP kinase.

114. A method according to claim 113 comprising administering an effective amount of
15 the antisense nucleic acid to the mammal.

115. A method according to claim 113 comprising administering to the mammal an effective amount of a vector incorporating an nucleic acid sequence complementary to the antisense nucleic acid for generation of the antisense nucleic sequence *in vivo*.

116. A method according to any one of claims 113 to 115, wherein the antisense nucleic
20 acid is an antisense oligonucleotide for hybridising with at least part of the sequence of the nucleic acid encoding the binding domain for the MAP kinase.

117. A method according to claim 116, wherein the oligonucleotide has a length of 150 nucleotides or less.

118. A method according to claim 117, wherein the oligonucleotide has a length of 90
25 nucleotides or less.

- 118 -

119. A method according to claim 118, wherein the oligonucleotide has a length of 50 nucleotides or less.

120. A method according to claim 119, wherein the oligonucleotide has a length of from 15 to 30 nucleotides.

5 121. A method according to any one of claims 113 to 120 wherein the integrin subunit is $\beta 6$.

122. A method according to any one of claims 113 to 121, wherein the cancer is colon cancer.

123. A transgenic animal with cells containing heterologous nucleic acid encoding for
10 an integrin subunit with a mutagenised binding domain for a MAP kinase.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 January 2001 (04.01.2001)

PCT

(10) International Publication Number
WO 01/00677 A1

- (51) International Patent Classification⁷: C07K 14/71, C12N 15/11 (74) Agent: BALDWIN SHELSTON WATERS; 60 Margaret Street, Sydney, NSW 2000 (AU).
- (21) International Application Number: PCT/AU00/00729 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 28 June 2000 (28.06.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
PQ 1248 28 June 1999 (28.06.1999) AU
PQ 8003 6 June 2000 (06.06.2000) AU
- (71) Applicant (*for all designated States except US*): THE UNIVERSITY OF NEWCASTLE RESEARCH ASSOCIATES LIMITED [AU/AU]; Industry Development Centre, University Drive, Callaghan, NSW 2308 (AU).
- (72) Inventor; and
(73) Inventor/Applicant (*for US only*): AGREZ, Michael, Valentine [AU/AU]; 14 Summer Place, Merewether, NSW 2291 (AU).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: A METHOD OF MODULATING INTEGRIN MEDIATED CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME

(57) Abstract: There is disclosed agents capable of inhibiting the binding of a MAP kinase to a binding domain of an integrin for the MAP kinase, and methods of modulating the activity of a cell utilising the agents. The methods are particularly suitable for inhibiting the growth of cancer cells.

WO 01/00677 A1




Figure 1




Figure 2




Figure 3




Figure 4

10/019816

PCT/AU00/00729




Figure 5

10/019816




Figure 6



Figure 7




Figure 8




Figure 9




Figure 10

10/019816




Figure 11

107/019816




Figure 12





Figure 13




Figure 14

A



B




Figure 15

10/019816





Figure 16

10/019816

Binding of GST.ERK2 (0.25ug/100ul) to overlapping peptide fragments from B6 cytoplasmic tail(1ug/100ul).


Figure 17



Overlapping peptide fragments of B6 cytoplasmic tail (see legend)

Binding of GST.ERK2 to B6 cytoplasmic tail and peptide fragments.

Figure 18






Figure 19




Figure 20





Figure 21

Binding of GST.ERK2 (1 μ M) to biotinylated B6 peptides derived from seq. 4



μ M biotinylated peptide
bound to streptavidin plate

Figure 22


Binding of ERK2 (1 μ M, thrombin cleaved) to B6 peptide fragments

Figure 23




Figure 24






Figure 25

**β 6 Expression on
SW480 cells - full length β 6
and β 6 deletion mutant**



FULL LENGTH β 6



**β 6 DELETION
 Δ 746-764**

Figure 26


A $\beta 6$ Immunoprecipitation**B** $\beta 6$ -bound ERK

Figure 27

Proliferation assay for HT29 colon cancer cells showing effect of penetratin, peptide alone and penetratin bearing peptide




Figure 28

SW480 β 6 Proliferation Assay




Figure 29





Figure 30

Inhibition of Proliferation of SW480 Colon Cancer Cells by Penetratin - Peptide Complex



Proliferation of SW480 colon cancer cells




FIG. 31(b)

Proliferation of SW480 colon cancer cells




FIG. 32(A).

Proliferation of SW480 colon cancer cells




FIG. 32(B)

Proliferation of $\beta 6$ Deletion Mutant in a Collagen Matrix Over 10 Days




FIG. 32 (C)


ERK2 (1 μ M) binding to B6, B1, B2, B3 & B5 peptides.

FIG. 34

Binding of ERK2 to B6 seq 4 and alanine substituted seq 4 (ASAAAWQTGTNPLYA)




FIG. 33(B)

Inhibition effect of penetratin-peptide complexes on proliferation of SW480 β 6-expressing cells




FIG. 33 (A)

10/01

Sheet 1 of 3

Attorney
Docket No.: SW-046XX**DECLARATION AND POWER OF ATTORNEY**

I, a below-named inventor, I hereby declare that:

my residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

A METHOD OF MODULATING INTERFERON MEDIATED CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME

The specification of which (check one):

☐ is attached hereto. ☒ was filed on December 28, 2001 as Application No. 10/019,816 amended on _____ (if applicable).

☒ was filed as PCT International Appl. No. PCT/AU99/00722 on 28 June 2000 and was amended under PCT Article 19 on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations §1.55(a).

I hereby claim foreign priority benefits under Title 35, USC §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

<u>Prior Foreign Application(s)</u>		<u>Date Filed</u>	<u>Priority Claimed</u>	
<u>PQ 1268</u> (Number)	<u>Australia</u> (Country)	<u>28 June 1999</u> (Day/Month/Year)	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
<u>PQ 8003</u> (Number)	<u>Australia</u> (Country)	<u>06 June 2000</u> (Day/Month/Year)	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
<u> </u> (Number)	<u> </u> (Country)	<u> </u> (Day/Month/Year)	<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under Title 35, USC §119(e) of any United States provisional application(s) listed below:

<u>(Application Number)</u>	<u>(Filing Date)</u>
<u>(Application Number)</u>	<u>(Filing Date)</u>
<u>(Application Number)</u>	<u>(Filing Date)</u>

Express Mail Number
EV 009950073 US

10/01

Sheet 2 of 3

Attorney
Docket No.: SW-046XX

I hereby claim the benefit under Title 35 USC §120 of any United States application(s) listed below and insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35 USC §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

(Application No.) (Filing Date) (Patented/pending/abandoned)

(Application No.) (Filing Date) (Patented/pending/abandoned)

(Application No.) (Filing Date) (Patented/pending/abandoned)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) to prosecute this application and transact all business connected therewith in the Patent and Trademark Office, and to file with the USPO any International Application based thereon.

Stanley M. Schurigin, Reg. No. 20,972
Charles L. Gagnabin III, Reg. No. 25,467
Victor B. Lebovici, Reg. No. 30,864

Beverly B. Bjorth, Reg. No. 32,033
Kolliday C. Nease, Reg. No. 34,166
Gordon M. Moriarty, Reg. No. 38,973
James F. Thompson, Reg. No. 36,699

Address all correspondence to:
Attorney Number: 207

WEINGARTEN, SCHURIGIN, GAGNABIN & LEBOVICI LLP
Two Post Office Square
Boston, Massachusetts 02109
Telephone: (617) 542-2290
Telex: (617) 481-0313

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of First/Sole Inventor: Michael Valentine Agnes

City of Residence <u>Marewether</u>	State or Country <u>New South Wales, Australia</u>	Country of Citizenship <u>Aux</u>
Post Office Address <u>14 Summer Place</u>	City <u>Marewether</u> <u>New South Wales 2291</u>	State or Country Zip Code <u>Australia</u>
Signatures: (Please sign and date in permanent ink.) <u>X</u> <i>[Signature]</i>		Date signed: <u>X</u> <u>1. J. 2002</u>

.0/01

Sheet 3 of 3

Attorney
Docket No.: SW-0462X

Full Name of Second/Joint Inventor: Muzbat Ahmed

City of Residence Yallambie	State or Country Victoria, Australia	Country of Citizenship Australia
Post Office Address 33 Tom Roberts Crescent	City Yallambie, Victoria 3085	State or Country Zip Code Australia
Signature: (Please sign and date in permanent ink.) X		Date signed: X

CH/mc/2d4339-1

10/01

Sheet 1 of 3

Attorney
Docket No.: SW-046XXDECLARATION AND POWER OF ATTORNEY

I, a below-named inventor, I hereby declare that:

my residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

A METHOD OF MODULATING INTEGRIN MEDIATED CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME

The specification of which (check one):

[] is attached hereto. [X] was filed on December 28, 2001 as Application No. 10/019,816,
amended on _____ (if applicable).[X] was filed as PCT International. Appl. No. PCT/AU00/00729 on 28 June 2000
and was amended under PCT Article 19 on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations §1.56(a).

I hereby claim foreign priority benefits under Title 35, USC §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)	Date Filed	Priority Claimed
PO 1248 (Number) Australia (Country)	28 June 1999 (Day/Month/Year)	[X] [] Yes No
PQ 8003 (Number) Australia (Country)	06 June 2000 (Day/Month/Year)	[X] [] Yes No
(Number) (Country)	(Day/Month/Year)	[] [] Yes No

I hereby claim the benefit under Title 35, USC §119(e) of any United States provisional application(s) listed below:

(Application Number) _____

(Filing Date) _____

(Application Number) _____

(Filing Date) _____

(Application Number) _____

(Filing Date) _____

Express Mail Number

EV'009950073 US

10/01

Sheet 2 of 3

Attorney
Docket No.: BW-0462X

I hereby claim the benefit under Title 35 USC §120 of any United States application(s) listed below and insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35 USC §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application No.)	(Filing Date)	(Patented/pending/abandoned)
(Application No.)	(Filing Date)	(Patented/pending/abandoned)
(Application No.)	(Filing Date)	(Patented/pending/abandoned)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) to prosecute this application and transact all business connected therewith in the Patent and Trademark Office, and to file with the USPO any International Application based thereon.

Stanley M. Schurgin, Reg. No. 28,979
Charles L. Gagnebin III, Reg. No. 25,467
Victor B. Lebovici, Reg. No. 30,864

Beverly E. Hjorth, Reg. No. 32,033
Eolliday C. Heina, Reg. No. 34,346
Gordon R. Moriarty, Reg. No. 38,973
James F. Thompson, Reg. No. 36,699

address all correspondence to:
Customer Number: 207

WEINGARTEN, SCHURGIN, GAGNEBIN & LEOVICI LLP
Ten Post Office Square
Boston, Massachusetts 02109
Telephone: (617) 542-2290
Telecopier: (617) 451-0313

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or my patent issued thereon.

Full Name of First/Sole Inventor: Michael Valentine Agrez		
City of Residence	State or Country	Country of Citizenship
Merewether	New South Wales, Australia	Australia
Post Office Address	City	State or Country Zip Code
14 Summer Place	Merewether New South Wales 2291	Australia
Signature: (Please sign and date in permanent ink.)		Date signed:
X		X

.0/01

Sheet 3 of 3

Attorney
Docket No.: BW-046XX

Full Name of Second/Joint Inventor: <u>Nuzhat Ahmed</u> 2-00		
City of Residence <u>Yallambie</u>	State or Country Victoria, Australia	Country of Citizenship Australia <i>Aux</i>
Post Office Address 33 Tom Roberts Crescent	City Yallambie, Victoria 3085	State or Country Zip Code Australia
Signature: (Please sign and date in permanent ink.) X <i>N Ahmed</i>		Date signed: X <i>18/3/02</i> <i>N Ahmed</i>

10/019816 #5

SEQUENCE LISTING

<110> AGREZ, MICHAEL V
AHMED, NUZHAT

<120> A METHOD OF MODULATING INTEGRIN MEDIATED CELLULAR ACTIVITY AND AGENTS
USEFUL FOR SAME

<130> SW-046 XX

<140> US 10/019,816
<141> 2000-06-28

<150> PQ 1248
<151> 1999-06-28

<150> PQ 8003
<151> 2000-06-06

<160> 23

<170> PatentIn version 3.1

<210> 1
<211> 788
<212> PRT
<213> HOMO SAPIENS

<400> 1

Met Gly Ile Glu Leu Leu Cys Leu Phe Phe Leu Phe Leu Gly Arg Asn
1 5 10 15

Asp Ser Arg Thr Arg Trp Leu Cys Leu Gly Gly Ala Glu Thr Cys Glu
20 25 30

Asp Cys Leu Leu Ile Gly Pro Gln Cys Ala Trp Cys Ala Gln Glu Asn
35 40 45

Phe Thr His Pro Ser Gly Val Gly Glu Arg Cys Asp Thr Pro Ala Asn
50 55 60

Leu Leu Ala Lys Gly Cys Gln Leu Asn Phe Ile Glu Asn Pro Val Ser
65 70 75 80

Gln Val Glu Ile Leu Lys Asn Lys Pro Leu Ser Val Gly Arg Gln Lys
85 90 95

Asn Ser Ser Asp Ile Val Gln Ile Ala Pro Gln Ser Leu Ile Leu Lys
100 105 110

Leu Arg Pro Gly Gly Ala Gln Thr Leu Gln Val His Val Arg Gln Thr
115 120 125

Glu Asp Tyr Pro Val Asp Leu Tyr Tyr Leu Met Asp Leu Ser Ala Ser
130 135 140

Met Asp Asp Asp Leu Asn Thr Ile Lys Glu Leu Gly Ser Gly Leu Ser
145 150 155 160

Lys Glu Met Ser Lys Leu Thr Ser Asn Phe Arg Leu Gly Phe Gly Ser
 165 170
 Phe Val Glu Lys Pro Val Ser Pro Phe Val Lys Thr Thr Pro Glu Glu
 180 185 190
 Ile Ala Asn Pro Cys Ser Ser Ile Pro Tyr Phe Cys Leu Pro Thr Phe
 195 200 205
 Gly Phe Lys His Ile Leu Pro Leu Thr Asn Asp Ala Glu Arg Phe Asn
 210 215 220
 Glu Ile Val Lys Asn Gln Lys Ile Ser Ala Asn Ile Asp Thr Pro Glu
 225 230 235 240
 Gly Gly Phe Asp Ala Ile Met Gln Ala Ala Val Cys Lys Glu Lys Ile
 245 250 255
 Gly Trp Arg Asn Asp Ser Leu His Leu Leu Val Phe Val Ser Asp Ala
 260 265 270
 Asp Ser His Phe Gly Met Asp Ser Lys Leu Ala Gly Ile Val Ile Pro
 275 280 285
 Asn Asp Gly Leu Cys His Leu Asp Ser Lys Asn Glu Tyr Ser Met Ser
 290 295 300
 Thr Val Leu Glu Tyr Pro Thr Ile Gly Gln Leu Ile Asp Lys Leu Val
 305 310 315 320
 Gln Asn Asn Val Leu Leu Ile Phe Ala Val Thr Gln Glu Gln Val His
 325 330 335
 Leu Tyr Glu Asn Tyr Ala Lys Leu Ile Pro Gly Ala Thr Val Gly Leu
 340 345 350
 Leu Gln Lys Asp Ser Gly Asn Ile Leu Gln Leu Ile Ile Ser Ala Tyr
 355 360 365
 Glu Glu Leu Arg Ser Glu Val Glu Leu Glu Val Leu Gly Asp Thr Glu
 370 375 380
 Gly Leu Asn Leu Ser Phe Thr Ala Ile Cys Asn Asn Gly Thr Leu Phe
 385 390 395 400
 Gln His Gln Lys Lys Cys Ser His Met Lys Val Gly Asp Thr Ala Ser
 405 410 415
 Phe Ser Val Thr Val Asn Ile Pro His Cys Glu Arg Arg Ser Arg His
 420 425 430

Ile Ile Ile Lys Pro Val Gly Leu Gly Asp Ala Leu Glu Leu Leu Val
 435 440 445
 Ser Pro Glu Cys Asn Cys Asp Cys Gln Lys Glu Val Glu Val Asn Ser
 450 455 460
 Ser Lys Cys His His Gly Asn Gly Ser Phe Gln Cys Gly Val Cys Ala
 465 470 475 480
 Cys His Pro Gly His Met Gly Pro Arg Cys Glu Cys Gly Glu Asp Met
 485 490 495
 Leu Ser Thr Asp Ser Cys Lys Glu Ala Pro Asp His Pro Ser Cys Ser
 500 505 510
 Gly Arg Gly Asp Cys Tyr Cys Gly Gln Cys Ile Cys His Leu Ser Pro
 515 520 525
 Tyr Gly Asn Ile Tyr Gly Pro Tyr Cys Gln Cys Asp Asn Phe Ser Cys
 530 535 540
 Val Arg His Lys Gly Leu Leu Cys Gly Gly Asn Gly Asp Cys Asp Cys
 545 550 555 560
 Gly Glu Cys Val Cys Arg Ser Gly Trp Thr Gly Glu Tyr Cys Asn Cys
 565 570 575
 Thr Thr Ser Thr Asp Ser Cys Val Ser Glu Asp Gly Val Leu Cys Ser
 580 585 590
 Gly Arg Gly Asp Cys Val Cys Gly Lys Cys Val Cys Thr Asn Pro Gly
 595 600 605
 Ala Ser Gly Pro Thr Cys Glu Arg Cys Pro Thr Cys Gly Asp Pro Cys
 610 615 620
 Asn Ser Lys Arg Ser Cys Ile Glu Cys His Leu Ser Ala Ala Gly Gln
 625 630 635 640
 Ala Gly Glu Glu Cys Val Asp Lys Cys Lys Leu Ala Gly Ala Thr Ile
 645 650 655
 Ser Glu Glu Glu Asp Phe Ser Lys Asp Gly Ser Val Ser Cys Ser Leu
 660 665 670
 Gln Gly Glu Asn Glu Cys Leu Ile Thr Phe Leu Ile Thr Thr Asp Asn
 675 680 685
 Glu Gly Lys Thr Ile Ile His Ser Ile Asn Glu Lys Asp Cys Pro Lys
 690 695 700
 Pro Pro Asn Ile Pro Met Ile Met Leu Gly Val Ser Leu Ala Thr Leu
 Page 3

705 710 715 720

Leu Ile Gly Val Val₇₂₅ Leu Leu Cys Ile Trp₇₃₀ Lys Leu Leu Val Ser₇₃₅ Phe₇₄₀

His Asp Arg Lys₇₄₀ Glu Val Ala Lys Phe₇₄₅ Glu Ala Glu Arg Ser₇₅₀ Lys Ala₇₅₅

Lys Trp Gln Thr Gly Thr Asn Pro₇₆₀ Leu Tyr Arg Gly Ser₇₆₅ Thr Ser Thr₇₇₀

Phe Lys₇₇₀ Asn Val Thr Tyr Lys₇₇₅ His Arg Glu Lys Gln₇₈₀ Lys Val Asp Leu₇₈₅

Ser₇₈₅ Thr Asp Cys

<210>	2
<211>	15
<212>	PRT
<213>	HOMO SAPIENS
<400>	2

Arg Ser Lys Ala Lys Trp Gln Thr Gly Thr Asn Pro Leu Tyr Arg
1 5 10 15

<210>	3
<211>	10
<212>	PRT
<213>	HOMO SAPIENS

<400> 3

Arg Ser Lys Ala Lys Asn Pro Leu Tyr Arg
1 5 10

<210>	4
<211>	5
<212>	PRT
<213>	HOMO SAPIENS

<400> 4

Arg Ser Lys Ala Lys
1 5

<210> 5
<211> 5
<212> PRT
<213> HOMO SAPIENS

<400> 5

Asn Pro Leu Tyr Arg
1 5

$\langle 210 \rangle$	6
$\langle 211 \rangle$	41

<212> PRT
 <213> HOMO SAPIENS

<400> 6

His Asp Arg Arg Glu Phe Ala Lys Phe Glu Lys Glu Lys Met Asn Ala
 1 5 10 15

Lys Trp Asp Thr Gly Glu Asn Pro Ile Tyr Lys Ser Ala Val Thr Thr
 20 25 30

Val Val Asn Pro Lys Tyr Glu Gly Lys
 35 40

<210> 7
 <211> 40
 <212> PRT
 <213> HOMO SAPIENS

<400> 7

Ser Asp Leu Arg Glu Tyr Arg Arg Phe Glu Lys Glu Lys Leu Lys Ser
 1 5 10 15

Gln Trp Asn Asn Asp Asn Pro Leu Phe Lys Ser Ala Thr Thr Thr Val
 20 25 30

Met Asn Pro Lys Phe Ala Glu Ser
 35 40

<210> 8
 <211> 41
 <212> PRT
 <213> HOMO SAPIENS

<400> 8

His Asp Arg Lys Glu Phe Ala Lys Phe Glu Glu Glu Arg Ala Arg Ala
 1 5 10 15

Lys Trp Asp Thr Ala Asn Asn Pro Leu Tyr Lys Glu Ala Thr Ser Thr
 20 25 30

Phe Thr Asn Ile Thr Tyr Arg Gly Thr
 35 40

<210> 9
 <211> 52
 <212> PRT
 <213> HOMO SAPIENS

<400> 9

His Asp Arg Lys Glu Val Ala Lys Phe Glu Ala Glu Arg Ser Lys Ala
 1 5 10 15

Lys Trp Gln Thr Gly Thr Asn Pro Leu Tyr Arg Gly Ser Thr Ser Thr
 20 25 30

Phe Lys Asn Val Thr Tyr Lys His Arg Glu Lys Gln Lys Val Asp Leu
 35 40 45

Ser Thr Asp Ser
 50

<210> 10
 <211> 52
 <212> PRT
 <213> HOMO SAPIENS

<400> 10

His Asp Arg Lys Glu Val Ala Lys Phe Glu Ala Glu Arg Ser Lys Ala
 1 5 10 15

Lys Trp Gln Thr Gly Thr Asn Pro Leu Tyr Arg Gly Ser Thr Thr
 20 25 30

Phe Lys Asn Val Thr Tyr Lys His Arg Glu Lys Gln Lys Val Asp Leu
 35 40 45

Ser Thr Asp Cys
 50

<210> 11
 <211> 22
 <212> PRT
 <213> HOMO SAPIENS

<400> 11

His Asp Arg Lys Glu Val Ala Lys Phe Glu Ala Glu Arg Ser Lys Ala
 1 5 10 15

Lys Trp Gln Thr Gly Thr
 20

<210> 12
 <211> 20
 <212> PRT
 <213> HOMO SAPIENS

<400> 12

Arg Ser Lys Ala Lys Trp Gln Thr Gly Thr Asn Pro Leu Tyr Arg Gly
 1 5 10 15

Ser Thr Ser Thr
 20

<210> 13
 <211> 20
 <212> PRT
 <213> HOMO SAPIENS

<400> 13

Asn Pro Leu Tyr Arg Gly Ser Thr Ser Thr Phe Lys Asn Val Thr Tyr
1 5 10 15

Lys His Arg Glu
20

<210> 14
<211> 20
<212> PRT
<213> HOMO SAPIENS
<400> 14

Phe Lys Asn Val Thr Tyr Lys His Arg Glu Lys Gln Lys Val Asp Leu
1 5 10 15

Ser Thr Asp Ser
20

<210> 15
<211> 10
<212> PRT
<213> HOMO SAPIENS
<400> 15

Arg Ser Lys Ala Lys Trp Gln Thr Gly Thr
1 5 10

<210> 16
<211> 10
<212> PRT
<213> HOMO SAPIENS
<400> 16

Asn Pro Leu Tyr Arg Gly Ser Thr Ser Thr
1 5 10

<210> 17
<211> 10
<212> PRT
<213> HOMO SAPIENS
<400> 17

Trp Gln Thr Gly Thr Asn Pro Leu Tyr Arg
1 5 10

<210> 18
<211> 10
<212> PRT
<213> HOMO SAPIENS
<400> 18

Lys Phe Glu Ala Glu Arg Ser Lys Ala Lys
1 5 10

<210> 19
<211> 18

<212> PRT
<213> HOMO SAPIENS

<400> 19

Ala Glu Arg Ser Lys Ala Lys Trp Gln Thr Gly Thr Asn Pro Leu Tyr
1 5 10 15

Arg Gly

<210> 20
<211> 20
<212> PRT
<213> HOMO SAPIENS

<400> 20

Lys Phe Glu Lys Glu Lys Met Asn Ala Lys Trp Asp Thr Gly Glu Asn
1 5 10 15

Pro Ile Tyr Lys
20

<210> 21
<211> 16
<212> PRT
<213> HOMO SAPIENS

<400> 21

Lys Glu Lys Leu Lys Ser Gln Trp Asn Asn Asp Asn Pro Leu Phe Lys
1 5 10 15

<210> 22
<211> 15
<212> PRT
<213> HOMO SAPIENS

<400> 22

Arg Ala Arg Ala Lys Trp Asp Thr Ala Asn Asn Pro Leu Tyr Lys
1 5 10 15

<210> 23
<211> 15
<212> PRT
<213> HOMO SAPIENS

<400> 23

Arg Ser Arg Ala Arg Tyr Glu Met Ala Ser Asn Pro Leu Tyr Arg
1 5 10 15

WO 01/00677

PCT/AU00/00729

1

SEQUENCE LISTING

<110> The University of Newcastle Research Associates Lt

<120> A Method for Modulating Integrin-Mediated Cellular
Activity and Agents Useful for Same

<130> 25197wop00

<140>

<141>

<150> FQ1248

<151> 1999-06-28

<160> 1

<170> PatentIn Ver. 2.1

<210> 1

<211> 788

<212> PRT

<213> Homo sapiens

<400> 1

Met Gly Ile Glu Leu Leu Cys Leu Phe Phe Leu Phe Leu Gly Arg Asn
1 5 10 15

Asp Ser Arg Thr Arg Trp Leu Cys Leu Gly Gly Ala Glu Thr Cys Glu
20 25 30

Asp Cys Leu Leu Ile Gly Pro Gln Cys Ala Trp Cys Ala Gln Glu Asn
35 40 45

Phe Thr His Pro Ser Gly Val Gly Glu Arg Cys Asp Thr Pro Ala Asn
50 55 60

Leu Leu Ala Lys Gly Cys Gln Leu Asn Phe Ile Glu Asn Pro Val Ser
65 70 75 80

Gln Val Glu Ile Leu Lys Asn Lys Pro Leu Ser Val Gly Arg Gln Lys
85 90 95

Asn Ser Ser Asp Ile Val Gln Ile Ala Pro Gln Ser Leu Ile Leu Lys
100 105 110

Leu Arg Pro Gly Gly Ala Gln Thr Leu Gln Val His Val Arg Gln Thr
115 120 125

WO 01/00677

PCT/AU00/00729

2

Glu Asp Tyr Pro Val Asp Leu Tyr Tyr Leu Met Asp Leu Ser Ala Ser
130 135 140

Met Asp Asp Asp Leu Asn Thr Ile Lys Glu Leu Gly Ser Gly Leu Ser
145 150 155 160

Lys Glu Met Ser Lys Leu Thr Ser Asn Phe Arg Leu Glu Phe Gly Ser
165 170 175

Phe Val Glu Lys Pro Val Ser Pro Phe Val Lys Thr Thr Pro Glu Glu
180 185 190

Ile Ala Asn Pro Cys Ser Ser Ile Pro Tyr Phe Cys Leu Pro Thr Phe
195 200 205

Gly Phe Lys His Ile Leu Pro Leu Thr Asn Asp Ala Glu Arg Phe Asn
210 215 220

Glu Ile Val Lys Asn Gln Lys Ile Ser Ala Asn Ile Asp Thr Pro Glu
225 230 235 240

Gly Gly Phe Asp Ala Ile Met Gln Ala Ala Val Cys Lys Glu Lys Ile
245 250 255

Gly Trp Arg Asn Asp Ser Leu His Leu Leu Val Phe Val Ser Asp Ala
260 265 270

Asp Ser His Phe Gly Met Asp Ser Lys Leu Ala Gly Ile Val Ile Pro
275 280 285

Asn Asp Gly Leu Cys His Leu Asp Ser Lys Asn Glu Tyr Ser Met Ser
290 295 300

Thr Val Leu Glu Tyr Pro Thr Ile Gly Gln Leu Ile Asp Lys Leu Val
305 310 315 320

Gln Asn Asn Val Leu Leu Ile Phe Ala Val Thr Gln Glu Gln Val His
325 330 335

Leu Tyr Glu Asn Tyr Ala Lys Leu Ile Pro Gly Ala Thr Val Gly Leu
340 345 350

Leu Gln Lys Asp Ser Gly Asn Ile Leu Gln Leu Ile Ile Ser Ala Tyr
355 360 365

Glu Glu Leu Arg Ser Glu Val Glu Leu Glu Val Leu Gly Asp Thr Glu
370 375 380

WO 01/00677

PCT/AU00/00729

3

Gly Leu Asn Leu Ser Phe Thr Ala Ile Cys Asn Asn Gly Thr Leu Phe
 385 390 395 400
 Gln His Gln Lys Lys Cys Ser His Met Lys Val Gly Asn Thr Ala Ser
 405 410 415
 Phe Ser Val Thr Val Asn Ile Pro His Cys Glu Arg Arg Ser Arg His
 420 425 430
 Ile Ile Ile Lys Pro Val Gly Leu Gly Asp Ala Leu Glu Leu Leu Val
 435 440 445
 Ser Pro Glu Cys Asn Cys Asp Cys Gln Lys Glu Val Glu Val Asn Ser
 450 455 460
 Ser Lys Cys His His Gly Asn Gly Ser Phe Gln Cys Gly Val Cys Ala
 465 470 475 480
 Cys His Pro Gly His Met Gly Pro Arg Cys Glu Cys Gly Glu Asp Met
 485 490 495
 Leu Ser Thr Asp Ser Cys Lys Glu Ala Pro Asp His Pro Ser Cys Ser
 500 505 510
 Gly Arg Gly Asp Cys Tyr Cys Gly Gln Cys Ile Cys His Leu Ser Pro
 515 520 525
 Tyr Gly Asn Ile Tyr Gly Pro Tyr Cys Gln Cys Asp Asn Phe Ser Cys
 530 535 540
 Val Arg His Lys Gly Leu Leu Cys Gly Gly Asn Gly Asp Cys Asp Cys
 545 550 555 560
 Gly Glu Cys Val Cys Arg Ser Gly Trp Thr Gly Glu Tyr Cys Asn Cys
 565 570 575
 Thr Thr Ser Thr Asp Ser Cys Val Ser Glu Asp Gly Val Leu Cys Ser
 580 585 590
 Gly Arg Gly Asp Cys Val Cys Gly Lys Cys Val Cys Thr Asn Pro Gly
 595 600 605
 Ala Ser Gly Pro Thr Cys Glu Arg Cys Pro Thr Cys Gly Asp Pro Cys
 610 615 620
 Asn Ser Lys Arg Ser Cys Ile Glu Cys His Leu Ser Ala Ala Gly Gln
 625 630 635 640

WO 01/00677

PCT/AU00/00729

4

Ala Gly Glu Glu Cys Val Asp Lys Cys Lys Leu Ala Gly Ala Thr Ile
645 650 655

Ser Glu Glu Glu Asp Phe Ser Lys Asp Gly Ser Val Ser Cys Ser Leu
660 665 670

Gln Gly Glu Asn Glu Cys Leu Ile Thr Phe Leu Ile Thr Thr Asp Asn
675 680 685

Glu Gly Lys Thr Ile Ile His Ser Ile Asn Glu Lys Asp Cys Pro Lys
690 695 700

Pro Pro Asn Ile Pro Met Ile Met Leu Gly Val Ser Leu Ala Thr Leu
705 710 715 720

Leu Ile Gly Val Val Leu Leu Cys Ile Trp Lys Leu Leu Val Ser Phe
725 730 735


His Asp Arg Lys Glu Val Ala Lys Phe Glu Ala Glu Arg Ser Lys Ala
740 745 750

Lys Trp Gln Thr Gly Thr Asn Pro Leu Tyr Arg Gly Ser Thr Ser Thr
755 760 765

Phe Lys Asn Val Thr Tyr Lys His Arg Glu Lys Gln Lys Val Asp Leu
770 775 780

Ser Thr Asp Cys
785

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ *Scanned copy is best availables on me page drawing are very dark*